Apramycin derivatives

ABSTRACT

The invention relates to derivatives of apramycin-based aminoglycoside antibacterial drugs modified in positions C5 and/or C6 and O5 and/or O6. The modifications impart favourable properties regarding increased selectivity and retention of activity in the presence of resistance determinants of the AAC(3) class. The invention further relates to said compounds for use in the therapy of bacterial infection by systemic administration, especially in instances where the infection is caused by a pathogen comprising a resistance determinant of the AAC(3) class, in particular AAC(3)-IV.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to U.S. Provisional Patent Application No. 62/492,474 filed on May 1, 2017, which is incorporated herein by reference in its entirety as if fully set forth herein.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with government support under grant 1R01Al123352-01 awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD OF THE DISCLOSURE

The present invention relates to aminoglycoside compounds based on the apramycin scaffold having improved antibacterial properties. The invention further relates to use of the compounds of the invention in the treatment of infections by pathogens carrying certain resistance genes rendering such pathogens refractive to classical aminoglycoside antibacterial drugs.

BACKGROUND OF THE DISCLOSURE

The clinically important class of aminoglycoside antibiotics (AGAs) derive their activity from binding to bacterial ribosomal RNA. Aminoglycosides are an important class of broad spectrum antibiotics owing to the combination of their high potency, lack of allergic response, and minimal effect on the host's microbiome. AGAs currently in clinical practice, however, are compromised by toxicity issues (mainly irreversible ototoxicity) and the rise of resistant pathogens. No new aminoglycosides have been introduced into clinical practice since the early 1990s. There is therefore an unmet need for new aminoglycoside drugs that retain their favorable characteristics yet overcome the now widespread resistance determinants and do so without significant toxicity.

Apramycin is an unusual monosubstituted 2-deoxystreptamine (DOS) type aminoglycoside antibiotic that is currently being evaluated as a possible clinical candidate for the treatment of carbapenem resistant enterobacteriaceae (CREs). Apramycin has the advantage over other AGAs currently in clinical use of displaying little ototoxicity. Furthermore, its unusual structure safeguards it from susceptibility to many of the aminoglycoside modifying enzymes (AMEs) that act on the various AGAs in clinical use and from susceptibility to the ribosomal methyl transferase ArmA that modifies the target ribosome and destroys the activity of all members of the 4,6-class of disubstituted DOS AGAs. Apramycin is however susceptible to aminoglycoside acetyltransferases (AAC) of the AAC(3) class, including the enzyme AAC(3)-IV.

Based on the above-mentioned state of the art, the objective of the present invention is to provide improved apramycin derivatives that overcome the problems found in the prior art. This objective is attained by the claims of the present specification.

DESCRIPTION

Many aminoglycoside antibiotic drug candidates have been developed over more than 50 years, and a vast number of synthetic approaches are known to the skilled artisan. Useful reviews of modern aminoglycoside chemistry are available in Wang and Chang, Aminoglycoside Antibiotics: From Chemical Biology to Drug Discovery, 2^(nd) Ed. (Editor: D. Arya), Wiley 2007, and in Berkov-Zrihen and Fridman, Modern Synthetic Methods in Carbohydrate Chemistry (Editors: D. B. Werz and S. Vidal) with the latter covering protecting group strategies in the apramycin class.

Apramycin is a monosubstituted 2 deoxystreptamine (DOS) type aminoglycoside antibiotic (AGA) characterized by the following formula (1)

Apramycin consists of four rings, the numbering of which is indicated in formula (1) above, where the complete central bicyclic moiety is called ring II.

Position C5 of apramycin in the context of the present specification relates to the carbon atom designated 5 in ring I. Position O5 relates to the oxygen atom attached to C5.

Bacteria evade the action of existing aminoglycoside antibiotics by expression of aminoglycoside modifying enzymes (AMEs) which inactivate the drug. While AMEs vary between different bacteria, only a limited number of positions on the AGA framework are modified across the complete spectrum of bacteria.

Due to its structural uniqueness, apramycin has remained inherently potent against otherwise highly drug resistant pathogenic bacteria. Among the numerous classes of AMEs only the isoform AAC(3)-IV of the AAC(3) class of aminoacetyltransferases acting on N3 in the 2-deoxystreptamine ring of the AGAs gives rise to apramycin resistance.

Whole genome sequencing conducted by the inventors has identified the presence of AAC(3)-IV in human clinical isolates from the University of Zurich Institute of Medical Microbiology (IMM). It is to be expected that, if apramycin is approved for use in human medicine, resistance due to the presence of the AAC(3)-IV determinant will eventually emerge.

The inventors have found that certain modifications of apramycin at position C5 result in the retention of activity in the presence of the AAC(3) class of AME, including AAC(3)-IV.

In the context of the present specification, “apmA” refers to an apramycin-resistant aminocyclitol acetyltransferase gene identified from bovine multi drug resistant

Staphylococcus aureus (MRSA) as described in Fessler et al. 2011. Antimicrob. Agents Chemother. 55(1):373-5.

In their effort to modify and improve apramycin, the inventors have surprisingly found that modification by introduction of a β-D-ri bofuranosyl group carrying a basic substituent at the ultimate 3′″-position results in a set of highly active compounds at the target level and in antibacterial assays including clinical isolates carrying the AAC(3)-IV AME. Many of the compounds also provide increased target specificity for bacterial versus human rRNA.

The inventors have additionally found that simple manipulation of the apramycin 5-OH by either deoxygenation, inversion, substitution by a halogen atom or by alkylation provides significant protection against the influence of the AAC(3)-IV AME. These improvements are made without loss of activity against wild type bacterial strains and exhibit improved activity when compared to the parent.

In a further related finding, the inventors have discovered that alkylation of the apramycin 6-OH provides increased target specificity for bacterial versus human rRNA.

The inventors provide apramycin derivatives with increased potency that circumvent inactivation by AAC(3)-VI. Further beneficial effects are increased antibacterial potency, protection against apmA, increased target specificity for bacterial versus human, and retained activity against G1405 methylated ribosomes.

As the derivatives are straightforward to prepare, this invention has enormous potential for the treatment of CREs and other multi-drug-resistant bacterial infections.

Terms and Definitions

A C₁-C₄ alkyl in the context of the present invention signifies a saturated linear or branched hydrocarbon having 1, 2, 3 or 4 carbon atoms, wherein in certain embodiments one carbon-carbon bond may be unsaturated and/or one CH₂ moiety may be exchanged for oxygen (ether bridge) or nitrogen (NH, or NR with R being methyl, ethyl, or propyl; amino bridge). Non-limiting examples for a C₁-C₄ alkyl are methyl, ethyl, propyl, prop-2-enyl, n-butyl, 2-methylpropyl, tert-butyl, but-3-enyl, prop-2-inyl and but-3-inyl. In certain embodiments, a C₁-C₄ alkyl is a methyl, ethyl, propyl or butyl moiety.

The term C₁-C₆ alkyl similarly refers to C₁-C₄ alkyls and their higher homologues, including additionally 3-methylbut-2-enyl, 2-methylbut-3-enyl, 3-methylbut-3-enyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1,2-dimethylpropyl, pent-4-inyl, 3-methyl-2-pentyl, and 4-methyl-2-pentyl. In certain embodiments, a C₅ alkyl is a pentyl moiety and a C₆ alkyl is a hexyl or cyclohexyl moiety.

Where used in the context of chemical formulae, the following abbreviations may be used: Me is methyl CH₃ or —CH₂—, Et is ethyl —CH₂CH₃ or —CH₂CH₂—, Prop is propyl —(CH₂)₂CH₃ or —(CH₂)₃— (n-propyl, n-pr) or —CH(CH₃)₂ (iso-propyl, i-pr), but is butyl —C₄H₉, or —C₄H₈—, —(CH₂)₃CH₃, —CHCH₃CH₂CH₃, —CH₂CH(CH₃)₂ or —CH(CH₃)₃.

The term amino-substituted alkyl or hydroxy-substituted alkyl refers to an alkyl according to the above definition that is modified by one or several amine or hydroxyl groups NH₂, NHR, NR₂ or OH, wherein the R substituent as used in the current paragraph, different from other uses assigned to R in the body of the specification, is methyl, ethyl or propyl unless otherwise specified. An alkyl having more than one carbon may comprise more than one amine or hydroxyl. Unless otherwise specified, the term “substituted alkyl” refers to alkyl in which each C is only substituted by one amine or hydroxyl group, in addition to bonds to the alkyl chain, terminal methyl, or hydrogen.

Non-limiting examples of amino-substituted alkyl include —CH₂NH₂, —CH₂NHMe, —CH₂NHEt, —CH₂CH₂NH₂, —CH₂CH₂NHMe, —CH₂CH₂NHEt, —(CH₂)₃NH₂, —(CH₂)₃NHMe, —(CH₂)₃NHEt, —CH₂CH(NH₂)CH₃, —CH₂CH(NHMe)CH₃, —CH₂CH(NHEt)CH₃, —(CH₂)₃CH₂NH₂, —(CH₂)₃CH₂NHMe, —(CH₂)₃CH₂NHEt, —CH(CH₂NH₂)CH₂CH₃, —CH(CH₂NHMe)CH₂CH₃, —CH(CH₂NHEt)CH₂CH₃, —CH₂CH(CH₂NH₂)CH₃, —CH₂CH(CH₂NHMe)CH₃, —CH₂CH(CH₂NHEt)CH₃, —CH(NH₂)(CH₂)₂NH₂, —CH(NHMe)(CH₂)₂NHMe, —CH(NHEt)(CH₂)₂NHEt, —CH₂CH(NH₂)CH₂NH₂, —CH₂CH(NHMe)CH₂NHMe, —CH₂CH(NHEt)CH₂NHEt, —CH₂CH(NH₂)(CH₂)₂NH₂, —CH₂CH(NHMe)(CH₂)₂NHMe, —CH₂CH(NHEt)(CH₂)₂NHEt, —CH₂CH(CH₂NH₂)₂, —CH₂CH(CH₂NHMe)₂ and —CH₂CH(CH₂NHEt)₂.

Non-limiting examples of hydroxy-substituted alkyl include —CH₂OH, —(CH₂)₂OH, —(CH₂)₃OH, —CH₂CH(OH)CH₃, —(CH₂)₄OH, —CH(CH₂OH)CH₂CH₃, —CH₂CH(CH₂OH)CH₃, —CH(OH)(CH₂)₂OH, —CH₂CH(OH)CH₂OH, —CH₂CH(OH)(CH₂)₂OH and —CH₂CH(CH₂OH)₂.

The term fluoro-substituted alkyl refers to an alkyl according to the above definition that is modified by one or several fluorine moieties F. Non-limiting examples of fluoro-substituted alkyl include —CH₂F, —CHF₂, —CF₃, —(CH₂)₂F, —(CHF)₂H, —(CHF)₂F, —C₂F₅, —(CH₂)₃F, —(CHF)₃H, —(CHF)₃F, —C₃F₇, —(CH₂)₄F, —(CHF)₄H, —(CHF)₄F and —C₄F₉.

Non-limiting examples of hydroxyl-and fluoro-substituted alkyl include —CHFCH₂OH, —CF₂CH₂OH, —(CHF)₂CH₂OH, —(CF₂)₂CH₂OH, —(CHF)₃CH₂OH, —(CF₂)₃CH₂OH, —(CH₂)₃OH, —CF₂CH(OH)CH₃, —CF₂CH(OH)CF₃, —CF(CH₂OH)CHFCH₃, and —CF(CH₂OH)CHFCF₃.

The term “C₁ to C₄ alkenyl or alkynyl” refers to unsaturated linear carbon chains, particularly unsubstituted carbon chains, i.e. the moiety thus referred to is constituted of carbon and hydrogen atoms only. It encompasses, but is not limited to, ethenyl (—CHCH₂), ethynyl (—CCH) or allyl (CH—CHCH₂) and but-2-enyl (—CH₂CHCHCH₃).

Unless explicitly stated otherwise, the following letters, when contained as capital lettering in a formula, refer to atoms: H hydrogen, C carbon, F fluorine, N nitrogen, O oxygen, S sulphur, P phosphorus. CHO designates a formyl moiety. NHCONH₂ designates an ureido moiety.

A first aspect of the invention relates to a compound characterized by a general formula (100)

wherein

E is selected from H, —COR^(E), —CONHR^(E), —CON(OH)R^(E) and unsubstituted C₁ to C₄ alkyl or amino- and/or hydroxyl-substituted C₂ to C₄ alkyl, wherein

-   -   R^(E) is H or an unsubstituted or amino- and/or         hydroxyl-substituted C₁ to C₆ alkyl (particularly R^(E) is H or         an amino- and/or hydroxyl-substituted C₁ to C₅ alkyl),         particularly wherein E is selected from H and         (S)-4-amino-2-hydroxybutyryl, (S)-3-amino-2-hydroxypropionyl,         —CON(OH)(CH₂)₂NH₂), (2R,3S)-2-hydroxy-4,5-diamino-pentanoyl, and         (2S,3R)-2,5-dihydroxy-4-aminopentanoyl;

V is selected from H and —CH₂D, wherein

-   -   D is selected from OH, NH₂, —NHCHO, NHR^(D) and —NHCONHR^(D),         wherein R^(D) is selected from H, OH, unsubstituted or amino-         and/or hydroxy-substituted C₁ to C₆ alkyl, particularly wherein         D is selected from OH, —NHCHO and —NHCONH₂;

U and W are selected from the following alternatives:

-   -   one of U and W is —R^(W) and the other one is selected from H,         F, OH, or     -   one of U and W is -OR′″ and the other one is H, or     -   one of U and W is F and the other one is H, both are H or both         are F, or     -   one of U and W is OH and the other one is H,     -   wherein         -   R^(W) is selected from an amino- and/or hydroxy-substituted             C₁ to C₆ alkyl, —CH₂(CH₂)_(n)NH(CH₂)₃NH₂ and             —CH₂(CH₂)_(n)R^(N), wherein n is selected from 1, 2 or 3,         -   R^(N) is selected from NXY and a moiety characterized by             formula (400)

wherein

-   -   -   X and Y are independently selected from H, and unsubstituted             or amino- and/or hydroxyl-substituted C₁ to C₃ alkyl,             particularly from H and CH₃, CH₂CH₃ and —CH₂CH₂OH or             —CH₂CH₂NH₂ and Z is selected from O, NX (where X has the             same meaning as indicated above in this paragraph) and CH₂,

    -   or

    -   one of U and W (particularly W) is described by a moiety         characterized by formula (300), (301), (304) or (305) and the         other one of U and W is H

-   -   wherein R″ is selected from H and an amino- and/or         hydroxy-substituted C₁ to C₆ alkyl,     -   particularly wherein one of U and W (particularly W) is

with the proviso that the molecule is not described by the following combination of parameters:

-   -   D is OH, U is H and W is OH.

Furthermore, with effect to certain countries not including Australia, Brazil, Mexico, Singapore, the USA, and Ukraine, the following compounds are disclaimed:

-   -   V and U are H and W is OH,     -   D is OH, U is H and W is —O(CH₂)₂NH₂,     -   D is OH, U is H and W is a moiety characterized by formula         (302).

In certain embodiments, V is —CH₂OH.

In certain embodiments, V is H.

In certain embodiments, V is selected from —CH₂NHCHO and —CH₂NHCONH₂.

In certain embodiments, V is —CH₂NHR^(D) and R^(D) has the same meaning as indicated above.

In certain embodiments, E is H or —COR^(E), wherein R^(E) is an amino- and/or hydroxy-modified C₁ to C₅ alkyl.

In certain embodiments, one of U and W is —R^(W) and the other one is selected from H, F and OH, wherein R^(W) has the same meaning as indicated above.

In certain embodiments, one of U and W is —OR^(W) and the other one is H, wherein R^(W) has the same meaning as indicated above.

In certain embodiments, one of U and W is —OR^(W), with R^(W) being selected from (CH₂)₂OH, (CH₂)₂NH₂, (CH₂)₂NMe₂, (CH₂)₂NEt₂, (CH₂)₂NHMe, (CH₂)₂NHEt, (CH₂)₃OH, (CH₂)₃NH₂, (CH₂)₃NMe₂, (CH₂)₃NEt₂, (CH₂)₃NHMe, (CH₂)₃NHEt, CH₂CHOHCH₂OH, CH₂CHOHCH₂NH₂, CH₂CHOHCH₂NMe₂, CH₂CHOHCH₂NEt₂, CH₂CHOHCH₂NHMe and CH₂CHOHCH₂NHEt.

In certain embodiments, one of U and W is —R^(W), with R^(W) being selected from (CH₂)₂OH, (CH₂)₂NH₂, (CH₂)₂NMe₂, (CH₂)₂NEt₂, (CH₂)₂NHMe, (CH₂)₂NHEt, (CH₂)₃OH, (CH₂)₃NH₂, (CH₂)₃NMe₂, (CH₂)₃NEt₂, (CH₂)₃NHMe, (CH₂)₃NHEt, CH₂CHOHCH₂OH, CH₂CHOHCH₂NH₂, CH₂CHOHCH₂NMe₂, CH₂CHOHCH₂NEt₂, CH₂CHOHCH₂NHMe and CH₂CHOHCH₂NHEt.

In certain embodiments, one of U and W is F and the other one is H, both are H or both are F.

In certain embodiments, one of U and W is OH and the other one is H.

In certain embodiments, W is —R^(W) and U is selected from H, F, OH; or W is —OR^(W) and U is H, wherein R^(W) has the same meaning as indicated above.

In certain embodiments, the compound is characterized by a general formula (110)

wherein R^(AP) designates a moiety described by formula (2)

E has the meaning as defined above in the broadest sense, or in more narrowly defined embodiments of E;

V is selected from H and —CH₂D, wherein

-   -   D is selected from OH, NH₂, —NHCHO and —NHCONHR^(D), wherein         R^(D) is selected from H, OH, unsubstituted or amino- and/or         hydroxy-substituted C₁ to C₃ alkyl, particularly wherein D is         selected from OH, —NHCHO and —NHCONH₂;

W is F and U is selected from OH and F and

denotes the position where the apramycin backbone is attached to the compound described by general formula (110).

In certain embodiments, the compound is characterized by a general formula (112), (113) or (114)

wherein U is selected from OH and F and n, R^(AP), R″, R^(N) and V have the same meaning as indicated above.

In certain embodiments, E is H, V is —CH₂NHCHO, U is H and W is OH [5-O-β-(5′″-Formamido-5′″-deoxy-D-ribofuranosyl) apramycin DCWSU177].

In certain embodiments, the compound is characterized by the general formula

-   -   a. (112), wherein E is H, R^(N) is OH, V is CH₂OH and n is 1         [5-O-β-[3′″-O-(2-hydroxyethyl)-D-ribofuranosyl] apramycin;         DCWSU178];     -   b. (112), wherein E is H, R^(N) is NH₂, V is CH₂NH₂ and n is 1         [5-O-β-[5-amino-3-O-(2-aminoethyl)-5-deoxy-D-ribofuranosyl]         apramycin; DCWSU185];     -   c. (112), wherein E is H, V is CH₂NHCOH, R^(N) is NH₂ and n is 1         [5-O-β-[3-O-(2-aminoethyl)-5-deoxy-5-formamido-D-ribofuranosyl]         apramycin; DCWSU186].

In certain embodiments, the compound is characterized by the general formula (100), wherein

-   -   a. E, U and V are H and W is —OR^(W), and R^(W) is selected from         (CH₂)₂OH, (CH₂)₂NH₂, (CH₂)₂NMe₂, (CH₂)₂NEt₂, (CH₂)₂NHMe,         (CH₂)₂NHEt, (CH₂)₃OH, (CH₂)₃NH₂, (CH₂)₃NMe₂, (CH₂)₃NEt₂,         (CH₂)₃NHMe, (CH₂)₃NHEt, CH₂CHOHCH₂OH, CH₂CHOHCH₂NH₂,         CH₂CHOHCH₂NMe₂, CH₂CHOHCH₂NEt₂, CH₂CHOHCH₂NHMe and         CH₂CHOHCH₂NHEt;     -   b. E and U are H, V is CH₂OH and W is a moiety described by         formula (300), with R″ selected from H, (CH₂)₂OH, (CH₂)₂NH₂,         (CH₂)₂NMe₂, (CH₂)₂NEt₂, (CH₂)₂NHMe and (CH₂)₃NHEt;     -   c. E and W are H, U is OH and V is selected from CH₂OH and         CH₂NH₂;     -   d. E is H, V is CH₂D with D being selected from OH, NH₂ and         —NHCHO, and one of

U and W is F, and the other one of U and W is H.

These compounds are claimed with effect in Australia, Brazil, Mexico, Singapore, the USA, and Ukraine: compounds according to formula (100), wherein U is H and

-   -   a. V is H and W is OH,     -   b. D is OH, U is H and W is O(CH₂)₂NH₂,     -   c. D is OH, U is H and W is a moiety characterized by formula         (302).

The intermediates in a synthesis for an apramycin derivative antibacterial drug:

-   -   a.         3-O-(2-azidoethyl)-5-O-benzyl-1,2-O-isopropylidene-α-D-ribofuranose         (E FIG. 1);     -   b.         3-O-(2-azidoethyl)-5-O-benzyl-1,2-di-O-(4-nitrobenzoyl)-α-D-ribofuranose         (F FIG. 1)     -   c.         5,6,2″,3″,6″-penta-O-acetyl-1,3,2′,4″-tetraazido-5-epi-6′,7′-oxazolidino-apramycin         (j; FIG. 12);     -   d.         6,2″,3″,6″-tetra-O-acetyl-1,3,2′,4″-tetraazido-5-epi-6′,7′-oxazolidino-apramycin         (k; FIG. 12)     -   e. 5,2″,3″,6″-tetra-O-acetyl-6-O-allyl-1,3,2′, 4″-tetraazido-6′,         7′-oxazolidino-apramycin (AK; FIG. 16)     -   f. 1,2,3-tri-O-acetyl-5-deoxy-5-phthalimido-α-D-ribofuranose (I;         FIG. 5);     -   g. 2,3-di-O-acetyl-5-deoxy-5-phthalimido-D-ribofuranosyl         trichloroacetimidate (J; FIG. 5);     -   h.         3-O-(2-azidoethyl)-5-di(benzyloxycarbonyl)amino-5-deoxy-1,2-O-isopropylidene-α-D-ribofuranose         (P; FIG. 7)     -   i.         3-O-(2-azidoethyl)-5-di(benzyloxycarbonyl)amino-5-deoxy-1,2-di-O-(p-nitrobenzoyl)-60         /β-D-ribofuranose (Q; FIG. 7);     -   and with effect for Australia, Brazil, Mexico, Singapore, the         USA, and Ukraine:     -   j. 6,2″, 3″, 6″-tetra-O-acetyl-1,3,2′, 4″-tetraazido-6′,         7′-oxazolidino-apramycin (A; FIG. 17)

According to another aspect, the invention relates to a compound characterized by a general formula (200)

wherein A or B or G is OR¹, and

-   -   if one of A and B is OR¹, the other is H and G is OH, or     -   if G is OR¹, one of A and B is OH and the other one is H,         wherein R¹ is an unsubstituted C₁ to C₆ alkyl or an amino-         and/or hydroxy-substituted C₂ to C₆ alkyl, particularly R¹ is an         amino- and/or hydroxy-substituted or C₂ to C₆ alkyl, more         particularly R¹ is selected from 3-aminopropyl (CH₂)₃NH₂,         3-hydroxypropyl (CH₂)₃OH, 2-hydroxy-3-aminopropyl         CH₂CH(OH)CH₂NH₂, and 2,3-dihydroxypropyl CH₂CH(OH)CH₂OH;     -   or

wherein one of A and B is F and the other one is H, or A and B together form a carbonyl oxygen (see compound AF in FIG. 13), and G is OH;

E is selected from H, —COR^(E), —CONHRE, —CON(OH)R^(E) and unsubstituted C₁ to C₄ alkyl or amino- and/or hydroxyl-substituted C₂ to C₄ alkyl, wherein

-   -   R^(E) is H or an unsubstituted or amino- and/or         hydroxyl-substituted C₁ to C₆ alkyl (particularly R^(E) is H or         an amino- and/or hydroxyl-substituted C₁ to C₅ alkyl),         particularly E is selected from H and         (S)-4-amino-2-hydroxybutyryl, (S)-3-amino-2-hydroxypropionyl,         —CON(OH)(CH₂)₂NH₂), (2R,3S)-2-hydroxy-4,5-diamino-pentanoyl, and         (2S,3R)-2,5-dihydroxy-4-aminopentanoyl;

with the proviso that that the molecule is not described by any one of the following combination of parameters:

-   -   A and G are OH and B and E are H,     -   A and G are OH, B is H and E is unsubstituted C₁ to C₄ alkyl or         amino- and/or hydroxyl-substituted C₂ to C₄ alkyl,     -   A and G are OH, B is H and E is —COC(OH)(CH₂)₂NH₂     -   A, B and E are H and G is OH,     -   A and E are H and B and G are OH     -   A and E are H, B is F and G is OH.

Furthermore, with effect to certain countries not including Australia, Brazil, Mexico, Singapore, the USA, and Ukraine, the following compounds are disclaimed:

-   -   B is H, G is OH and A is selected from —OCH₂CH₂EtOH,         —OCH₂CHOHCH₂OH (glyceryl), and —OEt.

In certain embodiments of this aspect of the invention, one of A and B is F.

In certain embodiments of this aspect of the invention, one of A and B is —OR¹, wherein R¹ has the meaning as indicated above.

In certain embodiments of this aspect of the invention, G is —OR¹.

In certain embodiments of this aspect of the invention, E is H or —COR^(E), wherein R^(E) is an amino- and/or hydroxy-modified C₁ to C₅ alkyl.

In certain embodiments of this aspect of the invention, E is H and:

-   -   a. A is F, B is H and G is OH;     -   b. B is H, G is OH and A is —OR¹, with R¹ being selected from         (CH₂)₂OH, CH₂CH₂CH₃, (CH₂)₂NH₂, (CH₂)₂NMe₂, (CH₂)₂NEt₂,         (CH₂)₂NHMe, (CH₂)₂NHEt, (CH₂)₃OH, (CH₂)₃NH₂, (CH₂)₃NMe₂,         (CH₂)₃NEt₂, (CH₂)₃NHMe, (CH₂)₃NHEt, CH₂CHOHCH₂OH, CH₂CHOHCH₂NH₂,         CH₂CHOHCH₂NMe₂, CH₂CHOHCH₂NEt₂, CH₂CHOHCH₂NHMe and         CH₂CHOHCH₂NHEt;

In certain embodiments of this aspect of the invention, E is —COCHOH(CH₂)₂NH₂, E is particularly (S)-2-hydroxy-4-aminobutyl, and:

-   -   a. G is OH and A and B are selected from the alternatives: A is         H and B is F or A is H and B is OH or A is F and B is H or A and         B are both H or A and B together form a carbonyl O;     -   b. B is H, G is OH and A is —OR¹, with R¹ being selected from         (CH₂)₂OH, CH₂CH₂CH₃, (CH₂)₂NH₂, (CH₂)₂NMe₂, (CH₂)₂NEt₂,         (CH₂)₂NHMe, (CH₂)₂NHEt, (CH₂)₃OH, (CH₂)₃NH₂, (CH₂)₃NMe₂,         (CH₂)₃NEt₂, (CH₂)₃NHMe, (CH₂)₃NHEt, CH₂CHOHCH₂OH, CH₂CHOHCH₂NH₂,         CH₂CHOHCH₂NMe₂, CH₂CHOHCH₂NEt₂, CH₂CHOHCH₂NHMe and         CH₂CHOHCH₂NHEt     -   c. A is OH, B is H, and G is —OR¹, with R¹ being selected from         (CH₂)₂OH, (CH₂)₂NH₂, (CH₂)₂NMe₂, (CH₂)₂NEt₂, (CH₂)₂NHMe,         (CH₂)₂NHEt, (CH₂)₃OH, (CH₂)₃NH₂, (CH₂)₃NMe₂, (CH₂)₃NEt₂,         (CH₂)₃NHMe, (CH₂)₃NHEt, CH₂CHOHCH₂OH, CH₂CHOHCH₂NH₂,         CH₂CHOHCH₂NMe₂, CH₂CHOHCH₂NEt₂, CH₂CHOHCH₂NHMe and         CH₂CHOHCH₂NHEt.

An alternative aspect of the invention relates to a compound characterized by a general formula (201)

-   -   wherein E is selected from CO—R^(E), CONHR^(E), CON(OH)R^(E) and         unsubstituted C₁ to C₄ alkyl or amino- and/or         hydroxyl-substituted C₂ to C₄ alkyl, wherein     -   R^(E) is H or an unsubstituted or amino- and/or         hydroxyl-substituted C₁ to C₆ alkyl (particularly R^(E) is H or         an amino- and/or hydroxyl-substituted C₁ to C₅ alkyl),     -   particularly E is selected from H and         (S)-4-amino-2-hydroxybutyryl, (S)-3-amino-2-hydroxypropionyl,         —CON(OH)(CH₂)₂NH₂), (2R,3S)-2-hydroxy-4,5-diamino-pentanoyl, and         (2S,3R)-2,5-dihydroxy-4-aminopentanoyl.

In certain embodiments, the compound is characterized by one of the following structures:

Another aspect of the invention relates to the use of a compound according to any of the previously described aspects and embodiments, or combinations of their particular features, in the therapy of bacterial infection by systemic administration. The skilled artisan is aware that on the basis of the data provided and the general description, certain compounds can be identified that show advantageous selectivity for bacterial, rather than eukaryotic mitochondrial, ribosomes. This aspect of the invention alternatively relates to a method of treatment of a patient suffering from bacterial infection and comprises systemic administration of an effective amount of a compound as defined in the present application.

Infections in which the compounds of the invention are of particular therapeutic interest include those caused by pathogens comprised in the family Enterobacteriaceae, particularly in the genera Enterobacter, Escherichia and Klebsiella, or caused by pathogens selected from a genus comprised in the group of Acinetobacter, Mycobacteria, Pseudomonas and Staphylococcus.

Another aspect of the invention relates to a compound for use in the therapy of bacterial infection, particularly by systemic administration, wherein the infection is caused by a pathogen carrying the AAC(3)-IV resistance determinant, and wherein the compound is characterized by a general formula (100) or (200).

The compounds disclaimed above have not been shown to provide advantages in treatment of pathogens carrying the resistance determinant AAC(3)-IV. Therefore, these compounds are not excluded from the compounds useful in the therapy of bacterial infection caused by a pathogen carrying the AAC(3)-IV resistance determinant, particularly by systemic administration. These compounds are selected from

a. a compound defined by formula (100), wherein

-   -   i. D is OH, U is H and W is OH;     -   ii. V and U are H and W is OH;     -   iii. D is OH, U is H and W is O(CH₂)₂NH₂;     -   iv. D is OH, U is H and W is a moiety characterized by formula         (302); and

b. a compound defined by formula (200), wherein

-   -   i. A and G are OH, B is H and E is unsubstituted C₁ to C₄ alkyl,         or amino- and/or hydroxyl-substituted C₂ to C₄ alkyl;     -   ii. A and G are OH, B is H and E is COC(OH)(CH₂)₂NH₂;     -   iii. A, B and E are H and G is OH;     -   iv. A and E are H and B and G are OH;     -   v. A and E are H, B is F and G is OH; and     -   vi. B is H, G is OH and A is selected from —OCH₂CH₂EtOH,         —OCH₂CHOHCH₂OH (glyceryl), and —OEt.

The same compounds as included in the preceding paragraph are also useful for infections caused by a pathogen, selected from a genus comprised in the group of Enterobacter, Klebsiella, Acinetobacter, and Mycobacteria.

A particular aspect of the invention relates to the use of a compound defined by formula (100),

-   -   wherein V is CH₂NH₂, W is —OR^(W), and     -   R^(W) is selected from (CH₂)₂OH, (CH₂)₂NH₂, (CH₂)₂NMe₂,         (CH₂)₂NEt₂, (CH₂)₂NHMe, (CH₂)₂NHEt, (CH₂)₃OH, (CH₂)₃NH₂,         (CH₂)₃NMe₂, (CH₂)₃NEt₂, (CH₂)₃NHMe, (CH₂)₃NHEt, CH₂CHOHCH₂OH,         CH₂CHOHCH₂NH₂, CH₂CHOHCH₂NMe₂, CH₂CHOHCH₂NEt₂, CH₂CHOHCH₂NHMe         and CH₂CHOHCH₂NHEt,         -   particularly wherein R^(W) is selected from (CH₂)₂NH₂,             (CH₂)₂NMe₂, (CH₂)₂NEt₂, (CH₂)₂NHMe, (CH₂)₂NHEt, (CH₂)₃NH₂,             (CH₂)₃NMe₂, (CH₂)₃NEt₂, (CH₂)₃NHMe, (CH₂)₃NHEt,             CH₂CHOHCH₂NH₂, CH₂CHOHCH₂NMe₂, CH₂CHOHCH₂NEt₂,             CH₂CHOHCH₂NHMe and CH₂CHOHCH₂NHEt, more particularly R^(W)             is selected from (CH₂)₂NH₂ and (CH₂)₃NH₂,     -   U is H and E is defined as above in the broadest definition,         particularly wherein E is selected from H and CO—R^(E), wherein         R^(E) is a C₁ to C₆ unsubstituted or amino- and/or         hydroxyl-substituted alkyl, more particularly E is selected from         H and (S)-4-amino-2-hydroxybutyryl,         (S)-3-amino-2-hydroxypropionyl, —CON(OH)(CH₂)₂NH₂),         (2R,3S)-2-hydroxy-4,5-diamino-pentanoyl, and         (2S,3R)-2,5-dihydroxy-4-aminopentanoyl,

in the therapy of bacterial infection, wherein the infection is caused by a pathogen comprised in the family Enterobacteriaceae, particularly in the genera Enterobacter, Escherichia and Klebsiella, or selected from a genus comprised in the group of Acinetobacter, Mycobacteria, Pseudomonas and Staphylococcus.

The position O5 modifications of apramycin with a β-D-ribofuranosyl group carrying a basic substituent at the ultimate 3′″-position are suitable modifications to the parent enabling the reduction of toxicity and surmounting the effect of the AAC(3)-IV resistance determinant. These modifications are suitable for use either alone or in combination with other tolerated aminoglycoside modifications designed to surmount other resistance mechanisms and/or reduce toxicity.

Similarly, the invention relates to a dosage form for the prevention or treatment of bacterial infection, the dosage form comprising an apramycin derived antibacterial drug according to one of the above aspects of the invention. Dosage forms may be for enteral administration, such as nasal, buccal, rectal, transdermal or oral administration, or as an inhalation form or suppository. Alternatively, parenteral administration may be used, such as subcutaneous, intravenous, intrahepatic or intramuscular injection forms. Optionally, a pharmaceutically acceptable carrier and/or excipient may be present.

Topical administration is also within the scope of the advantageous uses of the invention. The skilled artisan is aware of a broad range of possible recipes for providing topical formulations, as exemplified by the content of Benson and Watkinson (Eds.), Topical and Transdermal Drug Delivery: Principles and Practice (1st Edition, Wiley 2011, ISBN-13: 978-0470450291); and Guy and Handcraft: Transdermal Drug Delivery Systems: Revised and Expanded (2^(nd) Ed., CRC Press 2002, ISBN-13: 978-0824708610); Osborne and Amann (Eds.): Topical Drug Delivery Formulations (1st Ed. CRC Press 1989; ISBN-13: 978-0824781835).

Wherever alternatives for single separable features such as, for example, substituents A, B and D are laid out herein as “embodiments”, it is to be understood that such alternatives may be combined freely to form discrete embodiments of the invention disclosed herein.

The invention is further illustrated by the following examples and figures, from which further embodiments and advantages can be drawn. These examples are meant to illustrate the invention but not to limit its scope.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1 to 11 show the synthesis of exemplary compounds of the invention that are ribosylated at position 5.

FIGS. 12 to 14 show the synthesis of exemplary compounds of the invention that are modified at position 5.

FIG. 15 shows the synthesis of exemplary compounds of the invention that are modified at position 5 and at position 1-N.

FIG. 16 shows the synthesis of exemplary compounds of the invention that are modified at position 6.

FIG. 17 shows the synthesis of key intermediate compound 5-OH apramycin.

EXAMPLES Example 1 General Methods and Materials

All reagents and solvents were purchased from commercial suppliers and were used without further purification unless otherwise specified. Chromatographic purifications were carried out over silica gel. Analytical thin-layer chromatography was performed with pre-coated glass backed plates (w/UV 254) and visualized by UV irradiation (254 nm) or by staining with 25% H₂SO₄ in EtOH or ceric ammonium molybdate (ceric sulfate: (4.0 g); ammonium molybdate (10 g); H₂SO₄: 40 mL, H₂O: 360 mL) solution. Specific rotations were obtained using a digital polarimeter in the solvent specified at 589 nm and 23° C. on an Autopol III polarimeter (Rudolph Research Analytical, Hackettstown, N.J.) with a path length of 10 cm. Infrared spectra were recorded on a FT/IR instrument. High resolution mass spectra were recorded with an electrospray source coupled to a time-of-flight mass analyzer (Waters). ¹H, ¹³C and 2D NMR spectra were recorded on 400 MHz, 500 MHz or 600 MHz instruments as specified. Assignments in ¹H and ¹³C NMR were done by the assistance of H—H COSY, HSQC and/or HMBC experiments.

Chemistry: All syntheses were run under an atmosphere of nitrogen or argon. Solvents were dried and purified by standard techniques.

Minimal inhibitory concentrations (MIC) have been determined by broth microdilution assays (CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition. CLSI document M07-A10. Wayne, Pa.: Clinical and Laboratory Standards Institute; 2015.).

IC50 values for bacterial, human chimeric, and rabbit reticulocyte ribosomes have been determined by in-vitro translation assays as described previously (Proc. Nat. Ac. Sci USA 2012, 109(27):10984-10989).

Example 2 Apramycin Derivatives Active in the Presence of AAC(3) AMEs.

A) O5-ribosylated apramycin derivatives

Table 1 shows 5-ribosylated apramycin derivatives. Minimal inhibitory concentrations (MICs, pg/ml) against clinical isolates from Institute of Medical Microbiology, Univ. Zurich, and the IC50 values for bacterial, human mitochondrial and human cytosolic ribosomes are indicated.

Compounds 124 and 138, in which the β-D-ri bofuranosyl ring appended to the O5-position of apramycin is substituted with a basic residue at the 3′″-position show excellent antiribosomal and antibacterial activity even against the IMM clinical isolates carrying the gene for AAC(3)-IV. These compounds are distinct from the simple unsubstituted β-D-ribofuranosyl apramycin derivative (compound 131), which was described in 1981 by a Japanese group, and which shows no activity against the AAC(3)-IV carrying bacterial strains.

The introduction of a ribofuranosyl ring renders compound 124 and compound 138 susceptible to the APH(3′, 5″) resistance determinant, but modifications such as the inclusion of a 5″-formamido group as in compound 186 circumvent this problem. The introduction of a formamido group results in compounds that display increased selectivity for the bacterial ribosome over the mitochondrial (wild type and A1555G mutant) ribosomes, predictive of reduced ototoxicity.

In addition to its outstanding antibacterial profile, compound 124 shows excellent selectivity at the target level with only low activity against eukaryotic ribosomes, indicating that it will share and even improve on the toxicity profile of apramycin itself.

Compound 185 shows increased antibacterial potency not only against Enterobacteriaceae, but also and in particular for Pseudomonas, Acinetobacter, and Mycobacteria (Tables 4+5).

B) 5-OH manipulated apramycin derivatives

Table 2 shows 5-OH manipulated apramycin derivatives.

Examples include the manipulation of the 5-OH of apramycin by deoxygenation (compound 169), inversion (compound 161), substitution by a halogen atom (compound 170 and compound 168) or by alkylation.

Changes in the polarity or conformation of the substituent in position 5 (by oxygenation, inversion or substitution by a halogen atom) increase the antibacterial potency in comparison to the native apramycin. These compounds also circumvent the resistance mechamism apmA, a particular case in point being illustrated by compound 161.

Alkylation is expected to provide a similar effect as the ribosylation described above.

Minimal inhibitory concentrations (μg/ml) against clinical isolates from Institute of Medical Microbiology, Univ. Zurich, and the IC50 values for bacterial, human mitochondrial and human cytosolic ribosomes are indicated.

C) 6-OH manipulated apramycin derivatives

Table 3 shows apramycin derivatives in which the 6-OH of apramycin is manipulated by alkylation.

Compound 167 shows an increased target specificity for bacterial versus human rRNA.

The Minimal inhibitory concentrations (MICs, μg/ml) against clinical isolates from Institute of Medical Microbiology, Univ Zurich, and the IC50 values for bacterial, human mitochondrial and human cytosolic ribosomes are indicated.

Table 4 and 5 show the antibacterial activity of the compounds of the invention against bacterial reference strains (table 4) and against representative clinical isolates (table 5).

Table 6 shows the activity of the compounds of the invention against G1405-methylated 16S-rRNA.

Example 3 DCWSU123 and DCWSU124

See the synthetic scheme of FIG. 1.

3-O-(2-Azidoethyl)-5-O-benzyl-1,2-O-isopropylidenea-α-D-ribofuranose (E). 5-O-Benzyl-1,2-O-isopropylidene-α-D-ribofuranose (1.00 g, 3.57 mmol) was dissolved in dry THF (3 mL) and NaH (214 mg, 5.36 mmol) was added under argon. After stirring for 15 min, a solution of 2-azidoethyl tosylate (1.72 g, 7.14 mmol) in dry THF (3 mL) was added dropwise followed by stirring for 12 h. More NaH (150 mg, 3.75 mmol) and 2-azidoethyl tosylate (860 mg, 3.57 mmol) were added and stirring continued for 24 h. After completion, the reaction was quenched with methanol and concentrated in vacuo and the crude product was purified by column chromatography (eluent: 5% to 30% EtOAc/hexanes) to give E (974 mg, 78%) as a gum; [α]_(D) ²⁵==+71.2 (c=1.0); ¹H NMR (400 MHz, CDCl₃): δ 7.37-7.26 (m, 5H, ArH), 5.81 (d, J=3.8 Hz, 1H, H-1), 4.67-4.61 (m, 2H, H-2, PhCH₂), 4.55 (d, J=12.2 Hz, 1H, PhCH₂), 4.12 (ddd, J=9.0, 3.7, 2.1 Hz, 1H, H-4), 3.89-3.84 (m, 2H, H-3, H-5), 3.81 (dd, J=11.5, 2.2 Hz, 1H, OCH₂), 3.67-3.58 (m, 2H, OCH₂, H-5), 3.45 (ddd, J=13.3, 7.4, 3.5 Hz, 1H, CH₂N₃), 3.28 (ddd, J=13.3, 5.6, 3.5 Hz, 1H, CH₂N₃), 1.57 (s, 3H, CH₃), 1.35 (s, 3H, CH₃); ¹³C NMR (101 MHz, CDCl₃): δ 137.99 (Ar—C), 128.37 (Ar—C), 127.78 (Ar—C), 127.68 (Ar—C), 112.98 (CMe₂), 104.13 (C-1), 78.61 (C-2), 77.89 (C-3), 77.17 (C-4), 73.52 (PhCH₂), 69.38 (C-5), 67.65 (OCH₂), 50.59 (CH₂N₃), 26.69 (CH₃), 26.58 (CH₃); ESI-HRMS: m/z calcd for C₁₇H₂₃N₃O₅Na [M+Na]⁺ 372.1535, found 372.1533

3-O-(2-Azidoethyl)-5-O-benzyl-1,2-di-O-(4-nitrobenzoyl)-α-D-ribofuranose (F). A solution of E (822 mg, 2.36 mmol) in a 1:3 mixture of 1 N aqueous hydrochloric acid and p-dioxane (16 mL) was stirred for 1.5 h at ambient temperature then was concentrated and dried under reduce pressure. The residue was diluted with pyridine (40 mL) and treated with 4-dimethylaminopyridine (30 mg, 0.236 mmol) and p-nitrobenzoyl chloride (1.53 g, 8.26 mmol) at ambient temperature and stirred for 10 h. The reaction mixture was concentrated and the residue was purified by silica gel column chromatography (hexane: ethyl acetate 8:1 to 4:1). to give F as a white foam (643 mg, 1.06 mmol, 45%); [α]_(D) ²⁵ =+66.9 (c=1.0); ¹H NMR (600 MHz, CDCl₃) δ32 8.26 (s, 4H, ArH); 8.20 (d, J=8.8 Hz, ArH); 8.12 (d, J=8..8 Hz, ArH); 7.39-7.26 (m, 5H, ArH); 6.80 (d, J=4.4 Hz, 1H, H-1); 5.45 (dd, J=4.4 Hz, 6.6 Hz, 1H, H-2); 4.65 (d, J=11.7 Hz, 1H, PhCH); 4.58 (d, J=11.7 Hz, 1H, PhCH₂); 4.58 (m, 1H, H-4); 3.86 (dd, J=6.6 Hz, 2.9 Hz, 1H, H-3); 3.74-3.65 (m, 4H, H-5, CH₂CH₂N₃); 3.33 (m, 1H, CH₂CH₂N₃); 3.28 (m, 1H, CH₂CH₂N₃); ¹³C NMR (150 MHz, CDCl₃) δ=163.72, 163.56, 150.84, 150.79, 137.47, 131.00, 130.80, 128.55, 127.96, 127.70, 123.65 (18C, ArC.); 95.82 (C-1); 84.70 (C-4); 76.91 (C-3); 73.73 (PhCH₂); 73.14 (C-2); 70.33 (—CH₂CH₂N₃); 69.38 (C-5); 51.12 (CH₂CH₂N₃); ESI-HRMS: m/z calcd for C₂₈H₂₅N₅O₁₁Na [M+Na]⁺ 630.1448, found 630.1453.

5-O-α-[3′″-O-(2-Azidoethyl)-5′″-O-benzyl-2′″-O-(4-nitrobenzoyl)-D-ribofuranosyl]-6,2″, 3″, 6″-tetra-O-acetyl-1,3,2′, 4″-tetraazido-6′, 7′-oxazolidino-apramycin (Gα) and 5-O-β-[3′″-O-(2-Azidoethyl)-5′″-O-benzyl-2′″-O-(4-nitrobenzoyl)-D-ribofuranosyl]-6,2″, 3″, 6″-tetra-O-acetyl-1,3,2′, 4″-tetraazido-6′, 7′-oxazolidino-apramycin (Gβ) 3-O-(2-Azidoethyl)-5-O-benzyl-1,2-di-O-(4-nitrobenzoyl)-α-D-ribofuranose F (181 mg, 0.30 mmol) and apramycin derivative A (100 mg, 0.12 mmol) were charged to a round bottom flask, co-evaporated with toluene three times and dried in vacuo overnight. The flask was purged with argon and the mixture dissolved in dry DCM (1.5 mL) before cooling to 0° C., treatment with BF₃.OEt₂ (0.23 mL, 0.63 mmol) and stirring for 12 h. The reaction was quenched with triethylamine (0.2 mL), diluted with EtOAc and washed with aqueous NaHCO₃ and brine then concentrated. The crude product was purified using silica gel column chromatography (eluent: 20%-40% EtOAc/hexanes) to give Gα (35 mg, 23%) and Gβ (31 mg, 20%); α anomer: [α]_(D) ²⁵=+79.1 (c 1.1, DCM); ¹H NMR (600 MHz, CDCl₃): δ 8.32 (d, J=8.6 Hz, 2H, ArH), 8.23 (d, J=8.9 Hz, 2H, ArH), 7.36-7.29 (m, 5H, ArH), 5.68-5.65 (m, 1H, H-2′″), 5.56 (d, J=3.8 Hz, 1H, H-1′″), 5.38 (t, J=10.0 Hz, 1H, H-3″), 5.32 (d, J=3.8 Hz, 1H, H-1″), 5.15 (d, J=3.5 Hz, 1H, H-1), 4.94-4.87 (m, 3H, H-2″, H-6, H-8), 4.75 (dd, J=8.4, 3.1 Hz, 1H, H-6), 4.66 (dd, J=10.5, 3.1 Hz, 1H, H-5), 4.60 (d, J=11.9 Hz, 1H, CH₂Ph), 4.54 (d, J=12.0 Hz, 1H, CH₂Ph), 4.31 (dd, J=12.1, 1.8 Hz, 1H, H-6″), 4.25 (dt, J=7.0, 3.3 Hz, 1H, H-4′”), 4.21 (dd, J=12.2, 5.2 Hz, 1H, H-6″), 4.04 (dd, J=7.6, 5.1 Hz, 1H, H-3′″), 3.79 (dd, J=8.4, 3.0 Hz, 1H, H-7), 3.75-3.69 (m, 4H, H-4′, H-5, H-5′, H-5″), 3.68-3.62 (m, 1H, H-3), 3.62-3.57 (m, 3H, H-5′″, H-4′, OCH₂CH₂), 3.56-3.48 (m, 3H, H-1, H-4, OCH₂CH2), 3.29 (dt, J=12.8, 4.1 Hz, 1H, H-2′), 3.18 (t, J=4.9 Hz, 2H, OCH₂CH₂), 2.91 (s, 3H, NCH₃), 2.42 (dt, J=12.9, 4.4 Hz, 1H, H-2), 2.25 (dt, J=10.6, 4.3 Hz, 1H, H-3), 2.13 (s, 3H, COCH₃), 2.11 (s, 3H, COCH₃), 2.09 (m, 6H, COCH₃), 1.86 (q, J=11.5 Hz, 1H, H-3′), 1.55 (q, J=12.6 Hz, 1H, H-2); ¹³C NMR (151 MHz, CDCl₃): δ 170.3 (C═O), 169.9 (C═O), 169.8 (C═O), 164.3 (C═O), 156.9 (C═O), 150.9 (Ar—C), 137.5 (Ar—C), 134.6 (Ar—C), 131.1 (Ar—C), 128.5 (Ar—C), 127.9 (Ar—C), 127.8 (Ar—C), 123.8 (Ar—C), 102.8 (C-1′″), 97.8 (C-1), 95.0 (C-8), 94.2 (C-1″), 82.5 (C-5), 80.4 (C-4″), 80.1 (C-4), 77.2 (C-3′″), 73.6 (C-6), 73.6 (CH₂Ph), 71.3 (C-2′″), 70.7 (C-3′), 70.0 (C-2″), 69.9 (C-6), 69.9 (OCH₂CH₂), 68.9 (C-5′″), 68.7 (C-5″), 65.5 (C-5′), 65.2 (C-4′), 62.8 (C-6″), 60.2 (C-7′), 60.1 (C-4″), 58.3 (C-3), 58.1 (C-1), 56.7 (C-2′), 50.6 (OCH₂CH₂), 31.4 (C-2′), 30.3 (C-3), 29.8 (NCH₃), 21.2 (COCH₃), 20.8 (COCH₃), 20.8 (COCH₃), 20.7 (COCH₃); ESI-HRMS: m/z calcd. for C₅₁H₅₉N₁₇O₂₃ [M+Na]⁺ 1300.3867; found, 1300.3887; β anomer: [α]_(D) ²⁵=+70.8 (c 1.8, DCM); ¹H NMR (600 MHz, CDCl₃): δ 8.28 (d, J=8.6 Hz, 2H, ArH), 8.20 (d, J=8.7 Hz, 2H, ArH), 7.46-7.26 (m, 5H, ArH), 5.79 (d, J=3.4 Hz, 1H, H-1), 5.42 (t, J=10.0 Hz, 1H, H-3′″), 5.38 (s, 1H, H-1′″), 5.37 (d, J=3.8 Hz, 1H, H-1″), 5.23 (d, J=4.2 Hz, 1H, H-2′″), 4.92 (t, J=9.7 Hz, 1H, H-6), 4.86 (dd, J=10.3, 3.8 Hz, 1H, H-2″), 4.81 (d, J=4.4 Hz, 1H, H-8′), 4.76 (dd, J=7.5, 3.2 Hz, 1H, H-6′), 4.60 (d, J=11.9 Hz, 1H, CH₂Ph), 4.51 (d, J=11.9 Hz, 1H, CH₂Ph), 4.39 (dd, J=10.3, 3.2 Hz, 1H, H-5′), 4.33 (d, J=12.0 Hz, 1H, H-6″), 4.26-4.16 (m, 2H, H-6″, H-4′″), 4.14 (dd, J=7.1, 4.5 Hz, 1H, H-3′″), 3.84-3.71 (m, 3H, H-5, H-7′, H-5″), 3.71-3.52 (m, 8H, H-4, H-4′, H-4″, H-3, H-5′″, OCH₂CH₂), 3.47-3.37 (m, 1H, H-1), 3.17 (m, 2H, OCH₂CH₂), 3.09 (dt, J=12.8, 3.9 Hz, 1H, H-2′), 2.94 (s, 3H, NHCH₃), 2.41 (dt, J=12.9, 4.3 Hz, 1H, H-2), 2.19-1.99 (m, 13H, 4COCH₃, H-3′), 1.88 (q, J=11.8 Hz, 1H, H-3′), 1.57 (q, J=12.6 Hz, 1H, H-2); ¹³C NMR (151 MHz, CDCl₃): δ 170.4(C═O), 170.1(C═O), 169.8 (C═O), 169.7 (C═O), 163.8 (C═O), 157.1 (C═O), 150.8 (Ar—C), 137.7 (Ar—C), 134.5 (Ar—C), 131.1 (Ar—C), 130.9 (Ar—C), 128.5 (Ar—C), 127.8 (Ar—C), 127.7 (Ar—C), 123.7 (Ar—C), 123.6 (Ar—C), 106.9 (C-1′”), 97.3 (C-1), 96.4 (C-8′), 94.2 (C-1″), 82.0 (C-5), 80.5 (C-4′″), 77.8 (C-4), 76.8 (C-3′″), 75.7 (C-6), 75.0 (CH₂Ph), 73.4 (C-2′″), 71.0 (C-3″), 70.4 (C-2″), 70.2 (C-6′), 70.0 (OCH₂CH₂), 69.7 (C-5′″), 69.1 (C-5″), 65.9 (C-5′), 65.7 (C-4′), 62.9 (C-6″), 60.2 (C-7′), 60.1 (C-4″), 59.1 (C-3), 58.1 (C-1), 56.5 (C-2″), 50.6 (OCH₂CH₂), 31.3 (C-2), 30.1 (C-3′), 29.7(NCH₃), 20.9 (COCH₃), 20.8 (COCH₃), 20.7 (COCH₃), 20.7 (COCH3); ESI-HRMS: m/z calcd. for C₅₁H₅₉N₁₇O₂₃ [M+Na]⁺ 1300.3867; found, 1300.3835.

5-O-α-[3-O-(2-Aminoethyl)-D-ribofuranosyl] apramycin hexaacetate salt (DCWSU123). A stirred solution of compound Gα (30 mg, 0.02 mmol) in dioxane (0.5 mL) was treated with 3N NaOH (0.25 mL) and heated at 100° C. for 18 h. The reaction mixture was cooled to rt and neutralized with glacial acetic acid and concentrated in vacuo. The crude product was passed through a silica gel column (eluent: 50% methanol/DCM). The product-containing fractions was concentrated and dissolved in THF (0.6 mL) followed by the addition of 0.3N NaOH (0.3 mL) and 1M P(CH₃)₃ in THF (0.3 mL). The reaction mixture was stirred at 55° C. for 2 h then concentrated and purified by column chromatography (eluent: 5% to 50% ammonia/MeOH).

The product-containing fractions were concentrated, dissolved in dioxane:water:glacial acetic acid=1:2:0.2 (0.3 mL). Pd(OH)₂/C (0.5 equiv) was added and the reaction mixture was stirred at room temperature under 1 atm of hydrogen (balloon) for 4 h. After completion, the reaction mixture was filtered over Celite®, concentrated to dryness and dissolved in aqueous acetic acid solution (pH 4, 1 mL) before it was charged to a Sephadex column (CM Sephadex C-25). The column was flushed with D.I. water (20 mL), then eluted with a gradient of 0.1%-1.0% NH₄OH in D.I. water. The fractions containing the product were combined, acidified with glacial acetic acid and lyophilized to afford DCWSU123 (21 mg, 85%) as the peracetate salt in the form of a white solid; [α]_(D) ²⁵=+52.3 (c 1.1, H₂O); ¹H NMR (600 MHz, D₂O): δ 5.65 (d, J=3.4 Hz, 1H, H-1′), 5.33 (s, 1H, H-1″), 5.24 (d, J=4.4 Hz, 1H, H-1′″), 5.03 (d, J=8.4 Hz, 1H, H-8′), 4.40 (s, 1H, H-6′), 4.23-4.18 (m, 1H, H-2′″), 4.16 (q, J=3.6 Hz, 1H, H-4′″), 3.87-3.80 (m, 1H, H-4), 3.80-3.64 (m, 8H, H-3″, H-4′, H-5, H-5″, H-3′″, H-6″, OCH₂CH₂), 3.64-3.41 (m, 7H, H-6″, H-5′, H-6, H-5′″, H-2′, H-5′, H-2′″), 3.29-3.11 (m, 3H, H-1, H-3, H-7′), 3.05 (m, 3H, OCH₂CH₂, H-4″), 2.60 (s, 3H, NCH₃), 2.29-2.16 (m, 2H, H-2, H-3′), 1.91-1.80 (m, 1H, H-3′), 1.66-1.56 (m, 1H, H-2); ¹³C NMR (151 MHz, D₂O): δ 102.8 (C-1′″), 95.1 (C-1′), 94.4 (C-1″), 92.9 (C-8″), 84.3 (C-5), 83.2 (C-4′″), 78.4 (C-4), 78.0 (C-3′″), 71.6 (C-6), 70.9 (C-2′″), 70.3 (C-5″), 69.8 (C-2″), 68.7 (C-4′), 66.8 (OCH₂CH₂), 66.0 (C-5′), 62.8 (C-6′), 61.5 (C-5′″), 60.3 (C-6″), 59.5 (C-7′), 52.0 (C-4″), 50.0 (C-3), 48.6 (C-1′), 47.8 (C-2′), 39.1 (OCH₂CH₂), 30.1 (NCH₃), 29.2 (C-2), 27.0 (C-3′); ESI-HRMS: m/z calcd. for C₂₈H₅₅N₆O₁₅ [M+H]⁺ 715.3725; found, 715.3742.

5-O-β-(3′″-O-(2-Aminoethyl)-D-ribofuranosyl) apramycin hexaacetate salt (DCWSU124). Substrate Gβ (35 mg, 0.03 mmol) was deprotected in the same manner as compound Gα to yield DCWSU124 (30 mg, 95%) as a pentaacetate salt in the form of a white solid; [α]_(D) ²⁵=68.92 (c 0.5, H₂O); ¹H NMR (600 MHz, D₂O): δ 5.64 (d, J=3.6 Hz, 1H, H-1′), 5.28 (d, J=3.7 Hz, 1H, H-1″), 5.16 (s, 1H, H-1′″), 5.00 (d, J=8.5 Hz, 1H, H-8′), 4.37 (s, 1H, H-6′), 4.19 (d, J=2.9 Hz, 1H, H-2′″), 3.97-3.88 (m, 1H, H-4′″), 3.86-3.54 (m, 12H, H-4, H-3′′″, H-3″, H-5′″, H-6″, H-5″, H-4′, H-5, H-2′, OCH₂CH₂), 3.53-3.39 (m, 5H, H-2′, H-5′, H-5′″, H-2″, H-6), 3.31-3.21 (m, 1H, H-3), 3.18 (d, J=8.4 Hz, 1H, H-7′), 3.16-3.08 (m, 1H, H-1), 3.05 (t, J=10.3 Hz, 1H, H-4″), 3.01 (t, J=4.8 Hz, 2H, OCH₂CH₂), 2.57 (s, 3H, NHCH₃), 2.24 (dd, J=8.6, 4.0 Hz, 1H, H-2), 2.20-2.09 (m, 1H, H-3′), 1.84 (q, J=11.9 Hz, 1H, H-3′), 1.66-1.59 (m, 1H, H-2); ¹³C NMR (151 MHz, D₂O): δ 110.5 (C-1′″), 94.5 (C-1′), 94.3 (C-1″), 92.8 (C-8′), 84.9 (C-5), 81.0 (C-4′″), 77.0 (C-3′″), 75.8 (C-4), 73.2 (C-2′″), 72.5 (C-6), 70.2 (C-5″), 69.6 (C-2″), 69.5 (C-3″), 68.4 (C-4′), 66.0 (C-5′), 65.9 (OCH₂CH₂), 62.6 (C-6′), 61.0 (C-5′″), 60.2 (C-6″), 59.3 (C-7′), 51.9 (C-4″), 49.8 (C-3), 48.3 (C-1), 47.8 (C-2′), 39.2 (OCH₂CH₂), 30.0 (NCH₃), 28.5 (C-2), 26.7 (C-3); ESI-HRMS: m/z calcd. for C₂₈H₅₅N₆O₁₅ [M+H]⁺ 715.3725; found, 715.3690.

5-O-β-(3′″-O-(2-Aminoethyl)-D-ribofuranosyl) apramycin hexaacetate salt (DCWSU124). Substrate Gβ (35 mg, 0.03 mmol) was deprotected in the same manner as compound Gα to yield DCWSU124 (30 mg, 95%) as a pentaacetate salt in the form of a white solid; [α]_(D) ²⁵=68.92 (c 0.5, H2O); ¹H NMR (600 MHz, D₂O): δ 5.64 (d, J=3.6 Hz, 1H, H-1′), 5.28 (d, J=3.7 Hz, 1H, H-1″), 5.16 (s, 1H, H-1′″), 5.00 (d, J=8.5 Hz, 1H, H-8′), 4.37 (s, 1H, H-6′), 4.19 (d, J=2.9 Hz, 1H, H-2′″), 3.97-3.88 (m, 1H, H-4′″), 3.86-3.54 (m, 12H, H-4, H-3′″, H-3″, H-5′″, H-6″, H-5″, H-4′, H-5, H-2′, OCH₂CH₂), 3.53-3.39 (m, 5H, H-2′, H-5′, H-5′″, H-2″, H-6), 3.31-3.21 (m, 1H, H-3), 3.18 (d, J=8.4 Hz, 1H, H-7′), 3.16-3.08 (m, 1H, H-1), 3.05 (t, J=10.3 Hz, 1H, H-4″), 3.01 (t, J=4.8 Hz, 2H, OCH₂CH₂), 2.57 (s, 3H, NHCH₃), 2.24 (dd, J=8.6, 4.0 Hz, 1H, H-2), 2.20-2.09 (m, 1H, H-3′), 1.84 (q, J=11.9 Hz, 1H, H-3′), 1.66-1.59 (m, 1H, H-2); ¹³C NMR (151 MHz, D₂O): δ 110.5 (C-1′″), 94.5 (C-1′), 94.3 (C-1″), 92.8 (C-8′), 84.9 (C-5), 81.0 (C-4′″), 77.0 (C-3′″), 75.8 (C-4), 73.2 (C-2′″), 72.5 (C-6), 70.2 (C-5″), 69.6 (C-2″), 69.5 (C-3″), 68.4 (C-4′), 66.0 (C-5′), 65.9 (OCH₂CH₂), 62.6 (C-6′), 61.0 (C-5′″), 60.2 (C-6″), 59.3 (C-7′), 51.9 (C-4″), 49.8 (C-3), 48.3 (C-1), 47.8 (C-2′), 39.2 (OCH₂CH₂), 30.0 (NCH₃), 28.5 (C-2), 26.7 (C-3); ESI-HRMS: m/z calcd. for C₂₈H₅₅N₆O₁₅ [M+H]⁺ 715.3725; found, 715.3690.

Example 4 DCWSU131

See the synthetic scheme of FIG. 2.

5-O-β-[2′″,3′″,5′″-Tri-O-acetyl-D-ribofuranosyl]-6,2″, 3″, 6″-tetra-O-acetyl-1,3,2′, 4″-tetraazido-6′, 7′-oxazolidino-apramycin (C). A suspension of 2,3,5-tri-O-acetyl-D-ribofuranosyl trichloroacetimidate 125 (150 mg, 0.36 mmol), acceptor A (100 mg, 0.12 mmol) and activated 4 Å MS in dry DCM was stirred at rt for 1 h before cooling to 0° C. and addition of BF₃.OEt₂ (132 μL, 0.54 mmol). After 4 h of stirring at 0° C., the reaction was quenched with triethylamine (0.5 mL) and filtered through Celite®. The reaction mixture was diluted with EtOAc and washed with aqueous NaHCO₃ and brine then concentrated. The crude product was purified using silica gel column chromatography (eluent: 20%-40% EtOAc/hexanes) to give C α:β=1.9 (126 mg, 95%), further purification was done to give C (47 mg) as the 8-anomer in the form of a white solid with the remainder of the product isolated as a mixtures of anomers. [α]_(D) ²⁵=+47.2 (c 2.7, DCM); ¹H NMR (600 MHz, CDCl₃): δ 5.637 (d, J=3.5 Hz, 1H, H-1′), 5.43 (d, J=10.1 Hz, 1H, H-3″), 5.40 (d, J=2.3 Hz, 1H, H-1′″), 5.37 (d, J=3.8 Hz, 1H, H-1″), 5.11 (t, J=5.0 Hz, 1H, H-3′″), 5.07 (dd, J=4.9, 3.3 Hz, 1H, H-2′″), 4.92 (t, J=9.9 Hz, 1H, H-6), 4.85 (dd, J=10.4, 3.9 Hz, 1H, H-2″), 4.82 (d, J=4.6 Hz, 1H, H-8′), 4.76 (dd, J=7.4, 3.3 Hz, 1H, H-6′), 4.41 (dd, J=10.3, 3.3 Hz, 1H, H-5′), 4.32 (m, 2H, H-6″, H-5′″), 4.24 (q, J=4.0 Hz, 1H, H-4′″), 4.21 (dd, J=12.2, 5.4 Hz, 1H, H-6″), 4.09 (dd, J=12.1, 4.1 Hz, 1H, H-5′″), 3.79 (d, J=9.2 Hz, 1H, H-5), 3.77-3.64 (m, 4H, H-4, H-7′, H-4′, H-5″), 3.60-3.53 (m, 2H, H-4″, H-3), 3.46-3.38 (m, 1H, H-1), 3.22 (dt, J=12.9, 4.1 Hz, 1H, H-2′), 2.93 (s, 3H, NCH₃), 2.41 (dt, J=13.0, 4.5 Hz, 1H, H-2), 2.26-2.21 (m, 1H, H-3′), 2.20 (s, 3H, COCH₃), 2.14-2.02 (m, 18H, 6*COCH₃), 1.93 (q, J=11.7 Hz, 1H, H-3′), 1.58 (q, J=12.6 Hz, 1H, H-2); ¹³C NMR (151 MHz, CDCl₃): δ 170.8 (C═O), 170.4 (C═O), 170.2 (C═O), 169.8 (C═O), 169.6 (C═O), 169.5 (C═O), 169.5 (C═O), 157.0 (C═O), 106.1 (C-1′″), 97.4 (C-8′), 96.4 (C-1′), 94.0 (C-1″), 80.4 (C-5), 79.5 (C-4′″), 77.5 (C-4), 74.5 (C-6), 74.1 (C-2′″), 71.0 (C-6′), 70.9 (C-3′″), 70.3 (C-3″), 69.9 (C-2″), 69.1 (C-5″), 66.0 (C-5′), 65.7 (C-4′), 63.4 (C-5′″), 62.9 (C-6″), 60.2 (C-7′), 60.1 (C-4″), 59.1 (C-3), 58.1 (C-1), 56.6 (C-2′), 31.5 (C-2), 30.1 (NCH₃), 29.9 (C-3′), 20.8 (COCH₃), 20.8 (COCH₃), 20.7 (COCH₃), 20.7 (COCH₃), 20.7 (COCH₃), 20.4 (COCH₃), 20.4 (COCH₃); ESI-HRMS: m/z calcd. for C₄₁H₅₄N₁₃O₂₃ [M+H]⁺ 1118.3275; found, 1118.3234.

5-O-(β-D-Ribefuranosyl) apramycin pentaacetate salt (DCWSU131) A stirred solution of substrate C (47 mg, 0.04 mmol) in dioxane (0.5 mL) was treated with 3 N NaOH (0.25 mL) and heated at 100° C. for 12 h. The reaction mixture was cooled to rt and neutralized with glacial acetic acid before it was concentrated in vacuo. The crude product was purified through a silica gel column (eluent: 10-20% methanol/DCM). The product-containing fractions were concentrated, dissolved in dioxane:water:glacial acetic acid=1:2:0.2 (0.3 mL) and Pd/C (0.5 equiv) was added. The reaction mixture was stirred at room temperature under 1 atm of hydrogen (balloon) for 1 h. After completion, the reaction mixture was filtered over Celite® and the filtrate concentrated to dryness and dissolved in aqueous acetic acid solution (pH 4, 1 mL) before it was charged to a Sephadex column (CM Sephadex C-25). The column was flushed with D.I. water (20 mL), then eluted with a gradient of 0.1%-1.0% NH₄OH in D.I. water. The fractions containing the product were combined, acidified with glacial acetic acid and lyophilized to afford DCWSU131 (29 mg, 69%) as the pentaacetate salt in the form of a white solid [α]_(D) ²⁵=+66.25 (c 0.8, H₂O); ¹H NMR (600 MHz, D₂O): δ 5.66 (d, J=4.0 Hz, 1H, H-1′), 5.29 (d, J=3.8 Hz, 1H, H-1″), 5.14 (s, 1H, H-1′″), 5.01 (d, J=8.5 Hz, 1H, H-8′), 4.38 (s, 1H, H-6′), 4.00 (d, J=4.7 Hz, 1H, H-2′″), 3.98-3.93 (m, 1H, H-3′″), 3.86-3.74 (m, 3H, H-4′″, H-4, H-3′″), 3.74-3.63 (m, 5H, H-4′, H-5, H-5″, H-5′″, H-6″), 3.58 (dd, J=12.4, 4.4 Hz, 1H, H-6″), 3.53-3.41 (m, 5H, H-5′, H-2′, H-2″, H-6, H-5′″), 3.29-3.21 (m, 1H, H-3), 3.19 (dd, J=8.5, 2.4 Hz, 1H, H-7′), 3.12 (td, J=11.6, 4.3 Hz, 1H, H-1), 3.06 (t, J=10.4 Hz, 1H, H-4′″), 2.58 (s, 3H, NCH₃), 2.24 (dt, J=11.3, 3.1 Hz, 1H, H-2), 2.21-2.10 (m, 1H, H-3′), 1.92-1.81 (m, 1H, H-3′), 1.66-1.57 (m, 1H, H-2); ¹³C NMR (151 MHz, D₂O): δ 110.3 (C-1′″), 94.5 (C-1′), 94.3 (C-1″), 92.8 (C-8′), 84.9 (C-5), 82.3 (C-4′″), 75.9 (C-4), 75.1 (C-2′″) 72.5 (C-6), 70.2 (C-5″), 69.6 (C-2″), 69.6 (C-4′), 68.9 (C-3″), 68.4 (C-3′″), 66.0 (C-5′), 62.6 (C-6′), 60.8 (C-5′″), 60.2 (C-6″), 59.3 (C-7′), 52.0 (C-4″), 49.8 (C-3), 48.3 (C-1), 47.8 (C-2′), 30.0 (NCH₃), 28.6 (C-2), 26.7 (C-3′); ESI-HRMS: m/z calcd. for C₂₆H₄₉N₅NaO₁₅ [M+Na]⁺ 694.3123; found, 694.3122.

Example 5 DCWSU 138

See the synthetic scheme of FIG. 3.

p-Cresyl-2′,6′-diazido-2,5,3′4′-tetra(4-methoxybenzoyl)-1-thio-β-paromobioside (c). p-Cresyl-2′,6′-diazido-2,5,3′4′-tetra-O-acetyl-α-thioparomobioside a (375 mg, 0.59 mmol) was dissolved in dry methanol, then NaOMe (4.7 mg, 0.12 mmol) was added and the reaction mixture was stirred for 1.5 h. The reaction was quenched with glacial acetic acid and concentrated till dryness. The crude product was dissolved in pyridine (5 mL) and p-methoxybenzoyl chloride (802 mg, 4.72 mmol) was added followed by stirring for 48 h then diluting with EtOAc. The organic layer was washed with aqueous NaHCO₃ followed by brine, dried with Na₂SO₄, and concentrated. The crude product was purified via silica gel chromatography eluting with 10% to 40% EtOAc in hexanes to give c (398 mg, 76%) as a white solid; [α]_(D) ²⁵=−14.2 (c 13.2, DCM); ¹H NMR (600 MHz, CDCl₃): -δ 8.08 (d, J=8.8 Hz, 2H, ArH), 8.04 (d, J=8.8 Hz, 2H, ArH), 7.95 (d, J=8.8 Hz, 2H, ArH), 7.85 (d, J=8.9 Hz, 2H, ArH), 7.40 (d, J=8.0 Hz, 2H, ArH), 7.02 (d, J=7.8 Hz, 2H, ArH), 6.97-6.88 (m, 6H, ArH), 6.78 (d, J=8.9 Hz, 2H, ArH), 5.51 (d, J=4.5 Hz, 1H, H-1), 5.43 (t, J=4.9 Hz, 1H, H-2), 5.23 (t, J=2.8 Hz, 1H, H-3′), 5.16 (d, J=1.8 Hz, 1H, H-1′), 5.04 (d, J=1.8 Hz, 1H, H-4′), 4.78 (t, J=5.6 Hz, 1H, H-3), 4.68 (dd, J=12.0, 2.7 Hz, 1H, H-5), 4.56 (td, J=5.8, 5.2, 2.7 Hz, 1H, H-4), 4.50 (dd, J=12.1, 4.6 Hz, 1H, H-5′), 4.24 (ddd, J=8.5, 4.1, 1.9 Hz, 1H, H-5′), 3.87 (s, 3H, OCH₃), 3.85-3.73 (m, 9H, 3 OCH₃), 3.57 (dd, J=13.1, 8.4 Hz, 1H, H-6′), 3.41 (t, J=2.2 Hz, 1H, H-2′), 3.27 (dd, J=13.1, 4.0 Hz, 1H, H-6′), 2.22 (s, 3H, CH₃); 13C NMR (151 MHz, CDCl₃): δ 166.0 (C═O), 165.4 (C═O), 165.0 (C═O), 164.03 (C═O), 163.97 (Ar—C), 163.9 (Ar—C), 163.7 (Ar—C), 163.4 (Ar—C), 138.6 (Ar—C), 133.9 (Ar—C), 132.3 (Ar—C), 132.0 (Ar—C), 131.9 (Ar—C), 131.8 (Ar—C), 129.8 (Ar—C), 127.7 (Ar—C), 122.3 (Ar—C), 121.1 (Ar—C), 120.9 (Ar—C), 120.8 (Ar—C), 99.3 (C-1′), 88.2 (C-1), 81.2 (C-4), 76.7 (C-3), 74.5 (C-2), 74.2 (C-5′), 69.1 (C-3′), 65.7 (C-4′), 63.8 (C-5), 56.9 (C-2′), 55.52 (OCH₃), 55.46 (OCH₃), 55.4 (2 OCH₃), 50.8 (C-6′), 21.1 (CH₃); ESI-HRMS: m/z calcd. for C₅₀H₄₈N₆NaO₁₅S [M+Na]⁺ 1027.2796; found, 1027.2749.

p-Cresyl-2′,6′-diazido-2,5,3′4′-tetra(4-methoxybenzoyl)-β-thio-paromobiosyl S-oxide (d). A solution of compound c (198 mg, 0.2 mmol) in dry DCM (15 mL) was cooled to −78° C. before ozone gas was bubbled in for 5 min till the solution turned blue. The solution was then warmed to rt, concentrated and the crude product purified by gradient chromatography over silica gel (eluent: 40% EtOAc/hexanes) to give d (162 mg, 80%) as a white solid; [α]_(D) ²⁵=+60.0 (c 0.5, DCM); ¹H NMR (400 MHz, CDCl₃): δ 8.16 (d, J=9.0 Hz, 2H, ArH), 8.12-8.03 (m, 4H, ArH), 7.68 (d, J=9.0 Hz, 2H, ArH), 7.51 (d, J=8.2 Hz, 2H, ArH), 7.24 (d, J=7.9 Hz, 2H, ArH), 7.00 (d, J=9.0 Hz, 2H, ArH), 6.96 (d, J=4.3 Hz, 2H, ArH), 6.93 (d, J=4.4 Hz, 2H, ArH), 6.78 (d, J=9.0 Hz, 2H, ArH), 6.14 (dd, J=5.0, 1.9 Hz, 1H, H-2), 5.28 (d, J=1.6 Hz, 1H, H-1′), 5.23 (t, J=2.7 Hz, 1H, H-3′), 5.09-5.03 (m, 1H, H-4′), 5.00 (dd, J=7.1, 5.1 Hz, 1H, H-3), 4.90 (d, J=1.9 Hz, 1H, H-1), 4.76 (dd, J=11.3, 1.5 Hz, 1H, H-5), 4.64-4.52 (m, 2H, H-5, H-4), 4.28 (ddd, J=7.7, 4.4, 1.7 Hz, 1H, H-5′), 3.92 (s, 3H, OCH₃), 3.86 (s, 3H, OCH₃), 3.85 (s, 3H, OCH₃), 3.82 (s, 3H, OCH₃), 3.54 (dd, J=13.0, 8.1 Hz, 1H, H-6′), 3.42-3.36 (m, 1H, H-2′), 3.32 (dd, J=13.0, 4.5 Hz, 1H, H-6′), 2.30 (s, 3H, CH₃); ¹³C NMR (101 MHz, CDCl₃): δ 166.0 (C═O), 165.0 (C═O), 164.8 (C═O), 164.1 (C═O), 163.94 (Ar—C), 163.86 (Ar—C), 163.6 (Ar—C), 142.2 (Ar—C), 136.6 (Ar—C), 132.3 (Ar—C), 132.1 (Ar—C), 131.9 (Ar—C), 131.7 (Ar—C), 130.0 (Ar—C), 124.6 (Ar—C), 122.1 (Ar—C), 121.1 (Ar—C), 121.0 (Ar—C), 120.6 (Ar—C), 113.94 (Ar—C), 113.86 (Ar—C), 113.8 (Ar—C), 113.7 (Ar—C), 100.1 (C-1), 99.1 (C-1), 81.6 (C-4), 75.9 (C-3), 74.1 (C-5′), 70.1 (C-2), 69.1 (C-3′), 65.7 (C-4′), 62.7 (C-5), 56.7 (C-2′), 55.54 (OCH₃), 55.46 (OCH₃), 55.4 (OCH₃), 50.7 (C-6′); ESI-HRMS: m/z calcd. for C₅₀H₄₈N₆NaO₁₆S [M+Na]⁺1043.2745; found, 1043.2717.

5-O-β-[2″″,6″″-Diazido-2′″,5′″,3″″4″″-tetra(4-methoxybenzoyl) paromobiosyl]-6,2″,3″,6″-tetra-O-acetyl-1,3,2′,4″-tetraazido-6′,7′-oxazolidino-apramycin (e). A suspension of donor d (140 mg, 0.14 mmol), acceptor 124 (150 mg, 0.18 mmol) and activated 4 Å MS in dry DCM (2 mL) was stirred at rt for 1 h before addition of freshly distilled triflic anhydride (33 μL, 0.2 mmol). After 5 h of stirring at rt, the reaction was quenched with triethylamine (0.1 mL) and filtered through Celite® then concentrated in vacuo. The crude product was purified by flash column chromatography on silica gel (20% EtOAc/toluene) to afford e (113 mg, 48%) as a white foam; [α]_(D) ²⁵=+84.9 (c 0.3, DCM);¹H NMR (600 MHz, CDCl₃): δ 8.10-8.04 (m, 4H, ArH), 8.02 (d, J=8.9 Hz, 2H, ArH), 7.83 (d, J=8.9 Hz, 2H, ArH), 7.01-6.94 (m, 4H, ArH), 6.92 (d, J=8.9 Hz, 2H, ArH), 6.82 (d, J=9.0 Hz, 2H, ArH), 5.58 (d, J=3.5 Hz, 1H, H-1′), 5.44 (d, J=1.7 Hz, 1H, H-1′″), 5.39 (t, J=10.0 Hz, 1H, H-3″), 5.33 (d, J=3.8 Hz, 1H, H-1″), 5.24-5.18 (m, 2H, H-2′″, H-3″″), 5.14 (d, J=1.5 Hz, 1H, H-1″″), 5.07-5.04 (m, 1H, H-4′″), 4.89-4.80 (m, 4H, H-2′, H-5′″, H-6, H-8′), 4.77-4.72 (m, 2H, H-3′″, H-6′), 4.50-4.44 (m, 2H, H-4′″, H-5′″), 4.43 (dd, J=10.4, 3.3 Hz, 1H, H-5′), 4.32-4.26 (m, 2H, H-5″″, H-6″), 4.20 (dd, J=12.2, 5.4 Hz, 1H, H-6″), 3.87 (s, 3H, OCH₃), 3.85 (s, 3H, OCH₃), 3.83 (s, 3H, OCH₃), 3.81 (s, 3H, OCH₃), 3.75-3.68 (m, 3H, H-5, H-5″, H-7′), 3.64-3.49 (m, 4H, H-3, H-4′, H-4″, H-6″″), 3.41-3.30 (m, 4H, H-1, H-2″″, H-4, H-6″″), 3.12 (dt, J=12.9, 4.1 Hz, 1H, H-2′), 2.92 (s, 3H, NCH₃), 2.38 (dt, J=12.9, 4.4 Hz, 1H, H-2), 2.17-2.12 (m, 1H, H-3′), 2.11-2.07 (m, 9H, 3COCH₃), 2.03 (s, 3H, COCH₃), 1.88-1.81 (m, 1H, H-3′), 1.44 (q, J=12.6 Hz, 1H, H-2); ¹³C NMR (151 MHz, CDCl₃): δ 170.4 (C═O), 170.1 (C═O), 169.9 (C═O), 169.6 (C═O), 165.9 (C═O), 165.5 (C═O), 165.0(C═O), 164.1(C═O), 164.0 (Ar—C), 163.9 (Ar—C), 163.8 (Ar—C), 163.6 (Ar—C), 157.1(C═O), 132.3 (Ar—C), 132.1 (Ar—C), 131.8 (Ar—C), 122.2 (Ar—C), 121.1 (Ar—C), 121.0 (Ar—C), 120.7 (Ar—C), 113.9 (Ar—C), 113.9 (Ar—C), 113.9 (Ar—C), 113.8 (Ar—C), 106.8 (C-1′″), 99.3 (C-1″″), 96.9 (C-1′), 96.6 (C-8′), 94.1 (C-1″), 81.4 (C-5), 79.9 (C-4′″), 78.0 (C-4), 75.7 (C-3”), 74.9 (C-6), 74.5 (C-5′″), 74.2 (C-3”), 70.8 (C-3′″), 70.5 (C-6), 69.9 (C-2″), 69.2 (C-2′″), 69.0 (C-5″), 65.7 (C-4′″), 65.6 (C-5′), 63.0 (C-5′″), 62.9 (C-6″), 60.1 (C-7′, C-3), 58.8 (C-4″), 58.1 (C-1), 56.8 (C-2″″), 56.6 (C-2′), 55.5 (OCH₃), 55.5 (OCH₃), 50.7 (C-6″″), 31.2 (C-2′), 30.4 (C-3′), 30.0 (NCH₃), 21.0 (COCH₃), 20.8 (COCH₃), 20.8 (COCH₃), 20.7 (COCH₃); ESI-HRMS: m/z calcd. for C₇₃H₇₉N₁₉NaO₃₁ [M+Na]⁺ 1740.5087; found, 1740.5109.

5-O-β-(Paromobiosyl) apramycin heptaacetate salt (DCWSU138). A stirred solution of compound e (40 mg, 0.02 mmol) in dioxane (0.5 mL) was treated with 3N NaOH (0.5 mL) and heated at 120° C. for 2 h. The reaction mixture was cooled to rt and neutralized with glacial acetic acid before it was concentrated in vacuo. The crude product was purified with silica gel column chromatography (eluent: 5%-15% methanol/DCM) to give a residue that was directly subjected to Staudinger reaction by dissolving in THF (0.6 mL) followed by the addition of 0.3N NaOH (0.3 mL) and 1M P(CH₃)₃ in THF (0.3 mL). The reaction mixture was stirred at 55° C. for 2 h, then concentrated and purified by column chromatography (eluent: 5% to 50% ammonia/MeOH). The product-containing fractions were concentrated and dissolved in D.I. water (1 mL), acidified by glacial acetic acid till pH=3-4 and loaded to a Sephadex column (CM Sephadex C-25) from which the product was flushed with D.I. water (20 mL), then gradient elution of 0.1%-1.0% NH₄OH in D.I. water. The fractions containing the product were combined, acidified with glacial acetic acid and lyophilized to afford DCWSU138 (8 mg, 35%) as a peracetate salt in the form of a white foam; [α]_(D) ²⁵=+54.4 (c 0.5, H₂O);¹H NMR (600 MHz, D₂O): δ 5.68 (d, J=3.9 Hz, 1H, H-1′), 5.32 (d, J=3.9 Hz, 1H, H-1″), 5.22 (d, J=2.4 Hz, 1H, H-1′″), 5.10 (d, J=1.4 Hz, 1H, H-1″″), 5.03 (d, J=8.5 Hz, 1H, H-8′), 4.41 (s, 1H, H-6′), 4.31 (t, J=5.7 Hz, 1H, H-3′″), 4.21 (dd, J=3.8, 2.8 Hz, 1H, H-2′″), 4.15-4.09 (m, 1H, H-5″″), 4.08-4.00 (m, 2H, H-3″″, H-4′″), 3.83 (t, J=9.7 Hz, 1H, H-4), 3.79 (dt, J=10.2, 3.9 Hz, 1H, H-5″), 3.77-3.65 (m, 5H, H-5′″, H-3″, H-4′, H-5, H-6″), 3.65-3.58 (m, 2H, H-4″″, H-6″), 3.58-3.44 (m, 5H, H-6, H-2′, H-5′, H-2″, H-5′″), 3.39 (s, 1H, H-2″″), 3.32-3.25 (m, 1H, H-3), 3.25-3.19 (m, 2H, H-7′, H-6″″), 3.19-3.12 (m, 2H, H-1, H-6″″), 3.09 (t, J=10.3 Hz, 1H, H-4″), 2.60 (s, 3H, NCH₃), 2.27 (dt, J=11.8, 3.1 Hz, 1H, H-2), 2.22-2.13 (m, 1H, H-3′), 1.87 (dd, J=24.1, 11.8 Hz, 1H, H-3′), 1.64 (q, J=13.0 Hz, 1H, H-2); ¹³C NMR (151 MHz, D₂O): δ 110.1 (C-1′″), 95.3 (C-1″″), 94.5 (C-1′), 94.4 (C-1″), 92.8 (C-8′), 84.9 (C-5), 81.3 (C-4′″), 76.0 (C-4), 75.2 (C-3′″), 73.4 (C-2′″), 72.5 (C-2″), 70.2 (C-5″″), 70.1 (C-5″), 69.7 (C-6), 69.5 (C-5′), 68.4 (C-3″), 67.5 (C-3′″), 67.2 (C-4′″), 65.9 (C-4′), 62.6 (C-6′), 60.2 (C-5′″), 60.0 (C-6″), 59.3 (C-7′), 52.0 (C-4″), 50.7 (C-2″″), 49.8 (C-1), 48.4 (C-3), 47.8 (C-2′), 40.3 (C-6″″), 30.0 (NCH₃), 28.6 (C-2), 26.7 (C-3); ESI-HRMS: m/z calcd. for C₃₂H₆₂N₇O₁₈ [M+H]⁺ 832.4151; found, 832.4131.

Example 6 DCWSU146

See the synthetic scheme of FIG. 4.

Erythrolactone 2,3-di-O-benzoate (T). An aqueous solution of isoascorbic acid (7.04 g, 40 mmol) in water (100 mL) was ice-cooled and Na₂CO₃ (8.48 g, 80 mmol) was added slowly followed by aqueous solution of H₂O₂ (30%, 9.2 mL). The reaction mixture was stirred at 42° C. for 30 min after which charcoal (2 g) was added and the mixture stirred at 75° C. for 30 min to destroy excess H₂O₂. The reaction mixture was filtered while hot and neutralized with 6 N HCl then concentrated till dryness. The resulting residue was dissolved in dry pyridine (50 mL) and cooled to 0° C. before addition of benzoyl chloride dropwise (11.6 mL, 100 mmol). The reaction mixture was stirred at rt for 12 h before it was diluted with EtOAc and washed with aqueous NaHCO₃ and brine. The organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by gradient chromatography over silica gel (eluent: 10% to 35% EtOAc in hexanes) to give T (9.0 g, 69%) as a white solid; [α]_(D) ²⁵=−145.78 (c 1.2, DCM); ¹H NMR (400 MHz, CDCl₃): δ 7.97 (m, 4H), 7.65-7.50 (m, 2H, ArH), 7.41 (m, 2H, ArH), 7.35 (m, 2H, ArH), 6.07-5.95 (m, 2H, H-2, H-3), 4.73 (dd, J=11.4, 3.1 Hz, 1H, H-4), 4.65 (d, J=11.4 Hz, 1H, H-4); ¹³C NMR (101 MHz, CDCL3): δ 170.3 (C═O), 165.3 (ArC), 164.9 (ArC), 133.9 (ArC), 130.1 (ArC), 129.8 (ArC), 128.6 (ArC), 128.5 (ArC), 128.5 (ArC), 128.0 (ArC), 69.9 (C-4), 69.7 (C-2), 67.7(C-3); ESI-HRMS: m/z calcd. for C₁₈H₁₄NaO₆ [M+Na]⁺ 349.0688; found, 349.0691.

2,3-Di-O-benzoyl-α/β-D-erythrofuranose (U). A stirred solution of erythrolactone 2,3-di-O-benzoate T (1.00 g, 3.06 mmol) in dry THF was cooled to −78° C. and DIBAL (1 M in hexanes, 6 mL) was added. The mixture was stirred for 4 h before it was quenched with methanol (20 mL). The so-formed residue was filtered through Celite® and the filtrate was concentrated and dissolved in EtOAc. The organic layer was washed with aqueous NaHCO₃ and brine. The organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by gradient chromatography over silica gel (eluent: 10% to 25% EtOAc in hexanes) to give U (360 mg, 36%) as an α/β mixture (0.5:1) in the form of a gum; [α]_(D) ²⁵=−29.1 (c 0.3, DCM); ¹H NMR (400 MHz, CDCl₃): δ 8.18-8.01 (m, 2H, ArH), 8.00-7.93 (m, 2H, ArH), 7.92-7.84 (m, 2H, ArH), 7.57-7.42 (m, 2H, ArH), 7.42-7.24 (m, 7H, ArH), 5.90-5.78 (m, 1.5H, H-3b, H-3α), 5.74 (dd, J=7.2, 4.7 Hz, 0.5H, H-1α), 5.72-5.67 (m, 1H, H-1β), 5.59 (dd, J=5.3, 1.6 Hz, 1H, H-2β), 5.33 (dd, J=5.9, 4.7 Hz, 0.5H, H-2β), 4.72-4.63 (m, 1H, OH), 4.58 (dd, J=10.0, 6.0 Hz, 1H, H-4β), 4.37-4.26 (m, 1H, H-4α), 4.13 (dd, J=10.0, 4.2 Hz, 1H, H-4β); ¹³C NMR (101 MHz, CDCl₃): δ 165.8 (C═O), 165.7 (C═O), 133.5 (ArC), 133.5 (ArC), 133.4 (ArC), 133.4 (ArC), 133.3 (ArC), 130.00 (ArC), 139.95 (ArC), 129.9 (ArC), 129.83 (ArC), 129.79 (ArC), 129.7 (ArC), 129.18 (ArC), 129.15 (ArC), 128.6 (ArC), 128.51 (ArC), 128.45 (ArC), 128.41 (ArC), 128.36 (ArC), 100.4 (C-1β), 94.9 (C-1α), 77.0 (C-2β), 76.9 (C-2α), 72.3 (C-3β), 72.2 (C-3α), 69.9 (C-4β), 69.8 (C-4α); ESI-HRMS: m/z calcd. for C₁₈H₁₆NaO₆ [M+Na]⁺ 349.0688; found, 349.0691.

2,3-Di-O-benzoyl-β-D-erythrofuranosyl trichloroacetimidate (V). 2,3-O-Dibenzoyl-α-β-D-erythrofuranose (U) (360 mg, 1.10 mmol) and trichloroacetonitrile (2 mL) were dissolved in dry DCM (2 mL) and ice-cooled before addition of DBU (2 drops). The reaction mixture was stirred at rt for 5 min and concentrated. The crude mixture was passed through a silica gel column that had been basified with 0.5% triethylamine/hexanes, eluting with 0.5% triethylamine in EtOAc/hexanes to give compound V (458 mg, 88%) as a gum; [α]_(D) ²⁵=−78.9 (c 1.6, DCM); ¹H NMR (400 MHz, CDCl₃): δ 8.69 (s, 1H, NH), 8.05-7.97 (m, 2H, ArH), 7.93-7.86 (m, 2H, ArH), 7.54 (m, 2H, ArH), 7.40 (m, 2H, ArH), 7.32 (m, 2H, ArH), 6.58 (s, 1H, H-1), 5.94-5.84 (m, 2H, H-2, H-3), 4.66-4.58 (m, 1H, H-4), 4.30 (dd, J=9.8, 3.4 Hz, 1H, H-4); ¹³C NMR (101 MHz, CDCl₃): δ 165.6 (ArC), 165.1 (ArC), 160.8 (C═N), 133.6 (ArC), 133.4 (ArC), 129.9 (ArC), 129.7 (ArC), 128.9 (ArC), 128.8 (ArC), 128.5 (ArC), 128.4 (ArC), 103.2 (C-1), 77.2 (CCI₃), 75.5 (C-2), 71.8 (C-4), 71.5 (C-3); ESI-HRMS: m/z calcd. for C₂₀H₁₆Cl₃NaO₆ [M+Na]⁺ 493.9941; found, 493.9945.

5-O-β-[2′″,3′″-Di-O-benzoyl-D-eryth rofu ranosyl]-6,2″,3″,6″-tetra-O-acetyl-1,3,2′,4″-tetraazido-6′,7′-oxazolidino-apramycin (W). Donor V (109 mg, 0.36 mmol), acceptor A (100 mg, 0.12 mmol) and activated 4 Å MS were stirred in dry DCM (2.5 mL) at rt for 1 h before cooling to −78° C. BF₃.OEt₂(200 μL, 0.54 mmol) was added and reaction mixture was stirred for 3 h at −78° C. The reaction was quenched at −78° C. with triethylamine (0.5 mL) and filtered through Celite® before it was diluted with EtOAc. The organic layer was washed with NaHCO₃ and brine then concentrated. The crude product was purified using silica gel column chromatography (eluent: 0.4%-0.8% Methanol/DCM) to give the β anomer W (68 mg, 50%) in the form of a white solid; [α]_(D) ²⁵=+64.1 (c 4.5, DCM); ¹H NMR (400 MHz, CDCl₃): δ 7.90 (m, 4H, ArH), 7.53 (m, 2H, ArH), 7.35 (m, 4H, ArH), 5.63 (m, 2H, H-3′″, H-1′″), 5.54 (d, J=3.5 Hz, 1H, H-1′), 5.51 (dd, J=5.0, 1.4 Hz, 1H, H-2′″), 5.44 (t, J=10.0 Hz, 1H, H-3″), 5.39 (d, J=3.8 Hz, 1H, H-1″), 5.02 (t, J=9.9 Hz, 1H, H-6), 4.93-4.86 (m, 2H, H-2″, H-8′), 4.82 (dd, J=7.7, 3.3 Hz, 1H, H-6′), 4.62-4.50 (m, 2H, H-5′, H-4′″), 4.33 (dd, J=12.1, 1.9 Hz, 1H, H-6″), 4.23 (dd, J=12.2, 5.3 Hz, 1H, H-6″), 4.16 (dd, J=9.9, 4.9 Hz, 1H, H-4′″), 3.93 (t, J=9.2 Hz, 1H, H-5), 3.84-3.70 (m, 4H, H-4, H-4′, H-5″, H-7′), 3.70-3.54 (m, 2H, H-3, H-4″), 3.49 (ddd, J=12.5, 10.5, 4.3 Hz, 1H, H-1), 3.34 (dt, J=12.9, 4.1 Hz, 1H, H-2′), 2.94 (s, 3H, NCH₃), 2.47 (dt, J=12.9, 4.5 Hz, 1H, H-2), 2.33-2.23 (m, 1H, H-3′), 2.11 (m, 12H, 4COCH₃), 1.97 (q, J=11.8 Hz, 1H, H-3′), 1.65 (q, J=12.5 Hz, 1H, H-2); ¹³C NMR (101 MHz, CDCl₃): δ 170.4 (C═O), 170.2 (C═O), 169.8 (C═O), 169.6 (C═O), 165.5 (Ar—C), 165.3 (Ar—C), 157.0 (Ar—C), 133.6 (Ar—C), 133.4 (Ar—C), 129.6 (Ar—C), 129.0 (Ar—C), 128.9 (Ar—C), 128.5 (Ar—C), 128.4 (Ar—C), 106.4 (C-1′″), 97.4 (C-1′), 96.8 (C-8′), 94.1 (C-1″), 79.2 (C-5), 78.1 (C-4), 75.8 (C-2′″), 74.8 (C-6), 71.6 (C-3′″), 70.8 (C-6′), 70.6 (C-2″), 70.4 (C-4′″), 69.9 (C-3″), 69.1 (C-5″), 66.0 (C-5′), 65.6 (C-4′), 62.9 (C-6″), 60.2 (C-7′), 60.1 (C-3), 59.0 (C-4″), 58.2 (C-1), 56.5 (C-2′), 31.5 (C-2), 30.1 (NCH₃′), 29.7(C-3′) 20.9 (2COCH₃), 20.8 (COCH₃), 20.7 (COCH₃); ESI-HRMS: m/z calcd. for C₄₈H₅₃N₁₃NaO₂₁ ₆ [M+Na]⁺ 1170.3377; found, 1170.3353.

5-O-β-D-(Erythrofuranosyl) apramycin pentaacetate salt (DCWSU146). A stirred solution of compound W (60 mg, 0.02 mmol) in dioxane (1mL) was treated with 3N NaOH (1 mL) and heated at 100° C. for 2 h. The reaction mixture was cooled to 55° C. and 1M P(CH₃)₃ in THF (0.3 mL) was added and stirring continued for 2 h. The reaction mixture was neutralized with glacial acetic acid, concentrated in vacuo, the residue dissolved in aqueous acetic acid solution (pH 4, 1 mL) and was charged to a Sephadex column (CM Sephadex C-25). The column was flushed with D.I. water (20 mL), then gradient eluted with 0.1%-1.0% NH₄OH in D.I. water. The fractions containing the product were combined, acidified with glacial acetic acid, and lyophilized to afford compound DCWSU146 (35 mg, 71%) as the peracetate salt in the form of a white solid; [α]_(D) ²⁵=+58.71 (c 2.3, H₂O); ¹H NMR (600 MHz, D₂O): δ 5.67 (d, J=4.1 Hz, 1H, H-1′), 5.28 (d, J=3.9 Hz, 1H, H-1″), 5.18 (d, J=3.8 Hz, 1H, H-1′″), 5.00 (d, J=8.5 Hz, 1H, H-8′), 4.38 (s, 1H, H-6′), 4.16 (q, J=4.4 Hz, 1H, H-3′″), 4.04 (dd, J=9.6, 4.9 Hz, 1H, H-4′″), 3.98 (t, J=4.2 Hz, 1H, H-2′″), 3.85 (t, J=9.7 Hz, 1H, H-4), 3.77 (dt, J=10.2, 3.9 Hz, 1H, H-5″), 3.74-3.65 (m, 3H, H-4′, H-5, H-3″), 3.74-3.65 (m, 2H, H-4′″, H-6″), 3.57 (dd, J=12.5, 4.5 Hz, 1H, H-6″), 3.54-3.43 (m, 4H, H-2′, H-2″, H-5′, H-6), 3.34-3.27 (m, 1H, H-3), 3.18 (dd, J=8.5, 2.7 Hz, 1H, H-7′), 3.13 (td, J=12.0, 4.2 Hz, 1H, H-1), 3.08 (t, J=10.4 Hz, 1H, H-4″), 2.57 (s, 3H, NCH₃), 2.26 (dt, J=12.5, 4.1 Hz, 1H, H-2), 2.16 (dt, J=9.7, 4.4 Hz, 1H, H-3′), 1.86-1.80 (m, 1H, H-3′), 1.65 (q, J=12.6 Hz, 1H, H-2); ¹³C NMR (151 MHz, D₂O): δ 110.0 (C-1″), 94.3 (C-1′), 93.9 (C-1″), 92.7 (C-8′), 84.4 (C-5), 75.6 (C-2′″), 75.1 (C-4), 72.4 (C-6), 71.4 (C-4′″), 70.1 (C-5″), 69.6 (C-2″), 69.6 (C-4′), 69.3 (C-3″), 68.1 (C-3′″), 65.7 (C-5′), 62.5 (C-6′), 60.2 (C-6″), 59.2 (C-7′), 51.9 (C-4″), 49.4 (C-3), 48.4 (C-1), 47.4 (C-2′), 29.9 (NCH₃), 28.0 (C-2), 26.8 (C-3′); ESI-HRMS: m/z calcd. for C₂₅H₄₈N₅O₁₄ [M+H]⁺ 642.3198; found, 642.3182.

Example 7 DCWSU 161, 170, 168, and 169

See the synthetic scheme of FIG. 12.

5,6,2″,3″,6″-Penta-O-acetyl-1,3,2′,4″-tetraazido-5-epi-6′,7′-oxazolidino-apramycin (j). To a stirred solution of compound A (100 mg, 0.12 mmol) in dry DCM (1.5 mL), pyridine (0.1 mL) was added and reaction mixture was cooled to 0° C. before triflic anhydride (40 μL, 0.24 mmol) was added. The reaction mixture was stirred for 1 h and additional triflic anhydride (40 μL, 0.24 mmol) was added. After 2 h, the reaction mixture was poured into an iced aqueous solution of NaHCO₃ and extracted with EtOAc. The organic layer was washed with brine and dried over Na₂SO₄ and concentrated in vacuo. The crude was dissolved in dry DMF (1 mL), treated with potassium acetate (174 mg, 1.78 mmol) and stirred at 50° C. for 1 h. After completion, the reaction was diluted with EtOAc and washed with NaHCO₃ and brine then concentrated. The crude was purified using silica gel column chromatography (eluent: 0.6%-1.0% methanol/DCM) to give compound j (75 mg, 72%) as a white solid; [α]_(D) ²⁵=+154.25 (c 1.2, DCM); ¹H NMR (400 MHz, CDCl₃): δ 5.75 (t, J=2.7 Hz, 1H, H-5), 5.51-5.38 (m, 2H, H-1″, H-3″), 5.06 (d, J=3.5 Hz, 1H, H-1′), 4.87-4.68 (m, 4H, H-6, H-6′, H-8′, H-2′), 4.34 (dd, J=12.3, 2.2 Hz, 1H, H-6″), 4.22 (dd, J=12.2, 5.4 Hz, 1H, H-6″), 3.97 (dd, J=10.2, 3.7 Hz, 1H, H-5′), 3.91-3.83 (m, 2H, H-1, H-3), 3.80 (dd, J=10.2, 2.6 Hz, 1H, H-4), 3.78-3.71 (m, 2H, H-7′, H-5″), 3.66 (td, J=10.8, 4.4 Hz, 1H, H-4′), 3.56 (t, J=10.1 Hz, 1H, H-4″), 3.20 (dt, J=12.7, 4.0 Hz, 1H, H-2′), 2.97 (s, 3H, NCH₃), 2.38 (dt, J=13.5, 4.7 Hz, 1H, H-2), 2.27 (dt, J=11.4, 4.4 Hz, 1H, H-3′), 2.17 (s, 3H, COCH₃), 2.12 (d, J=6.5 Hz, 6H, 2*COCH₃), 2.08-1.94 (m, 7H, H-3′, 2*COCH₃), 1.41 (q, J=12.6 Hz, 1H, H-2); ¹³C NMR (101 MHz, CDCl₃): δ 170.4 (C═O), 170.2 (C═O), 169.7 (C═O), 169.6 (C═O), 169.5 (C═O), 156.9 (C═O), 99.9 (C-8′), 94.1 (C-1″), 93.8 (C-1′), 74.6 (C-4), 72.9 (C-6), 71.8, (C-6′) 69.9 (C-3″,2″), 69.4 (C-5″), 66.9 (C-5′), 66.1 (C-5), 65.9 (C-4′), 62.8 (C-6″), 60.2 (C-4″), 60.1 (C-7′), 58.0 (C-1), 56.2 (C-3), 55.5 (C-2′), 32.2 (C-2), 30.5 (NCH₃), 28.1 (C-3′), 20.7 (COCH₃), 20.6 (COCH₃), 20.5 (COCH₃); ESI-HRMS: m/z calcd. for C₃₂H₄₁N₁₃NaO₁₇ [M+H]⁺ 902.2641; found, 902.2639.

5-Epi-apramycin pentaacetate salt (DCWSU161). A stirred solution of compound (j) (60 mg, 0.057 mmol) in dioxane (0.2 mL) was treated with 3N NaOH (0.2 mL) and heated at 100° C. for 2 h. The reaction mixture was treated with 1M P(CH₃)₃ in THF (0.15 mL) and stirred at 55° C. for 2 h. The reaction mixture was then concentrated and dissolved in aqueous acetic acid solution (pH 4, 1 mL) before it was charged to a Sephadex column (CM Sephadex C-25). The column was flushed with D.I. water (20 mL), then gradient eluted with 0.1%-1.0% NH₄OH in D.I. water. The fractions containing the product were combined, acidified with glacial acetic acid, and lyophilized to afford DCWSU161 (39 mg, 65%) as the peracetate salt in the form of a white solid; [α]_(D) ²⁵=+90.0 (c 0.7, H₂O); ¹H NMR (600 MHz, D₂O): δ 5.29 (d, J=4.0 Hz, 1H, H-1″), 5.21 (d, J=3.8 Hz, 1H, H-1′), 5.02 (d, J=8.5 Hz, 1H, H-8′), 4.34 (s, 1H, H-6′), 4.29 (s, 1H, H-5), 3.82-3.69 (m, 4H, H-4, H-4′, H-3″, H-5″), 3.65 (dd, J=12.5, 3.5 Hz, 1H, H-6″), 3.58 (dd, J=13.0, 4.5 Hz, 1H, H-6″), 3.56-3.47 (m, 4H, H-3, H-6, H-2′, H-2″), 3.44 (dd, J=10.0, 2.6 Hz, 1H, H-5′), 3.34 (ddd, J=12.3, 10.6, 4.5 Hz, 1H, H-1), 3.15 (dd, J=8.5, 2.8 Hz, 1H, H-7′), 3.09 (t, J=10.4 Hz, 1H, H-4″), 2.58 (s, 3H, NCH₃), 2.27 (dt, J=12.5, 4.4 Hz, 1H, H-2), 2.20 (dt, J=11.4, 4.6 Hz, 1H, H-3′), 1.92-1.86 (m, 1H, H-3′), 1.55 (q, J=12.5 Hz, 1H, H-2); ¹³C NMR (151 MHz, D₂O): δ 94.3 (C-1″), 92.7 (C-8′), 89.9 (C-1′), 72.9 (C-4), 70.1 (C-6), 69.8 (C-2″), 69.4 (C-5′), 69.3 (C-5″), 68.2 (C-3″), 66.0 (C-5), 65.8 (C-4′), 62.5 (C-6′), 60.2 (C-6″), 59.4 (C-7′), 52.0 (C-4″), 48.1 (C-1), 47.4 (C-2′), 46.7 (C-3), 29.9 (NCH₃), 28.1 (C-2), 26.9 (C-3′); ESI-HRMS: m/z calcd. for C₂₁H₄₂N₅O₁₁ [M+H]⁺ 540.2881; found, 540.2855.

6,2″,3″,6″-Tetra-O-acetyl-1,3,2′,4″-tetraazido-5-epi-6′,7′-oxazolidino-apramycin (k). To a stirred solution of compound A (100 mg, 0.12 mmol) in dry DCM (1.5 mL), pyridine (0.1 mL) was added and reaction mixture was cooled to 0° C. before triflic anhydride (40 μL, 0.24 mmol) was added. The reaction mixture was stirred for 1 h and additional triflic anhydride (40 μL, 0.24 mmol) was added. After 2 h, the reaction mixture was poured into an iced aqueous solution of NaHCO₃ and extracted with EtOAc. The organic layer was washed with brine and dried over Na₂SO₄ and concentrated in vacuo. The crude product was dissolved in dry DMF (1 mL), treated with sodium nitrite (40 mg, 0.60 mmol) and stirred at 50° C. for 1 h. After completion, the reaction was diluted with EtOAc and washed with brine then concentrated. The crude product was purified using silica gel column chromatography (eluent: 0.6%-1.0% Methanol/DCM) to give compound k (60 mg, 60%) as a white solid; [α]_(D) ²⁵=+100.5 (c 0.6, DCM); ¹H NMR (600 MHz, CDCl₃): δ 5.43 (t, J=10.1 Hz, 1H, H-3″), 5.39 (d, J=3.8 Hz, 1H, H-1″), 4.99 (d, J=3.5 Hz, 1H, H-1′), 4.83 (dd. J=10.4. 3.8 Hz, 1H, H-2″), 4.81-4.76 (m, 2H, H-6′, H-8′), 4.64 (dd, J=10.4, 2.6 Hz, 1H, H-6), 4.39 (q, J=2.7 Hz, 1H, H-5), 4.32 (dd, J=12.2, 2.2 Hz, 1H, H-6″), 4.25-4.19 (m, 2H, H-6″, H-5′), 4.01 (ddd, J=12.3, 10.4, 4.7 Hz, 1H, H-1), 3.92 (ddd, J=12.4, 9.9, 4.9 Hz, 1H, H-3), 3.77 (dd, J=7.3, 5.0 Hz, 1H, H-7′), 3.72 (ddd, J=10.6, 5.3, 2.2 Hz, 1H, H-5″), 3.67 (td, J=10.9, 4.4 Hz, 1H, H-4′), 3.61 (dd, J=9.9, 2.7 Hz, 1H, H-4), 3.57 (t, J=10.2 Hz, 1H, H-4″), 3.45 (dt, J=12.6, 4.1 Hz, 1H, H-2′), 3.13 (d, J=2.7 Hz, 1H, OH), 2.94 (s, 3H, NCH₃), 2.36-2.26 (m, 2H, H-2, H-3′), 2.16 (s, 3H, COCH₃), 2.15-2.05 (m, 6H, 2*COCH₃), 1.99 (dd, J=23.9, 12.0 Hz, 1H, H-3′), 1.33 (q, J=12.7 Hz, 1H, H-2); ¹³C NMR (151 MHz, CDCl₃): δ 170.4 (C═O), 170.2 (C═O), 169.7 (C═O), 157.1 (C═O), 98.0 (C-8′), 94.5 (C-1′), 94.2 (C-1″), 78.6 (C-4), 74.8 (C-6), 71.3 (C-6′), 70.1 (C-2″), 69.9 (C-3″), 69.3 (C-5″), 66.7 (C-5), 66.6 (C-5′), 65.6 (C-4′), 62.8 (C-6″), 60.2 (C-7′), 60.1 (C-4″), 57.15 (C-3), 57.07 (C-2′), 55.7 (C-1), 32.0 (C-2), 30.2 (NCH₃), 29.4 (C-3′), 20.9 (COCH₃), 20.7 (COCH₃), 20.7 (COCH₃); ESI-HRMS: m/z calcd. for C₃₀H₃₉N₁₃NaO₁₆ [M+Na]⁺ 860.2535; found, 860.2530.

6,2″,3″,6″-Tetra-O-acetyl-1,3,2′,4″-tetraazido-5-deoxy-5-fluoro-6′, 7′-oxazolidino-apramycin (I). A stirred ice-cooled solution of compound k (36 mg, 0.04 mmol) in dry DCM (0.2 mL), was treated with diethylaminosulfur trifluoride (45 μL, 0.34 mmol) and stirred at 0° C. for 1 h and at rt for 30 min. After completion, the reaction mixture was purified by gradient chromatography over silica gel (eluent: 0.7% to 0.8% MeOH in DCM) to give I (29 mg, 81%) as a white solid; [α]_(D) ²⁵=+127.76 (c 1.9, DCM); ¹H NMR (400 MHz, CDCl₃): δ 5.40 (t, J=10.0 Hz, 1H, H-3″), 5.35 (d, J=3.8 Hz, 1H, H-1″), 5.21-5.07 (m, 2H, H-6, H-1′), 4.96-4.86 (m, 2H, H-8′, H-2″), 4.82 (dd, J=8.2, 3.4 Hz, 1H, H-6′), 4.57 (dd, J=10.4, 3.3 Hz, 1H, H-5′), 4.45 (dt, J=50.3, 9.1 Hz, 1H, H-5), 4.34 (dd, J=12.2, 2.4 Hz, 1H, H-6″), 4.23 (dd, J=12.2, 5.1 Hz, 1H, H-6″), 3.86-3.66 (m, 5H, H-3, H-4, H-4′, H-7′, H-5″), 3.65-3.58 (m, 1H, H-4″), 3.53 (ddd, J=12.3, 10.2, 4.4 Hz, 1H, H-1), 3.30 (dt, J=12.9, 4.1 Hz, 1H, H-2′), 2.94 (s, 3H, NCH₃), 2.47 (dt, J=13.2, 4.4 Hz, 1H, H-2), 2.27 (dt, J=11.4, 4.4 Hz, 1H, H-3′), 2.20-2.06 (m, 12H, 4*COCH₃), 1.94 (q, J=11.5 Hz, 1H, H-3′), 1.67 (q, J=12.5 Hz, 1H, H-2); ¹³C NMR (101 MHz, CDCl₃): δ 170.3 (C═O), 170.0 (C═O), 169.9 (C═O), 169.5 (C═O), 156.9 (C═O), 98.6 (C-1′), 96.1 (C-8′), 94.6 (C-1″), 93.34 (d, J=187.8 Hz, C-5), 79.78 (d, J=17.1 Hz, C-4), 73.05 (d, J=18.5 Hz, C-6), 70.6 (C-3″), 70.2 (C-2″), 70.0 (C-6′), 69.0 (C-5″), 65.8 (C-5′), 65.4 (C-4′), 62.8 (C-6″), 60.2 (C-7′), 60.1 (C-4″), 57.58 (d, J=10.6 Hz, C-3), 57.00 (d, J=9.3 Hz, C-1), 56.4 (C-2′), 31.7 (C-2), 30.0 (NCH₃), 29.7 (C-3′), 20.9 (COCH₃), 20.8 (COCH₃), 20.7 (COCH₃), 20.7 (COCH₃);¹⁹F NMR (376 MHz, CDC13): δ−196.30 (dt, J=50.4, 11.5 Hz); ESI-HRMS: m/z calcd. for C₃₀H₃₈FN₁₃NaO₁₅ [M+Na]⁺ 862.2492; found, 862.2511.

5-Deoxy-5-fluoro apramycin pentaacetate salt (DCWSU170). A stirred solution of compound 1 (29 mg, 0.035 mmol) in dioxane (0.2 mL) was treated with 3N NaOH (0.2 mL) and heated at 100° C. for 2 h. 1M P(CH₃)₃ in THF (0.3 mL) was added and the reaction mixture was stirred at 55° C. for 2 h. The reaction mixture was then concentrated and dissolved in aqueous acetic acid solution (pH 4, 1 mL) then charged to a Sephadex column (CM Sephadex C-25). The column was flushed with D.I. water (20 mL), then gradient eluted with 0.1%-1.0% NH₄OH in D.I. water. The fractions containing the product were combined, acidified with glacial acetic acid, and lyophilized to afford DCWSU170 (16 mg, 56%) as the peracetate salt in the form of a white solid; [α]_(D) ²⁵=+89.91 (c 1.1, H₂O); ¹H NMR (600 MHz, D₂O): δ 5.35 (d, J=3.4 Hz, 1H, H-1′), 5.28 (d, J=3.8 Hz, 1H, H-1″), 5.00 (d, J=8.5 Hz, 1H, H-8′), 4.43 (dt, J=50.8, 9.0 Hz, 1H, H-5), 4.35 (s, 1H, H-6′), 4.04 (q, J=9.6 Hz, 1H, H-4), 3.79-3.69 (m, 4H, H-6, H-4′, H-3″, H-5″), 3.63 (dd, J=12.3, 2.9 Hz, 1H, H-6″), 3.56 (dd, J=12.5, 4.5 Hz, 1H, H-6″), 3.52 (d, J=10.3 Hz, 1H, H-5′), 3.49 (dd, J=9.8, 3.9 Hz, 1H, H-2″), 3.44 (dt, J=12.3, 3.9 Hz, 1H, H-2′), 3.34 (td, J=11.7, 10.9, 4.0 Hz, 1H, H-3), 3.21-3.14 (m, 2H, H-1, H-7′), 3.07 (t, J=10.4 Hz, 1H, H-4″), 2.57 (s, 3H, NCH₃), 2.29 (dt, J=12.8, 4.3 Hz, 1H, H-2), 2.15 (dt, J=10.1, 4.5 Hz, 1H, H-3′), 1.87-1.83 (m, 1H, H-3′), 1.73-1.66 (m, 1H, H-2); ¹³C NMR (151 MHz, D₂O): δ 95.33 (d, J=190.2 Hz, C-5), 94.8 (C-1′), 94.3 (C-1″), 92.7 (C-8′), 75.72 (d, J=16.8 Hz, C-4), 70.27 (d, J=20.5 Hz, C-6), 70.2 (C-2″), 69.5 (C-5′), 69.3 (C-5″), 68.2 (C-3″), 65.8 (C-4′), 62.6 (C-6′), 60.2 (C-6″), 59.3 (C-7′), 52.0 (C-4″), 48.67 (d, J=11.5 Hz, C-1), 47.6 (C-2′), 47.34 (d, J=11.3 Hz, C-3), 29.9 (NCH₃), 28.0 (C-2), 26.6 (C-3′).¹⁹F NMR (376 MHz, D₂O): δ −195.08 (dt, J=50.9, 11.7 Hz); ESI-HRMS: m/z calcd. for C₂₁H₄₁FN₅O₁₀ [M+H]⁺ 542.2837; found, 542.2838.

6,2″,3″,6″-Tetra-O-acetyl-1,3,2′,4″-tetraazido-5-deoxy-5-epifluoro-6′,7′-oxazolidino-apramycin (m). To a stirred ice-cooled solution of compound 124 (50 mg, 0.06 mmol) in dry DCM (0.2 mL), diethylaminosulfur trifluoride (65 μl, 0.48 mmol) was added, and the reaction mixture was stirred at rt for 3 h. After completion, the reaction mixture was purified by gradient chromatography over silica gel (eluent: 0.7% to 0.8% MeOH in DCM) to give m (37 mg, 74%) as a white solid; [α]_(D) ²⁵=+104.39 (c 2.5, DCM); ¹H NMR (600 MHz, CDCl₃): δ 5.42 (t, J=10.0 Hz, 1H, H-3″), 5.38 (d, J=3.8 Hz, 1H, H-1″), 5.09-4.96 (m, 2H, H-5, H-1′), 4.90-4.84 (m, 2H, H-8′, H-2″), 4.80 (dd, J=7.7, 3.5 Hz, 1H, H-6′), 4.70 (ddd, J=27.3, 10.5, 1.8 Hz, 1H, H-6), 4.35 (dd, J=10.4, 3.4 Hz, 1H, H-5′), 4.32 (dd, J=12.2, 2.2 Hz, 1H, H-6″), 4.21 (dd, J=12.2, 5.3 Hz, 1H, H-6″), 4.02-3.92 (m, 2H, H-1, H-3), 3.80 (dd, J=7.6, 4.3 Hz, 1H, H-7′), 3.78-3.69 (m, 2H, H-4′, H-5″), 3.67-3.55 (m, 2H, H-4, H-4″), 3.34 (dt, J=12.8, 4.0 Hz, 1H, H-2′), 2.94 (s, 3H, NCH₃), 2.45 (dt, J=13.5, 4.9 Hz, 1H, H-2), 2.29 (dt, J=11.3, 4.4 Hz, 1H, H-3′), 2.17 (s, 3H, COCH₃), 2.10 (d, J=10.8 Hz, 6H, 2*COCH₃), 2.06 (s, 3H, COCH₃), 2.01-1.94 (m, 1H, H-3′), 1.42 (q, J=12.7 Hz, 1H, H-2); ¹³C NMR (151 MHz, CDCl₃): δ 170.4 (C═O), 169.9 (C═O), 169.7 (C═O), 156.9 (C═O), 96.7 (C-8′), 96.2 (C-1′), 94.1 (C-1″), 87.65 (d, J=184.1 Hz, C-5), 77.55 (d, J=17.9 Hz, C-4), 73.45 (d, J=17.1 Hz, C-6), 70.6 (C-6′), 70.3 (C-3″), 69.8 (C-2″), 69.1 (C-5″), 66.4 (C-5′), 65.5 (C-4′), 62.9 (C-6″), 60.2 (C-4″), 60.0 (C-7′), 57.03 (d, J=3.8 Hz, C-3), 56.0 (C-2′), 55.76 (d, J=4.1 Hz, C-1), 32.0 (C-2), 30.1 (NCH₃), 29.2 (C-3′), 20.7 (COCH₃), 20.7 (COCH₃), 20.7 (COCH₃);¹⁹F NMR (376 MHz, CDCl₃): δ −213.48 (dt, J=52.6, 26.8 Hz); ESI-HRMS: m/z calcd. for C₃₀H₃₈FN₁₃NaO₁₅ [M+Na]⁺ 862.2492; found, 862.2502.

5-Deoxy-5-epi-fluoro apramycin pentaacetate salt (DCWSU168). A stirred solution of compound m (37 mg, 0.044 mmol) in dioxane (0.2 mL) was treated with 3 N NaOH (0.2 mL) and heated at 100° C. for 2 h. 1 M P(CH₃)₃ in THF (0.3 mL) was added and the reaction mixture stirred at 55° C. for 2h. The reaction mixture was then concentrated and dissolved in aqueous acetic acid solution (pH 4, 1 mL) before it was charged to a Sephadex column (CM Sephadex C-25). The column was flushed with D.I. water (20 mL), then gradient eluted with 0.1%-1.0% NH₄OH in D.I. water. The fractions containing the product were combined, acidified with glacial acetic acid, and lyophilized to afford DCWSU168 (22 mg, 59%) as the peracetate salt in the form of a white solid; [α]_(D) ²⁵=+152.0 (c 0.1, H₂O); ¹H NMR (600 MHz, D₂O): δ 5.25 (d, J=3.9 Hz, 1H, H-1″), 5.24 (d, J=3.8 Hz, 1H, H-1′), 5.13 (d, J=51.7 Hz, 1H, H-5), 4.98 (d, J=8.5 Hz, 1H, H-8′), 4.31 (s, 1H, H-6′), 3.94 (dd, J=26.1, 10.7 Hz, 1H, H-4), 3.78-3.63 (m, 4H, H-6, H-4′, H-3″, H-5″), 3.61 (dd, J=12.5, 3.5 Hz, 1H, H-6″), 3.57-3.50 (m, 2H, H-3, H-6″), 3.49-3.44 (m, 2H, H-2′, H-2″), 3.42 (dd, J=10.1, 2.6 Hz, 1H, H-5′), 3.33 (td, J=11.7, 4.3 Hz, 1H, H-1), 3.12 (dd, J=8.5, 2.8 Hz, 1H, H-7′), 3.05 (t, J=10.4 Hz, 1H, H-4″), 2.54 (s, 3H, NCH₃), 2.29 (dt, J=12.6, 4.4 Hz, 1H, H-2), 2.19-2.10 (m, 1H, H-3′), 1.90-1.82 (m, 1H, H-3′), 1.59 (q, J=12.6 Hz, 1H, H-2); ¹³C NMR (151 MHz, D₂O): δ 94.3 (C-1″), 92.7 (C-8′), 90.3 (C-1′), 87.37 (d, J=181.7 Hz, C-5), 72.01 (d, J=17.8 Hz, C-4), 70.1 (C-2″), 69.5 (C-5′), 69.2 (C-5″), 68.55 (d, J=17.2 Hz, C-6), 68.1 (C-3″), 65.7 (C-4′), 62.5 (C-6′), 60.2 (C-6″), 59.3 (C-7′), 52.0 (C-4″), 48.09 (d, J=4.4 Hz, C-1), 47.3 (C-2′), 46.61 (d, J=4.2 Hz, C-3), 29.9 (NCH₃), 27.9 (C-2), 26.7 (C-3′); ¹⁹F NMR (376 MHz, D₂O): δ −217.88 (dt, J=51.8, 27.2 Hz); ESI-HRMS: m/z calcd. for C₂₁H₄₁FN₅O₁₀ [M+H]⁺ 542.2837; found, 542.2825.

6,2″,3″,6″-Tetra-O-acetyl-1,3,2′,4″-tetraazido-5-deoxy-5-epiiodo-6′,7′-oxazolidino-apramycin (n). To a stirred solution of compound A (100 mg, 0.12 mmol) in dry DCM (1.5 mL), pyridine (0.1 mL) was added and reaction mixture was cooled to 0° C. before triflic anhydride (40 μL, 0.24 mmol) was added. The reaction mixture was stirred for 1 h and additional triflic anhydride (40 μL, 0.24 mmol) was added. After 2 h, the reaction mixture was poured into an iced aqueous solution of NaHCO₃ and extracted with EtOAc. The organic layer was washed with brine and dried over Na₂SO₄ and concentrated in vacuo. The crude product was dissolved in dry acetone (25 mL), heated to reflux under stirring with sodium iodide (266 mg, 1.78 mmol) for 12 h. After completion, the reaction mixture was concentrated, diluted with EtOAc and washed with brine then concentrated. The crude product was purified using silica gel column chromatography (eluent: 0.6%-1.0% Methanol/DCM) to give compound n (93 mg, 89%) as a white solid; [α]_(D) ²⁵=+172.23 (c 6.2, DCM); ¹H NMR (600 MHz, CDCl₃): δ 5.46-5.38 (m, 2H, H-1″, H-3″), 4.92 (d, J=3.4 Hz, 1H, H-1′), 4.84 (t, J=3.2 Hz, 1H, H-5), 4.80-4.72 (m, 3H, H-6′, H-8′, H-2″), 4.31 (dd, J=12.3. 2.2 Hz. 1H. H-6″), 4.20 (dd, J=12.2, 5.4 Hz, 1H, H-6″), 4.04-3.98 (m, 2H, H-3, H-4), 3.98-3.90 (m, 2H, H-1, H-5′), 3.80-3.70 (m, 2H, H-7′, H-5″), 3.66 (td, J=10.8, 4.5 Hz, 1H, H-4′), 3.55 (t, J=10.2 Hz, 1H, H-4″), 3.25 (dt, J=12.8, 3.9 Hz, 1H, H-2′), 3.06 (dd, J=9.7, 3.6 Hz, 1H, H-6), 2.94 (s, 3H, NCH₃), 2.28 (ddt, J=12.6, 8.7, 4.6 Hz, 2H, H-2, H-3′), 2.15 (s, 3H, COCH₃), 2.13-2.03 (m, 7H, H-3′,2*COCH₃), 2.01 (s, 3H, COCH₃), 1.41-1.29 (m, 1H, H-2); ¹³C NMR (151 MHz, CDCl₃): δ 170.4 (C═O), 170.2 (C═O), 169.6 (C═O), 169.6 (C═O), 156.8 (C═O), 99.8 (C-8′), 94.3 (C-1″), 93.9 (C-1′), 74.1 (C-6), 72.6 (C-4), 71.7 (C-6′), 69.9 (C-2″), 69.8 (C-3″), 69.4 (C-5″), 67.2 (C-5′), 65.8 (C-4′), 62.8 (C-6″), 60.6 (C-1), 60.2 (C-4″), 60.1 (C-7′), 59.2 (C-3), 55.4 (C-2′), 32.8 (C-5), 32.6 (C-2), 30.4 (NCH₃), 28.0 (C-3′), 20.9 (COCH₃), 20.8 (COCH₃), 20.7 (COCH₃), 20.7 (COCH₃); ESI-HRMS: m/z calcd. for C₃₀H₃₆IN₁₃NaO₁₅ [M+Na]⁺ 970.1553; found, 970.1571.

5-Deoxy-apramycin pentaacetate salt (DCWSU169). To a solution of compound n (45 mg, 0.05 mmol) in dry methanol (5 mL), sodium methoxide (10 mg, 0.06 mmol) was added and the reaction mixture was stirred for 30 min. The reaction was quenched with Amberlyst®, filtered and the solvent was evaporated in vacuo. The crude product was dissolved in dioxane:water:glacial acetic acid=1:2:0.2 (0.3 mL) and 10% Pd/C (60 mg, 1.1 equiv.) was added. The reaction was stirred at room temperature under 1 atm of hydrogen (balloon) for 12 h. After completion, the reaction mixture was filtered over Celite® and filtrate concentrated to dryness. The residue was dissolved in dioxane (0.5 mL) and treated with 3N NaOH (0.25 mL) and heated at 100° C. for 30 min. The reaction mixture was cooled to rt and neutralized with glacial acetic acid before concentration in vacuo. The crude product was dissolved in aqueous acetic acid solution (pH 4, 1 mL) before it was charged to a Sephadex column (CM Sephadex C-25). The column was flushed with D.I. water (20 mL), then gradient eluted with 0.1%-1.0% NH₄OH in D.I. water. The fractions containing the product were combined, acidified with glacial acetic acid and lyophilized to afford the peracetate salt of DCWSU169 (18.5 mg, 47%) as a white solid; [α]_(D) ²⁵=+105.0 (c 0.2, H₂O); 1H NMR (600 MHz, D₂O): δ 5.35 (d, J=4.0 Hz, 1H, H-1″), 5.23 (d, J=3.8 Hz, 1H, H-1′), 5.07 (d, J=8.5 Hz, 1H, H-8′), 4.40 (s, 1H, H-6′), 3.87-3.73 (m, 4H, H-4, H-4′, H-3″, H-5″), 3.70 (dd, J=12.5, 3.3 Hz, 1H, H-6″), 3.63 (dd, J=12.5, 4.7 Hz, 1H, H-6″), 3.62-3.52 (m, 2H, H-6, H-2″), 3.52 (dt, J=12.8, 4.3 Hz, 1H, H-2′), 3.48 (dd, J=10.0, 3.0 Hz, 1H, H-5′), 3.34 (ddd, J=12.4, 10.1, 4.1 Hz, 1H, H-3), 3.21 (dd, J=8.5, 2.9 Hz, 1H, H-7′), 3.17-3.10 (m, 2H, H-1, H-4″), 2.63 (s, 3H, NCH₃), 2.55 (dt, J=12.2, 4.3 Hz, 1H, H-5), 2.33 (dt, J=12.6, 4.3 Hz, 1H, H-2), 2.23 (dt, J=10.8, 4.5 Hz, 1H, H-3′), 1.90 (q, J=11.8, 11.0 Hz, 1H, H-3′), 1.61 (q, J=12.5 Hz, 1H, H-2), 1.34 (q, J=11.7 Hz, 1H, H-5); ¹³C NMR (151 MHz, D₂O): δ 94.3 (C-1″), 92.7 (C-8′), 90.1 (C-1′), 70.8 (C-4), 70.2 (C-6), 69.4 (C-2″), 69.3 (C-5′), 68.2 (C-5″), 67.2 (C-3″), 65.8 (C-4′), 62.6 (C-6′), 60.2 (C-6″), 59.4 (C-7′), 52.5 (C-1), 52.0 (C-4″), 50.8 (C-3), 47.3 (C-2′), 33.8 (C-5), 30.0 (NCH₃), 28.5 (C-2), 26.9 (C-3′); ESI-HRMS: m/z calcd. for C₂₁H₄₂N₅O₁₀ [M+H]⁺ 524.2932; found, 524.2924.

Example 8 DCWSU 164 and 167

-   See the synthetic scheme of FIG. 16. -   Note intermediates AK-1 and AK-2 are not drawn in the scheme for     these two compounds     5,2″,3″,6″-Tetra-O-acetyl-6-O-allyl-1,3,2′,4″-tetraazido-6′,7′-oxazolidino-apramycin     (AK).     6,2″,3″,6″-Tetra-O-acetyl-1,3,2′,4″-tetraazido-6′,7′-oxazolidino-apramycin     A (100 mg, 0.12 mmol) was dissolved in dry DCM (0.5 mL) and treated     with allyl bromide (0.5 mL, 5.9 mmol) and silver oxide (400 mg, 1.7     mmol). The reaction mixture was covered with aluminium foil and     stirred at rt for 12 h. After completion, the reaction was filtered     through Celite® and concentrated to dryness. The crude product was     purified by column chromatography (eluent: 5% to 30% EtOAc/hexanes)     to give AK (60 mg, 59%) as a white solid; [α]_(D) ²⁵=+60.0 (c 0.2,     DCM); ¹H NMR (400 MHz, CDCl₃): δ 5.86 (ddt, J=16.3, 10.3, 5.9 Hz,     1H, CH₂CHCH₂O), 5.45-5.34 (m, 1H, H-3″), 5.32 (d, J=3.8 Hz, 1H,     H-1″), 5.25 (dd, J=17.2, 1.5 Hz, 1H, CH₂CHCH₂O), 5.22-5.16 (m, 1H,     CH₂CHCH₂O), 5.05 (t, J=9.9 Hz, 1H, H-5), 4.99-4.90 (m, 2H, H-8′,     H-2″), 4.87 (d, J=3.6 Hz, 1H, H-1′), 4.81 (dd, J=8.6, 3.2 Hz, 1H,     H-6′), 4.74 (dd, J=10.5, 3.2 Hz, 1H, H-5′), 4.36-4.17 (m, 3H, H-6″,     CH₂CHCH₂O), 4.09 (dd, J=12.2, 6.1 Hz, 1H, CH₂CHCH₂O), 3.92-3.82 (m,     2H, H-4′, H-7′), 3.82-3.76 (m, 1H, H-3), 3.76-3.67 (m, 1H, H-5″),     3.66-3.52 (m, 2H, H-1, H-4″), 3.48 (t, J=9.9 Hz, 1H, H-4), 3.39 (dt,     J=12.7, 4.1 Hz, 1H, H-2′), 3.19 (t, J=9.8 Hz, 1H, H-6), 2.92 (s, 3H,     NCH₃), 2.46 (dt, J=13.1, 4.6 Hz, 1H, H-2), 2.26 (dt, J=10.7, 4.1 Hz,     1H, H-3′), 2.21-2.02 (m, 12H, 4*C0CH₃), 1.85 (q, J=11.4 Hz, 1H,     H-3′), 1.49 (q, J=12.5 Hz, 1H, H-2); ¹³C NMR (101 MHz, CDCl₃): δ     170.3 (C═O), 170.3 (C═O), 170.0 (C═O), 169.4 (C═O), 156.9 (C═O),     133.6 (CH₂CHCH₂O), 118.1 (CH₂CHCH₂O), 99.1 (C-1′), 94.2 (C-8′,     C-1″), 81.9 (C-6), 80.3 (C-4), 74.3 (CH₂CHCH₂O), 74.0 (C-5), 70.7     (C-3″), 69.9 (C-2″), 69.7 (C-6′), 68.8 (C-5″), 65.4 (C-5′), 65.2     (C-4′), 62.9 (C-6″), 60.2 (C-4″), 60.0 (C-7′), 59.7 (C-1), 58.4     (C-3), 56.6 (C-2′), 32.1 (C-2), 30.0 (NCH₃), 29.8 (C-3′), 21.1     (COCH₃), 21.0 (COCH₃), 20.8 (COCH₃), 20.7 (COCH₃); ESI-HRMS: m/z     calcd. for C₃₃H₄₃N₁₃NaO₁₆ [M+Na]⁺ 900.2848; found, 900.2841.

5,2″,3″,6″-Tetra-O-acetyl-1,3,2′,4″-tetraazido-6-O-(2,3-dihydroxypropyl)-6′,7′-oxazolidino-apramycin (AK-1). A stirred solution of compound AK (20 mg, 0.02 mmol) in THF (0.4 mL) and water (0.1 mL) was treated with N-methylmorpholine-N-oxide (8 mg, 0.07 mmol) and 2.5% OsO₄ in tent-butanol (60 μL mg, 0.005 mmol). The reaction mixture was stirred at rt for 4 h. After completion, the reaction mixture was diluted with EtOAc and the organic layer was washed with aqueous NaHCO₃ followed by brine, dried with Na₂SO₄, and concentrated. The crude product was purified via silica gel chromatography eluting with 0.7% to 3% methanol in DCM to give AK-1 (15 mg, 71%) as a white solid; [α]_(D) ²⁵=+63.75 (c 1.3, DCM); ¹H NMR (400 MHz, CDCl₃): δ 5.38 (t, J=9.9 Hz, 1H, H-3′), 5.32 (d, J=3.8 Hz, 1H, H-1″), 5.08-5.01 (m, 1H, H-5), 4.98-4.91 (m, 2H, H-8′, H-2″), 4.88 (d, J=3.0 Hz, 1H, H-1′), 4.80 (dd, J=8.6, 3.1 Hz, 1H H-6′), 4.71 (dd, J=10.5, 3.1 Hz, 1H, H-5′), 4.36-4.27 (m, 1H, H-6″), 4.22 (dd, J=12.2, 5.0 Hz, 1H, H-6″), 3.90-3.68 (m, 6H, H-3, H-4′, H-7′, H-5″, CH₂OHCHOHCH₂O, CH₂OHCHOHCH₂O), 3.66-3.43 (m, 6H, H-1, H-4, H-4″, CH₂OHCHOHCH₂O, CH₂OHCHOHCH₂O), 3.37 (dt, J=12.6, 3.6 Hz, 1H, H-2′), 3.19 (t, J=9.8 Hz, 1H, H-6), 2.91 (s, 3H, NCH₃), 2.48 (dt, J=12.7, 4.2 Hz, 1H, H-2), 2.29-2.23 (m, 1H, H-3′), 2.17-2.07 (m, 12H, 4*C0CH₃), 1.90-1.80 (m, 1H, H-3′), 1.59-1.46 (m, 1H, H-2); ¹³C NMR (101 MHz, CDCl₃): δ 170.4 (C═O), 170.2 (C═O), 170.0 (C═O), 157.0 (C═O), 99.1 (C-1′), 94.5 (C-8′), 94.3 (C-1″), 82.9 (C-6), 80.0 (C-4), 74.8 (C-5), 74.4 (CH₂OHCHOHCH₂O), 70.7 (C-3″), 70.6 (C-2″), 69.9 (CH₂OHCHOHCH₂O), 69.7 (C-6′), 68.8 (C-5″), 65.4 (C-5′), 65.2 (C-4′), 63.1 (CH₂OHCHOHCH₂O), 62.9 (C-6″), 60.1 (C-4″), 60.0 (C-7′), 59.6 (C-1), 58.2 (C-3), 56.4 (C-2′), 31.8 (C-2), 29.9 (NCH₃), 29.8 (C-3′), 21.1 (COCH₃), 20.9 (COCH₃), 20.9 (COCH₃), 20.7 (COCH₃); ESI-HRMS: m/z calcd. for C₃₃H₄₅N₁₃NaO₁₈ [M+Na]⁺ 934.2903; found, 934.2905.

6-O-(2,3-Dihydroxypropyl)-apramycin pentaacetate salt (DCWSU164). A stirred solution of compound AK-1 (14 mg, 0.015 mmol) in dioxane (0.2 mL) was treated with 3N NaOH (0.2 mL) and heated at 100° C. for 2 h. 1M P(CH₃)₃ in THF (0.15 mL) was added and the reaction mixture was stirred at 55° C. for 2 h. The reaction mixture was cooled to 0° C., neutralized with glacial acetic acid and concentrated. The crude product was dissolved in aqueous acetic acid solution (pH 4, 1 mL) then charged to a Sephadex column (CM Sephadex C-25). The column was flushed with D.I. water (20 mL), then gradient eluted with 0.1%-1.0% NH₄OH in D.I. water. The fractions containing the product were combined, acidified with glacial acetic acid, and lyophilized to afford DCWSU164 (5.5 mg, 39%) as the peracetate salt in the form of a white solid; [α]_(D) ²⁵=+100.96 (c 0.2, H₂O); ¹H NMR (600 MHz, D₂O): δ 5.51 (s, 1H, H-1′), 5.28 (d, J=4.0 Hz, 1H, H-1″), 5.00 (dd, J=8.4, 1.5 Hz, 1H, H-8′), 4.35 (s, 1H, H-6′), 3.86-3.66 (m, 6H, H-4, H-4′, H-3″, H-5″, CH₂OHCHOHCH₂O, CH₂OHCHOHCH₂O), 3.66-3.52 (m, 5H, H-5, H-5′, H-6″, CH₂OHCHOHCH₂O), 3.50 (dd, J=9.3, 3.9 Hz, 1 H, H-2″), 3.48-3.34 (m, 4H, H-2′, CH₂OHCHOHCH₂O), 3.32-3.22 (m, 2H, H-3, H-6), 3.23-3.14 (m, 2H, H-1, H-7′), 3.08 (t, J=10.2 Hz, 1H, H-4″), 2.57 (s, 3H, NCH₃), 2.31-2.23 (m, 1H, H-2), 2.19-2.10 (m, 1H, H-3′), 1.66 (q, J=12.6 Hz, 1H, H-2); ¹³C NMR (151 MHz, D₂O) δ 95.4 (C-1′), 94.3 (C-1″), 92.7 (C-8′), 81.3 (C-6), 77.7 (C-4), 75.2 (C-5), 73.7 (CH₂OHCHOHCH₂O), 70.3 (CH₂OHCHOHCH₂O), 70.1 (C-2″), 69.6 (C-5′), 69.2 (C-5″), 68.2 (C-3″), 65.9 (C-4′), 62.6 (C-6′), 62.1 (CH₂OHCHOHCH₂O), 60.2 (C-6″), 59.3 (C-7′), 52.0 (C-4″), 48.8 (C-1), 48.2 (C-3), 47.8 (C-2′), 29.9 (NCH₃), 28.1 (C-2), 26.6 (C-3′); ESI-HRMS: m/z calcd. for C₂₄H₄₈N₅O₁₃ [M+H]⁺ 614.3249; found, 614.3242.

5,2″,3″,6″-Tetra-O-acetyl-1,3,2′,4″-tetraazido-6-O-(2-hydroxyethyl)-6′,7′-oxazolidino-apramycin (AK-2). To a stirred solution of compound AK-1 (22 mg, 0.024 mmol) in THF (0.4 mL) and water (0.1 mL), NalO₄ (15.5 mg, 0.07 mmol) was added and the reaction mixture was stirred at rt for 12 h. The reaction mixture was diluted with EtOAc and washed with aqueous NaHCO₃ and brine. The organic layer was dried over Na₂SO₄ and concentrated. To a solution of the residue in in THF (0.4 mL) and water (0.1 mL), NaBH₄ (1.8 mg, 0.048 mmol) and the reaction mixture was stirred at rt for 45 min. The reaction mixture was diluted with EtOAc and washed with aqueous NaHCO₃, brine, dried with Na₂SO₄ and concentrated. The crude product was purified using silica gel column chromatography (eluent: 0.75%-3% methanol/DCM) to give AK-2 (11 g, 52%) as a white solid; [α]_(D) ²⁵=+60.6 (c 0.3, DCM);¹H NMR (600 MHz, CD₃OD): δ 5.47-5.40 (m, 1H, H-3″), 5.38 (d, J=3.8 Hz, 1H, H-1″), 5.13 (d, J=2.1 Hz, 1H, H-8′), 5.02 (t, J=9.7 Hz, 1H, H-5), 4.97 (dd, J=10.3, 3.8 Hz, 1H, H-2″), 4.92-4.86 (m, 3H, H-1′, H-5′, H-6′), 4.35 (d, J=12.1 Hz, 1H, H-6″), 4.25 (dd, J=12.3, 4.1 Hz, 1H, H-6″), 4.10 (dd, J=8.9, 2.1 Hz, 1H, H-7′), 3.89-3.79 (m, 4H, H-4′, H-4″, H-5″, CH₂OHCH₂O), 3.79-3.73 (m, 1H, H-3), 3.72-3.63 (m, 2H, H-4, CH₂OHCH₂O), 3.63-3.54 (m, 3H, H-1, CH₂OHCH₂O), 3.57-3.49 (m, 1H, H-2′), 3.37 (t, J=9.8 Hz, 1H, H-6), 2.91 (s, 3H, NCH₃), 2.44 (dt, J=12.7, 4.6 Hz, 1H, H-2), 2.28 (dt, J=8.8, 4.2 Hz, 1H, H-3′), 2.18-2.04 (m, 12H, 4*COCH₃), 1.85-1.79 (m, 1H, H-3′), 1.61 (q, J=12.5 Hz, 1H, H-2); ¹³C NMR (151 MHz, CD₃OD): δ 170.9 (C═O), 170.5 (C═O), 170.4 (C═O), 158.2 (C═O), 99.1 (C-1′), 93.9 (C-1″), 93.0 (C-8′), 82.5 (C-6), 80.2 (C-4), 74.5 (C-5), 74.1 (CH₂OHCH₂O), 70.9 (C-3″), 70.2 (C-2″), 70.0 (C-6′), 68.7 (C-5″), 65.1 (C-5′), 65.1 (C-4′), 62.9 (C-6″), 60.8 (CH₂OHCH₂O), 60.1 (C-4″), 59.9 (C-7′), 59.8 (C-1), 58.2 (C-3), 56.6 (C-2′), 31.1 (C-2), 30.1 (C-3′), 28.6 (NCH₃), 20.1 (COCH₃), 20.0 (COCH₃), 19.4 (COCH₃), 19.2 (COCH₃); ESI-HRMS: m/z calcd. for C₃₂H₄₃N₁₃NaO₁₇ [M+Na]+904.2798; found, 904.2801.

6-O-(2-Hydroxyethyl)-apramycin pentaacetate salt (DCWSU167). A stirred solution of compound 176 (10 mg, 0.011 mmol) in dioxane (0.2 mL) was treated with 3N NaOH (0.2 mL) and heated at 100° C. for 1 h. 1M P(CH₃)₃ in THF (0.15 mL) was added and the reaction mixture was stirred at 55° C. for 2 h. The reaction mixture was cooled to 0° C., neutralized with glacial acetic acid and concentrated. The crude product was dissolved in aqueous acetic acid solution (pH 4, 1 mL) then charged to a Sephadex column (CM Sephadex C-25). The column was flushed with D.I. water (20 mL), then gradient eluted with 0.1%-1.0% NH₄OH in D.I. water. The fractions containing the product were combined, acidified with glacial acetic acid, and lyophilized to afford DCWSU167 (6.3 mg, 63%) as the peracetate salt in the form of a white solid; [α]_(D) ²⁵=+107.38 (c 0.4, H₂O); ¹H NMR (600 MHz, D₂O): δ 5.52 (d, J=3.8 Hz, 1H, H-1′), 5.32 (d, J=4.0 Hz, 1H, H-1″), 5.04 (d, J=8.5 Hz, 1H, H-8′), 4.38 (s, 1H, H-6′), 3.90-3.84 (m, 1H, CH₂OHCH₂O), 3.80-3.66 (m, 5H, H-4, H-4′, H-3″, H-5″, H-6″), 3.66-3.55 (m, 6H, H-5, H-5′, H-6″, CH₂OHCH₂O, CH₂OHCH₂O), 3.54 (dd, J=9.7, 4.0 Hz, 1H, H-2″), 3.47 (dt, J=13.0, 4.1 Hz, 1H, H-2′), 3.33 (t, J=9.7 Hz, 1H, H-6), 3.27-3.15 (m, 3H, H-1, H-3, H-7′), 3.08 (t, J=10.3 Hz, 1H, H-4″), 2.61 (s, 3H, NCH₃), 2.31-2.24 (m, 1H, H-2), 2.20 (dt, J=8.7, 3.9 Hz, 1H, H-3′), 1.86 (q, J=11.6 Hz, 1H, H-3′), 1.64 (q, J=11.7, 11.0 Hz, 1H, H-2); ¹³C NMR (151 MHz, D₂O): δ 95.6 (C-1′), 94.4 (C-1″), 92.9 (C-8′), 81.5 (C-6), 79.0 (C-4), 75.3 (C-5), 74.0 (CH₂OHCH₂O), 70.2 (C-2″), 69.7 (C-5′), 69.6 (C-5″), 68.6 (C-3″), 66.0 (C-4′), 62.8 (C-6′), 60.8 (CH₂OHCH₂O), 60.3 (C-6″), 59.4 (C-7′), 52.0 (C-4″), 49.1 (C-1), 48.3 (C-3), 47.9 (C-2′), 30.0 (NCH₃), 28.9 (C-2), 26.8 (C-3′); ESI-HRMS: m/z calcd. for C₂₄H₄₈N₅O₁₃ [M+H]⁺ 584.3143; found, 584.3129.

Example 9 DCWSU177

-   See the synthetic scheme of FIG. 5.

1,2,3-Tri-O-acetyl-5-deoxy-5-phthalimido-α-D-ribofuranose (I). 1,2,3-Tri-O-acetyl-5-O-p-tolylsulfonyl-D-ribofuranose H (1.00 g, 2.3 mmol) was dissolved in dry DMF (20 mL) and treated with potassium phthalimide (1.00 g, 5.4 mmol). The reaction mixture was stirred at 50° C. for 12 h before it was diluted with water and extracted with DCM three times. The organic layer wash then washed with 5% aqueous NaOH and brine, dried over Na₂SO₄, and concentrated. The residue was purified using silica gel column chromatography (eluent: 15% −35% EtOAc/hexanes) to give I (566 mg, 60%) as a white solid; [α]_(D) ²⁵=+49.66 (c 1.3, DCM); ¹H NMR (400 MHz, CDCl₃): δ 7.80-7.73 (m, 2H, ArH), 7.70-7.62 (dd, J=5.4, 3.1 Hz, 2H, ArH), 6.34 (d, J=4.5 Hz, 1H, H-1), 5.23 (dd, J=6.8, 4.5 Hz, 1H, H-2), 5.15 (dd, J=6.7, 3.4 Hz, 1H, H-3), 4.48 (td, J=6.8, 3.4 Hz, 1H, H-4), 3.86 (dd, J=6.8, 5.2 Hz, 2H, H-5), 2.03-1.95 (m, 9H, COCH₃);¹³C NMR (101 MHz, CDCl₃): δ 169.9 (C═O), 169.4 (C═O), 169.2 (C═O), 168.0 (C═O), 134.1 (ArC), 131.8 (ArC), 123.4 (ArC), 93.7 (C-1), 80.4 (C-4), 70.7 (C-3), 69.6 (C-2), 39.3 (C-5), 20.9 (COCH₃), 20.5 (COCH₃), 20.2 (COCH₃); ESI-HRMS: m/z calcd. for C₁₉H₁₉NNaO₉ [M+Na] 428.0958; found, 428.0964.

2,3-Di-O-acetyl-5-deoxy-5-phthalimido-D-ribofuranosyl trichloroacetimidate (J). To an ice-cooled solution of I (550 mg, 1.36 mmol) in DCM (5 mL), 33% HBr/acetic acid (0.7 mL, 4.07 mmol) was added followed by stirring for 45 min. After completion, solid NaHCO₃ was added to neutralize the reaction, then water was added and the aqueous layer was extracted with DCM three times. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified using silica gel column chromatography (eluent: 20% −60% EtOAc/hexanes) to give 2,3-di-O-acetyl-5-deoxy-5-phthalimido-α/β-D-ribofuranose as a mixture of anomers α:β=1:3 (200 mg, 41%) that was used directly in the next step. 2,3-Di-O-acetyl-5-deoxy-5-phthalimido-α/β-D-ribofuranose (190 mg, 0.53 mmol) and trichloroacetonitrile (2 mL) were dissolved in dry DCM (2 mL) and ice-cooled before addition of DBU (2 drops). The reaction mixture was stirred at rt for 5 min and concentrated. The crude product was passed through a silica gel column, basified with 0.5% triethylamine/hexanes, eluting with 0.5% triethylamine in EtOAc/hexanes to give compound J (270 mg, quant) which was used in the next step without further purification.

5-O-β-(2′″, 3′″-Di-O-acetyl-5′″-deoxy-5′″-phthalimido-D-ribofuranosyl)-6,2″,3″,6″-tetra-O-acetyl-1,3,2′,4″-tetraazido-6′,7′-oxazolidino-apramycin (K). Donor I (190 mg, 0.52 mmol), acceptor A (701 mg, 0.84 mmol) and activated 4 Å MS were stirred in dry DCM (3 mL) at rt for 1 h before cooling to 0° C. BF₃.OEt₂ (400 μL, 1.08 mmol) was added and reaction mixture was stirred for 2 h at 0° C. The reaction was quenched with triethylamine (0.5 mL) and filtered through Celite® before it was diluted with EtOAc and washed with aqueous NaHCO₃ and brine. The organic layer was dried over Na₂SO₄and concentrated. The crude product was purified using silica gel column chromatography (eluent: 0.6%-1.5% methanol/DCM) to give the glycoside K (470 mg, 76%) as the β anomer in the form of a white solid; [α]_(D) ²⁵=+131.96 (c 5.3, DCM); ¹H NMR (400 MHz, CDCl₃): δ 7.95-7.88 (m, 2H, ArH), 7.77-7.70 (m, 2H, ArH), 5.39 (t, J=9.9 Hz, 1H, H-3″), 5.34 (d, J=3.8 Hz, 2H, H-1′, H-1″), 5.30 (s, 1H, H-1′″), 5.12 (d, J=4.9 Hz, 1H, H-2′″), 5.06 (dd, J=7.2, 4.8 Hz, 1H, H-3″), 4.95-4.88 (m, 2H, H-8′, H-2″), 4.83 (dd, J=8.2, 2.9 Hz, 1H, H-6′), 4.66 (dd, J=10.5, 2.9 Hz, 1H, H-5′), 4.46 (t, J=9.9 Hz, 1H, H-6), 4.42-4.29 (m, 2H, H-6″, H-4′″), 4.22 (dd, J=12.2, 5.2 Hz, 1H, H-6″), 3.96 (d, J=5.0 Hz, 2H, H-5′″), 3.84-3.68 (m, 3H, H-4′, H-6′, H-5″), 3.65-3.53 (m, 3H, H-3, H-4, H-4″), 3.46-3.28 (m, 3H, H-1, H-5, H-2′), 2.94 (s, 3H, NCH₃), 2.41 (dt, J=12.6, 4.3 Hz, 1H, H-2), 2.23 (s, 4H, H-3′, COCH₃), 2.13-1.98 (m, 15H, 5*COCH₃), 1.78 (q, J=11.7 Hz, 1H, H-3′), 1.43 (q, J=12.6 Hz, 1H, H-2);¹³C NMR (101 MHz, CDCl₃): δ 170.3 (C═O), 170.2 (C═O), 169.9 (C═O), 169.8 (C═O), 169.5 (C═O), 168.2 (C═O), 157.2 (C═O), 134.1 (ArC), 132.0 (ArC), 123.7 (ArC), 106.9 (C-1′″), 97.0 (C-1′), 94.8 (C-8′), 93.8 (C-1″), 79.8 (C-5), 79.1 (C-4′″), 78.9 (C-4), 74.0 (2′″), 73.4 (C-6), 72.6 (C-3′″), 70.7 (C-6′), 70.3 (C-3″), 69.9 (C-2″), 68.9 (C-5″), 65.4 (C-5′), 65.3 (C-4′), 62.9 (C-6″), 60.21 (C-7′), 60.16 (C-4″), 58.4 (C-3), 58.2 (C-1), 57.7 (C-2), 39.5 (C-5′″), 31.4 (C-2), 31.3 (C-3′), 29.9 (NCH₃), 20.9 (COCH₃), 20.8 (COCH₃), 20.8 (COCH₃), 20.7 (COCH₃), 20.6 (COCH₃), 20.4 (COCH₃); ESI-HRMS: m/z calcd. for C₄₇H₅₄N₁₄NaO₂₃ [M+Na]⁺ 1205.3384; found, 1205.3359.

5-O-β-(5′″-Formamido-5′″-deoxy-D-ribefuranosyl) apramycin pentaacetate salt (DCWSU177). To a stirred solution of compound K (50 mg, 0.04 mmol) in an IPA:water mixture (7:3, 1.5 mL), NaBH₄ (90 mg, 2.4 mmol) was added followed by stirring for 2 h. The reaction mixture was diluted with methanol and glacial acetic acid was added dropwise until effervescence stopped. The reaction mixture was concentrated in vacuo followed by the addition of 3 N NaOH (0.5 mL) and water (0.5 mL). The reaction mixture was heated at 100° C. for 1 h before it was cooled, neutralized with glacial acetic acid and concentrated. The crude mixture was desalted using a Sephadex column and the product-containing fractions were concentrated. A part of the solid residue (8.2 mg, 0.009 mmol) was dissolved in water (0.2 mL) and treated with N-(diethylcarbamoyl)-N-methoxyformamide (2.4 μL, 0.014 mmol) and triethylamine (1 μL). The reaction mixture was stirred for 2 h and quenched with ammonium hydroxide (0.25 mL) followed by addition of 1M P(CH₃)₃ in THF (0.3 mL) and stirring at 60° C. for 3 h. The reaction mixture was then concentrated to dryness and dissolved in aqueous acetic acid solution (pH 4, 1 mL) before it was charged to a Sephadex column (CM Sephadex C-25). The column was flushed with D.I. water (20 mL), then gradient eluted with 0.1%-1.0% NH₄OH in D.I. water. The fractions containing the product were combined, acidified with acetic acid and lyophilized to afford DCWSU177 in (4.5 mg, 42%) as the peracetate salt in the form of a white solid; [α]_(D) ²⁵=+82.2 (c 0.2, H₂O);¹H NMR (600 MHz, D₂O): δ 7.98 (s, 1H, CHO), 5.67 (d, J=3.9 Hz, 1H, H-1′), 5.34 (d, J=3.9 Hz, 1H, H-1″), 5.14 (d, J=2.9 Hz, 1H, H-1′“), 5.06 (d, J=8.5 Hz, 1H, H-8′), 4.46-4.39 (m, 1H, H-6′), 4.02 (dd, J=4.4, 3.2 Hz, 1 H, H-2”), 3.94 (t, J=5.3 Hz, 1H, H-3′″), 3.90 (q, J=5.7 Hz, 1H, H-3′″), 3.85-3.67 (m, 6H, H-4, H-5, H-4′, H-3″, H-5″, H-6), 3.63 (dd, J=12.5, 4.6 Hz, 1H, H-6″), 3.56 (dd, J=9.8, 3.8 Hz, 1H, H-2″), 3.54-3.50 (m, 3H, H-6, H-2′, H-5′), 3.42 (dd, J=14.6, 4.2 Hz, 1H, H-5″′), 3.32 (dd, J=14.6, 6.2 Hz, 1H, H-5′″), 3.29-3.23 (m, 1H, H-3), 3.22 (dd, J=8.5, 2.7 Hz, 1H, H-7′), 3.16 (td, J=11.6, 10.9, 4.3 Hz, 1H, H-1), 3.10 (t, J=10.3 Hz, 1H, H-4″), 2.63 (s, 3H, NCH₃), 2.30-2.16 (m, 2H, H-2, H-3′), 1.94-1.83 (m, 1H, H-3′), 1.68-1.55 (m, 1H, H-2); ¹³C NMR (151 MHz, D₂O): δ 164.7(CHO), 110.0 (C-1′″), 94.4 (C-1″), 94.0 (C-1′), 92.9 (C-8′), 85.1 (C-5), 80.9 (C-4′″), 76.4 (C-4), 74.7 (C-2′″), 72.5 (C-6), 70.8 (C-3′″), 70.2 (C-2″), 69.7 (C-5″), 69.7 (C-4′), 68.6 (C-3″), 65.9 (C-5′), 62.7 (C-6′), 60.3 (C-6″), 59.4 (C-7′), 52.0 (C-4″), 49.8 (C-3), 48.5 (C-1), 47.7 (C-2′), 40.0 (C-5′″), 30.0 (NCH₃), 28.9 (C-2), 26.8 (C-3′); ESI-HRMS: m/z calcd. for C₂₇H₅₁N₆O₁₅ [M+H]⁺ 699.3412; found, 699.3410.

Example 10 DCWSU 178

-   See the synthetic scheme of FIG. 6.

5-O-Benzyl-3-O-(2-benzyloxyethyl)-1,2-O-isopropylidene-α-D-ribofuranose (g). 5-O-benzyl-1,2-O-isopropylidene-α-D-ribofuranose f (1.00 g, 3.57 mmol) was dissolved in dry THF (20 mL) and NaH (185 mg, 4.64 mmol) was added under argon. After stirring for 15 min, 2-benzyloxyethyl tosylate (1.31 g, 4.29 mmol) was added and stirring continued for 12 h. More NaH (185 mg, 4.64 mmol) and 2-benzyloxyethyl tosylate (1.31 g, 4.29 mmol) were added and the mixture stirred for 24 h. After completion, the reaction was quenched with methanol, diluted with EtOAc and washed with aqueous NaHCO₃ and brine. The organic layer was dried over Na₂SO₄ and concentrated. The crude product was purified using silica gel column chromatography (eluent: 5% to 12% EtOAc/hexanes) to give g (1.24 g, 83%) in the form of a colorless oil; [α]_(D) ²⁵=+42.22 (c 2.2, DCM); ¹H NMR (400 MHz, CDCl₃): δ 7.39-7.26 (m, 10H, ArH), 5.77 (d, J=3.7 Hz, 1H, H-1), 4.63 (d, J=4.1 Hz, 1H, H-2), 4.61 (d, J=4.1 Hz, 1H, CH₂Ph), 4.58-4.52 (m, 3H, CH₂Ph), 4.14 (ddd, J=9.1, 4.1, 2.0 Hz, 1H, H-4), 3.92-3.76 (m, 3H, H-3, H-5, CH₂CH₂), 3.76-3.56 (m, 4H, H-5, 3H—CH₂CH₂), 1.57 (s, 3H, CH₃), 1.35 (s, 3H, CH₃); ¹³C NMR (101 MHz, CDCl₃): δ 138.2 (ArC), 138.1 (ArC), 128.4 (ArC), 128.3 (ArC), 127.73 (ArC), 127.69 (ArC), 127.67 (ArC), 127.63 (ArC), 127.59 (ArC), 112.8(C(CH₃)₂), 104.0 (C-1), 79.0 (C-3), 77.9 (C-4), 77.5 (C-2), 73.5 (CH₂Ph), 73.2 (CH₂Ph), 70.7 (CH₂CH₂), 70.1 (CH₂CH₂), 68.2 (C-5), 26.8 (CH₃), 26.5 (CH₃); ESI-HRMS: m/z calcd. for C₂₄H₃₀NaO₆ [M+Na]⁺ 437.1940; found, 437.1939.

5-O-Benzyl-3-O-(2-benzyloxyethyl)-1,2-di-O-(4-nitrobenzoyl)-α-D-ribofuranose (hα) and 5-O-Benzyl-3-O-(2-benzyloxyethyl)-1,2-di-O-(4-nitrobenzoyl)-β-D-ribofuranose (hβ). To a stirred solution of compound g (600 mg, 1.45 mmol) in dioxane (10 mL), 1 N HCl (5 mL) was added and the reaction mixture was heated at 80° C. for 45 min. The reaction mixture was cooled, neutralized with solid NaHCO₃ then the solvent was evaporated. The residue was dissolved in EtOAc and washed with water and brine. The organic layer was dried over Na₂SO₄ and concentrated. To a solution of the residue in dry pyridine (10 mL), p-nitrobenzoyl chloride (672 mg, 3.6 mmol) and a catalytic amount of DMAP were added followed by stirring overnight. The reaction mixture was concentrated then diluted with EtOAc and washed with aqueous NaHCO₃, brine, dried with Na₂SO₄ and concentrated. The crude product was purified using silica gel column chromatography (eluent: 5%-25% EtOAc/hexanes) to give h α:β=1:1.5 (820 g, 84%, yellow oil). Further purification was done to separate analytical sample of anomers: hα (86 mg, 9%, yellow oil), hβ (63 mg, 6%, yellow oil); α anomer: [α]_(D) ²⁵=+74.69 (c 5.7, DCM); ¹H NMR (400 MHz, CDCl₃): δ 8.26-8.21 (m, 2H, ArH), 8.19-8.14 (m, 2H, ArH), 8.11-8.07 (m, 4H, ArH), 7.42-7.27 (m, 5H, ArH), 7.27-7.22 (m, 3H, ArH), 7.20-7.06 (m, 2H, ArH), 6.81 (d, J=4.4 Hz, 1H, H-1), 5.47 (dd, J=6.3, 4.4 Hz, 1H, H-2), 4.66-4.53 (m, 3H, H-4, CH₂Ph), 4.49-4.41 (m, 2H, CH₂Ph), 4.38 (dd, J=6.3, 2.8 Hz, 1H, H-3), 3.81-3.73 (m, 2H, CH₂CH₂), 3.71-3.65 (m, 2H, H-5), 3.66-3.56 (m, 2H, CH₂CH₂); ¹³C NMR (101 MHz, CDCl₃): δ 163.7 (C═O), 163.6 (C═O), 150.7 (ArC), 150.7 (ArC), 137.8 (ArC), 137.6 (ArC), 135.1 (ArC), 134.5 (ArC), 131.0 (ArC), 130.7 (ArC), 128.5 (ArC), 128.4 (ArC), 127.9 (ArC), 127.7 (ArC), 127.3 (ArC), 123.6 (ArC), 96.0 (C-1), 85.0 (C-4), 76.9 (C-3), 73.7 (CH₂Ph), 73.4 (CH₂Ph), 73.2 (C-2), 71.2 (CH₂CH₂), 69.9 (CH₂CH₂), 69.5 (C-5); ESI-HRMS: m/z calcd. for C₃₅H₃₂N₂NaO₁₂ [M+Na]⁺ 695.1853; found, 695.1859; β anomer: [α]_(D) ²⁵=−11.33 (c 0.042, DCM); ¹H NMR (400 MHz, CDCl₃): δ 8.22 (m, 4H, ArH), 8.12-8.05 (m, 2H, ArH), 8.05-7.99 (m, 2H, ArH), 7.29-7.16 (m, 10H, ArH), 6.55 (s, 1H, H-1), 5.74 (d, J=4.4 Hz, 1H, H-2), 4.66 (dd, J=7.7, 4.4 Hz, 1H, H-3), 4.51 (s, 2H, CH₂Ph), 4.46-4.39 (m, 3H, H-4, CH₂Ph), 3.85 (dd, J=11.0, 2.7 Hz, 1H, H-5), 3.83-3.75 (m, 2H, CH₂CH₂), 3.72 (dd, J=11.1, 3.5 Hz, 1H, H-5), 3.64-3.53 (m, 2H, CH₂CH₂); ¹³C NMR (101 MHz, CDCl₃): δ 163.6 (C═O), 163.0 (C═O), 150.7 (ArC), 150.6 (ArC), 137.9 (ArC), 137.8 (ArC), 134.6 (ArC), 131.0 (ArC), 130.9 (ArC), 128.4 (ArC), 128.3 (ArC), 127.7 (ArC), 127.6 (ArC), 127.5 (ArC), 123.6 (ArC), 123.5 (ArC), 99.5 (C-1), 82.2 (C-4), 77.3 (C-3), 75.2 (C-2), 73.5 (CH₂Ph), 73.2 (CH₂Ph), 71.1 (CH₂CH₂), 69.7 (CH₂CH₂), 68.8 (C-5); ESI-HRMS: m/z calcd. for C₃₅H₃₂N₂NaO₁₂ [M+Na]⁺ 695.1853; found, 695.1846.

5-O-β-[5′″-O-Benzyl-3′″-O-(2-benzyloxyethyl)-1′″,2′″-di-O-(4-nitrobenzoyl)-D-ribefuranosyl]-6,2″,3″,6″-tetra-O-acetyl-1,3,2′,4″-tetraazido-6′,7′-oxazolidino-apramycin (i). Donor h (161 mg, 0.24 mmol), acceptor A (67 mg, 0.08 mmol) and activated 4 Å MS were stirred in dry DCM at rt for 1 h before cooling to 0° C. BF₃.OEt₂(100 μL, 0.27 mmol) was added and reaction mixture was stirred for 48 h at 0° C. The reaction was quenched with triethylamine (0.5 mL) and filtered through Celite® before dilution with EtOAc and washing with aqueous NaHCO₃ and brine and concentration. The crude product was purified using silica gel column chromatography (eluent: 0.6%-1.5% methanol/DCM) to give the β anomer i (14 mg, 13%) as a white solid. An approximately equal amount of the α-anomer was also obtained but not charwcterized. [α]_(D) ²⁵=+56.85 (c 0.7, DCM); ¹H NMR (600 MHz, CDCl₃): δ 8.20-8.11 (m, 4H, ArH), 7.40-7.30 (m, 5H, ArH), 7.24-7.10 (m, 5H, ArH), 5.80 (d, J=3.6 Hz, 1H, H-1′), 5.43 (t, J=10.0 Hz, 1H, H-3″), 5.39-5.34 (m, 2H, H-1″, H-1′″), 5.26 (d, J=4.3 Hz, 1H, H-2′″), 4.91 (t, J=9.7 Hz, 1H, H-6), 4.87 (dd, J=10.3, 3.9 Hz, 1H, H-2”), 4.81 (d, J=4.5 Hz, 1H, H-8′), 4.76 (dd, J=7.4, 3.3 Hz, 1H, H-6′), 4.57 (d, J=12.0 Hz, 1H, CH₂Ph), 4.51 (d, J=12.0 Hz, 1H, CH₂Ph), 4.39 (dd, J=10.3, 3.4 Hz, 1H, H-5′), 4.37-4.31 (m, 3H, CH₂Ph, H-6″), 4.27-4.19 (m, 2H, H-6″, H-4′″), 4.14 (dd, J=7.5, 4.4 Hz, 1H, H-3′″), 3.87-3.71 (m, 4H, H-5, H-7′, H-5″, H-5′″), 3.71-3.63 (m, 3H, H-4, CH₂CH₂), 3.63-3.52 (m, 4H, H-3, H-5″ H-4′, H-4″), 3.51-3.37 (m, 3H, H-1, CH₂CH₂), 3.08 (dt, J=12.9, 4.2 Hz, 1H, H-2′), 2.95 (s, 3H, NHCH₃), 2.41 (dt, J=13.1, 4.5 Hz, 1H, H-2), 2.23-1.97 (m, 13H, 4COCH₃, H-3′), 1.87 (q, J=11.7 Hz, 1H, H-3′), 1.57 (q, J=12.6 Hz, 1H, H-2); ¹³C NMR (151 MHz, CDCl₃): δ 170.3 (C═O), 170.1 (C═O), 169.8 (C═O), 169.7 (C═O), 163.8 (C═O), 157.1 (ArC), 150.7 (ArC), 137.9 (ArC), 137.9 (ArC), 134.7 (ArC), 130.8 (ArC), 128.5 (ArC), 128.2 (ArC), 127.7 (ArC), 127.6 (ArC), 127.5 (ArC), 127.4 (ArC), 123.6 (ArC), 107.2 (C-1′″), 97.3 (C-8′), 96.4 (C-1′), 94.2 (C-1″), 82.0 (C-5), 80.7 (C-4′″), 77.8 (C-4), 77.7 (C-3′″), 75.7 (C-2″), 75.0 (C-6), 73.4 (CH₂Ph), 73.0 (CH₂Ph), 71.0 (C-6′), 70.8 (C-3″), 70.4 (CH₂CH₂), 70.3 (C-5′″), 69.9 (C-2″), 69.2 (C-5″), 69.1 (CH₂CH₂), 65.9 (C-5′), 65.7 (C-4′), 62.9 (C-6″), 60.20 (C-4″), 60.17 (C-7′), 59.1 (C-3), 58.1 (C-1), 56.5 (C-2′), 31.3 (C-2), 30.1 (C-3′), 29.7 (NCH₃), 20.9 (COCH₃), 20.8 (COCH₃), 20.7 (COCH₃); ESI-HRMS: m/z calcd. for C₅₈H₆₆N₁₄NaO₂₄ [M+Na]⁺ 1365.4272; found, 1365.4260.

5-O-β-[3′″-O-(2-Hydroxyethyl)-D-ribofuranosyl] apramycin pentaacetate salt (DCWSU178). A stirred solution of compound i (10 mg, 0.01 mmol) in dioxane (0.5 mL) was treated with 3N NaOH (0.25 mL) and heated at 100° C. for 3 h. The reaction mixture was cooled to rt and neutralized with Amberlyst® before concentration in vacuo. The crude product was dissolved in dioxane:water:glacial acetic acid=1:2:0.2 (0.3 mL) and Pd(OH)₂/C (0.5 equiv) was added. The reaction mixture was stirred at room temperature under 50 psi of hydrogen for 12 h. After completion, the reaction mixture was filtered through Celite® and concentrated to dryness. The residue was then dissolved in aqueous acetic acid solution (pH 4, 1 mL) before it was charged to a Sephadex column (CM Sephadex C-25). The column was flushed with D.I. water (20 mL), then gradient eluted with 0.1%-1.0% NH₄OH in D.I. water. The fractions containing the product were combined, acidified with glacial acetic acid and lyophilized to afford DCWSU178 (3.5 mg, 48%) as the peracetate salt in the form of a white solid; [α]_(D) ²⁵=+72.0 (c 0.1, H₂O); ¹H NMR (600 MHz, D₂O): δ 5.72 (d, J=3.6 Hz, 1H, H-1′), 5.34 (d, J=3.8 Hz, 1H, H-1″), 5.20 (s, 1H, H-1′″), 5.06 (d, J=8.5 Hz, 1H, H-8′), 4.43 (s, 1H, H-6′), 4.21 (d, J=4.3 Hz, 1H, H-2′″), 3.97-3.92 (m, 1H, H-4′″), 3.91-3.86 (m, 1H, H-4), 3.86-3.79 (m, 2H, H-5″, H-3′″), 3.78-3.66 (m, 7H, H-5, H-4′, H-5′″, H-6″, H-3″, CH₂CH₂), 3.63 (dd, J=12.4, 4.6 Hz, 1H, H-6″), 3.60-3.55 (m, 3H, H-2″,CH₂CH₂), 3.55-3.45 (m, 4H, H-6, H-2′, H-6′, H-5′″), 3.42-3.33 (m, 1H, H-3), 3.24 (d, J=8.9 Hz, 1H, H-7′), 3.21-3.09 (m, 2H, H-, H-1, H-4″), 2.63 (s, 3H, NCH₃), 2.32 (dt, J=12.3, 3.8 Hz, 1H, H-2), 2.23-2.15 (m, 1H, H-3′), 1.94-1.90 (m, 1H, H-3′), 1.70 (q, J=12.8 Hz, 1H, H-2); ¹³C NMR (151 MHz, D₂O): δ 110.4 (C-1′″), 94.6 (C-1′), 94.4 (C-1″), 92.8 (C-8′), 84.8 (C-5), 81.1 (C-4′″), 77.0 (C-3′″), 75.2 (C-4), 73.4 (C-2″), 72.4 (C-6), 71.4 (CH₂CH₂), 70.2 (C-5″), 69.7 (C-2″), 69.3 (C-3″), 68.2 (C-4′), 66.0 (C-5′), 62.6 (C-6′), 60.9 (C-5′″), 60.5 (CH₂CH₂), 60.3 (C-6″), 59.3 (C-7′), 52.0 (C-4″), 49.7 (C-3), 48.3 (C-1), 47.8 (C-2′), 30.0 (NCH₃), 28.0 (C-2), 26.6 (C-3′); ESI-HRMS: m/z calcd. for C₂₈H₅₄N₅O₁₆ [M+H]⁺ 716.3566; found, 716.3541.

Example 11 DCWSU 185 and 186

-   See the synthetic scheme of FIG. 7.

5-Azido-3-O-(2-benzyloxyethyl)-5-deoxy-1,2-O-isopropylidene-α-D-ribofuranose (M). 5-Azido-5-deoxy-1,2-O-isopropylidene-α-D-ribofuranose L (4.0 g, 18.6 mmol) was dissolved in dry THF (100 mL) and NaH (100 mg, 24.5 mmol) was added. After stirring for 15 min, 2-benzyloxyethyl tosylate (6.83 g, 22.3 mmol) was added and stirring continued for 36 h. After completion, the reaction was quenched with methanol, diluted with EtOAc and washed with aqueous NaHCO₃ and brine then concentrated. The crude product was purified using silica gel column chromatography (eluent: 10% to 20% EtOAc/hexanes) to give M (3.08 g, 47%) in the form of a colorless oil; [α]_(D) ²⁵=+119.83 (c 1.2, DCM); ¹H NMR (400 MHz, CDCl₃): δ 7.45-7.21 (m, 5H, ArH), 5.76 (d, J=3.5 Hz, 1H, H-1), 4.64 (t, J=3.9 Hz, 1H, H-2), 4.56 (s, 2H, CH₂Ph), 4.14 (dt, J=8.5, 3.2 Hz, 1H, H-4), 3.91-3.71 (m, 2H, H-3, CH₂CH₂), 3.76-3.64 (m, 4H, H-, CH₂CH₂, CH₂CH₂, H-5), 3.32 (dd, J=13.5, 4.0 Hz, 1H, H-5), 1.57 (s, 3H, CH₃), 1.35 (s, 3H, CH₃); ¹³C NMR (101 MHz, CDCl₃): δ 138.0 (ArC), 128.4 (ArC), 127.7 (ArC), 113.2(C(CH₃)₂), 103.9 (C-1), 79.5 (C-3), 77.4 (C-4), 77.3 (C-2), 73.3 (CH₂Ph), 70.1 (CH₂CH₂), 69.7 (CH₂CH₂), 50.6 (C-5), 26.8(CH₃), 26.5(CH₃). ; ESI-HRMS: m/z calcd. for C₁₇H₂₃N₃NaO₅ [M+Na]⁺ 372.1535; found, 372.1538.

5-Benzyloxycarbonylamino-5-deoxy-3-O-(2-hydroxyethyl)-1,2-O-isopropylidene-α-D-ribofuranose (N). To a solution of compound (M) (3.0 g, 8.6 mmol) in dioxane:water=5:1 (30 mL), 20% Pd(OH)₂/C (3.0 g, 0.5 equiv) was added and the reaction mixture stirred at room temperature under 50 psi of hydrogen for 18 h. After completion, the reaction mixture was filtered over Celite®, concentrated to dryness and dissolved in dioxane:water=3:1 (50 mL). K₂CO₃ (6.0 g, 43.5 mmol) and benzyloxy chloroformate (2.5 mL, 17.2 mmol) were added and the reaction mixture was stirred for 4 h. After completion, the reaction mixture was concentrated and purified using silica gel column chromatography (eluent: 0.8% to 1% methanol/DCM) to give N (1.67 g, 53%) as a colorless oil; [α]_(D) ²⁵=+35.47 (c 1.5, DCM); ¹H NMR (400 MHz, CDCl₃): δ 7.41-7.28 (m, 5H, ArI-1), 5.73 (d, J=3.8 Hz, 1H, H-1), 5.10 (d, J=1.4 Hz, 2H (CH₂Ph)), 4.60 (t, J=4.1 Hz, 1H, H-2), 4.03 (dt, J=9.0, 3.6 Hz, 1H, H-4), 3.77-3.61 (m, 5H, CH₂CH₂, CH₂CH₂, H-5), 3.55 (dd, J=9.0, 4.4 Hz, 1H, H-3), 3.45 (dt, J=14.6, 4.2 Hz, 1H, H-5), 3.04 (t, J=5.8 Hz, 1H, OH), 1.56 (s, 3H, CH₃), 1.35 (s, 3H, CH₃);¹³C NMR (101 MHz, CDCl₃): δ 156.9 (C═O), 136.3 (ArC), 128.5 (ArC), 128.2 (ArC), 113.1(C(CH₃)₂), 104.1 (C-1), 79.3 (C-3), 77.1 (C-2), 77.0 (C-4), 72.0 (CH₂CH₂), 67.0 (CH₂Ph), 61.6 (CH₂CH₂), 40.6 (C-5), 26.6 (CH₃), 26.5 (CH₃); ESI-HRMS: m/z calcd. for C₁₈H₂₅NNaO₇ [M+Na]⁺ 390.1529; found, 390.1537.

3-O-(2-Azidoethyl)-5-benzyloxycarbonylamino-5-deoxy-1,2-O-isopropylidene-α-D-ribofuranose (O). To a stirred solution of the alcohol N (1.0 g, 2.7 mmol) in dry THF (5 mL), triethylamine (2.8 mL, 20.4 mmol). The reaction mixture was ice-cooled before addition of p-tolylsulfonyl chloride (975 mg, 5.13 mmol) in dry THF (5 mL). The reaction mixture was stirred at 30° C. for 48 h before it was concentrated in vacuo. The crude product was dissolved in EtOAc and washed with aqueous NaHCO₃ and brine, dried over Na₂SO₄, and concentrated. The resulted solid was dissolved in dry DMF (10 mL) and treated with NaN₃ (1.05 g, 16.3 mmol) and stirred at 40° C. for 48 h. After completion, the reaction mixture was diluted with acetone and excess NaN₃ was filtered off. The solvent was partially removed under vacuum and the residue was diluted with EtOAc, washed with brine, dried over Na2SO4, and filtered. The solvent was removed under vacuum and the resulting product was purified using silica gel column chromatography (eluent: 10% to 25% EtOAc/hexanes) to give 0 (900 mg, 84% over two steps) as a viscous oil; [α]_(D) ²⁵=+35.38 (c 1.9, DCM); ¹H NMR (400 MHz, CDCl₃): δ 739-7.27 (m, 5H, ArI-1), 5.73 (d, J=3.7 Hz, 1H, H-1), 5.10 (s, 2H, CH₂Ph), 4.60 (t, J=4.1 Hz, 1H, H-2), 4.05 (dt, J=8.6, 4.1 Hz, 1H, H-4), 3.82 (ddd, J=10.1, 6.0, 3.8 Hz, 1H, CH₂O), 3.67 (ddd, J=10.3, 6.5, 3.9 Hz, 1H, CH₂O), 3.63-3.47 (m, 3H, H-3, H-5), 3.47-3.32 (m, 2H, CH₂N₃), 1.56 (s, 3H, CH₃), 1.34 (s, 3H, CH₃);¹³C NMR (101 MHz, CDCl₃): δ 156.5 (C═O), 136.4 (ArC), 128.5 (ArC), 128.1 (ArC), 113.3(C(CH₃)₂), 104.1 (C-1), 80.0 (C-3), 77.1 (C-2), 77.0 (C-4), 69.4 (CH₂O), 66.9 (CH₂Ph), 50.7 (CH₂N₃), 41.1 (C-5), 26.7 (CH₃), 26.6 (CH₃); ESI-HRMS: m/z calcd. for C₁₈H₂₄N₄NaO₆ [M+Na]⁺415.1594; found, 415.1589.

3-O-(2-Azidoethyl)-5-di(benzyloxycarbonyl)amino-5-deoxy-1,2-O-isopropylidene-α-D-ribofuranose (P)

A stirred solution of the compound O (200 mg, 0.51 mmol) in dry THF (8 mL) and HMPA (2 mL), was cooled to -78° C. under argon before KHMDS (0.5 M in toluene, 1.5 mL, 0.66 mmol) and benzyloxychloroformate (0.3 mL, 2.1 mmol) were added. The reaction mixture was stirred at −78° C. for 2 h before additional KHMDS (0.5 M in toluene, 3 mL, 1.5 mmol) was added. The reaction was stirred for 30 min and quenched with NH₄Cl, diluted with EtOAc, and washed with aqueous NaHCO₃ and brine. The organic layer was dried over Na₂SO₄ and concentrated. The crude product was purified using silica gel column chromatography (eluent: 10% to 25% EtOAc/hexanes) to give P (272 mg, quant) [α]_(D) ²⁵=+14.73 (c 1.5, DCM); ¹H NMR (400 MHz, CDCl₃): δ 7.48-7.28 (m, 10H, ArH), 5.70 (d, J=3.8 Hz, 1H, H-1), 5.42-5.12 (m, 4H, CH₂Ph), 4.56 (t, J=4.1 Hz, 1H, H-2), 4.20 (dt, J=8.9, 5.4 Hz, 1H, H-4), 4.07 (dd, J=5.4, 1.2 Hz, 2H, H-5), 3.72 (ddd, J=9.9, 6.0, 4.0 Hz, 1H, CH₂O), 3.57 (dd, J=8.8, 4.4 Hz, 1H, H-3), 3.45 (ddd, J=10.1, 6.3, 4.2 Hz, 1H, CH₂O), 3.34-3.16 (m, 2H, CH₂N₃), 1.51 (s, 3H, CH₃), 1.33 (s, 3H, CH₃);¹³C NMR (101 MHz, CDCl₃): δ 153.6 (C═O), 135.2 (ArC), 128.5 (ArC), 128.3 (ArC), 128.2 (ArC), 128.1 (ArC), 113.1(C(CH₃)₂), 104.2 (C-1), 81.3 (C-3), 77.4 (C-2), 77.1 (C-4), 68.9 (CH₂O), 68.8 (CH₂Ph), 66.9 (CH₂Ph), 50.5 (CH₂N₃), 47.1 (C-5), 26.7 (201-1₃); ESI-HRMS: m/z calcd. for C₂₆H₃₀N₄NaO₈ [M+Na]⁺ 549.1961; found, 549.1962.

3-O-(2-Azidoethyl)-5-di(benzyloxycarbonyl)amino-5-deoxy-1,2-di-O-(p-nitrobenzoyl)-α/β-D-ribofuranose (Q). To a stirred solution of compound P (268 mg, 0.51 mmol) in dioxane (10 mL), 1 N HCl (4 mL) was added and the reaction mixture was heated at 80° C. for 2 h. The reaction mixture was cooled, neutralized with solid NaHCO₃ and the solvent was evaporated. The residue was dissolved in EtOAc and washed with water and brine, dried with Na₂SO₄ and evaporated. To a solution of the crude mixture in dry pyridine (10 mL), p-nitrobenzoyl chloride (672 mg, 3.6 mmol) and a catalytic amount of DMAP were added followed by stirring overnight. The reaction mixture was diluted with EtOAc and washed with NaHCO₃, brine, dried with Na₂SO₄ then concentrated. The crude product was purified using silica gel column chromatography (eluent: 15%-40% EtOAc/hexanes) to give the oc isomer (235 mg, 59%) as a white solid and the β isomer (165 mg, 41%) as a white solid; a isomer: [α]_(D) ²⁵=+13.85 (c 0.4, DCM); ¹H NMR (400 MHz, CDCl₃): δ 8.31-8.17 (m, 6H, ArH), 8.12 (d, J=8.8 Hz, 2H, ArH), 7.48-7.17 (m, 10H, ArH), 6.64 (d, J=4.4 Hz, 1H, H-1), 5.36 (dd, J=6.6, 4.4 Hz, 1H, H-2), 5.34-5.21 (m, 4H, 2*CH₂Ph), 4.61 (td, J=6.2, 3.8 Hz, 1H, H-4), 4.18 (dd, J=6.6, 3.8 Hz, 1H, H-3), 4.15-3.99 (m, 2H, H-5), 3.47 (t, J=4.8 Hz, 2H, CH₂CH₂O), 3.20-3.12 (m, 2H, CH₂N₃).¹³C NMR (101 MHz, CDCl₃): δ 163.6 (C═O), 163.3 (C═O), 153.5 (C═O), 150.9 (ArC), 150.8 (ArC), 148.4 (ArC), 137.3 (ArC), 134.9 (ArC), 134.8 (ArC), 134.1 (ArC), 131.0 (ArC), 130.9 (ArC), 130.8 (ArC), 128.6 (ArC), 128.4 (ArC), 123.7 (ArC), 123.4 (ArC), 95.4 (C-1), 82.6 (C-4), 77.3 (C-3), 72.4 (C-2), 70.1 (CH₂CH₂O), 69.3 (CH₂Ph), 50.9 (CH₂N₃), 47.7 (C-5); ESI-HRMS: m/z calcd. for C₃₇H₃₂N₆NaO₁₄ [M+Na]⁺ 807.1874; found, 807.1852; β isomer: [α]_(D) ²⁵=−32.63 (c 0.5, DCM); ¹H NMR (400 MHz, CDCl₃): δ 8.53-7.91 (m, 8H, ArH), 7.29 (s, 10H, ArH), 6.52 (s, 1H, H-1), 5.71 (d, J=4.1 Hz, 1H, H-2), 5.19 (q, J=12.3 Hz, 4H, 2*CH₂Ph), 4.46 (dt, J=8.1, 4.9 Hz, 1H, H-4), 4.39 (dd, J=8.0, 4.2 Hz, 1H, H-3), 4.30-4.14 (m, 2H, H-5), 3.73 (ddd, J=9.9, 6.8, 3.3 Hz, 1H, CH₂CH₂O), 3.57 (ddd, J=9.5, 6.0, 3.3 Hz, 1H, CH₂O), 3.30-3.04 (m, 2H, CH₂N₃); ¹³C NMR (101 MHz, CDCl₃): δ 163.5 (C═O), 162.9 (C═O), 153.9 (C═O), 150.9 (ArC), 150.7 (ArC), 134.9 (ArC), 134.4 (ArC), 134.3 (ArC), 131.1 (ArC), 131.0 (ArC), 128.6 (ArC), 128.5 (ArC), 128.2 (ArC), 128.1 (ArC), 123.7 (ArC), 123.6 (ArC), 99.6 (C-1), 80.2 (C-4), 79.2 (C-3), 74.5 (C-2), 70.4 (CH₂CH₂O), 69.2 (CH₂Ph), 50.6 (CH₂N₃), 47.2 (C-5); ESI-HRMS: m/z calcd. for C₃₇H₃₂N₆NaO₁₄ [M+Na]⁺ 807.1874; found, 807.1877.

5-O-β-[3-O-(2-Azidoethyl)-5-di(benzyloxycarbonyl)amino-5-deoxy-2-O-p-nitrobenzoyl-D-ribofuranose]-6,2″,3″,6″-tetra-O-acetyl-1,3,2′,4″-tetraazido-6′,7′-oxazolidino-apramycin (R). Donor Q (β isomer, 165 mg, 0.21 mmol), acceptor A (440 mg, 0.52 mmol) and activated 4 A MS were stirred in dry DCM (3 mL) at rt for 1 h before cooling to 0° C. BF₃.OEt₂ (300 uL, 0.78 mmol) was added and reaction mixture was stirred for 48 h at 0° C. The reaction was quenched with triethylamine (0.5 mL) and filtered through Celite® before it was diluted with EtOAc. The organic layer was washed with aqueous NaHCO₃ and brine then concentrated. The crude product was purified using silica gel column chromatography (eluent: 0.6%-1.5°/O Methanol/DCM) to give the glycoside R (136 mg, 45%) as the β anomer in the form of a white solid; [α]_(D) ²⁵=+46.26 (c 0.9, DCM); ¹H NMR (600 MHz, CDCl₃): δ 8.29-8.21 (m, 2H, ArH), 8.19-8.09 (m, 2H, ArH), 7.39-7.32 (m, 4H, ArH), 7.32-7.25 (m, 6H, ArH), 5.43-5.35 (m, 3H, H-1′, H-3″, H-1″), 5.32 (d, J=3.9 Hz, 1H, H-1′″), 5.31-5.26 (m, 4H, 2*CH₂Ph), 5.25 (d, J=4.1 Hz, 1H, H-2′″), 4.89 (dd, J=10.3, 3.9 Hz, 1H, H-2”), 4.87 (d, J=3.4 Hz, 1H, H-8′), 4.84 (t, J=9.8 Hz, 1H, H-6), 4.78 (dd, J=8.2, 3.2 Hz, 1H, H-6′), 4.60 (dd, J=10.5, 3.2 Hz, 1H, H-5′), 4.31 (dd, J=12.3, 2.3 Hz, 1H, H-6″), 4.28-4.18 (m, 2H, H-6″, H-4′″), 4.18-4.10 (m, 2H, H-5′″), 4.08 (dd, J=7.8, 4.5 Hz, 1H, H-3′″), 3.79 (dd, J=8.2, 3.5 Hz, 1H, H-7′), 3.71 (ddd, J=10.7, 5.3, 2.3 Hz, 1H, H-5″), 3.66 (td, J=10.9, 4.3 Hz, 1H, H-4′), 3.63-3.52 (m, 4H, H-3, H-5, H-4″, CH₂CH₂O), 3.49-3.43 (m, 2H, H-4, CH₂CH₂O), 3.39 (ddd, J=12.5, 10.2, 4.2 Hz, 1H, H-1), 3.27 (dt, J=12.8, 4.3 Hz, 1H, H-2′), 3.12 (ddd, J=13.3, 7.3, 3.2 Hz, 1H, CH₂N₃), 3.02 (ddd, J=13.3, 5.7, 3.2 Hz, 1H, CH₂N₃), 2.92 (s, 3H, NCH₃), 2.38 (dt, J=12.9, 4.5 Hz, 1H, H-2), 2.20 (s, 3H, COCH₃), 2.17-2.11 (m, 1H, H-3′), 2.08 (d, J=4.4 Hz, 6H, 2*COCH₃), 2.04 (s, 3H, COCH₃), 1.77 (q, J=11.8 Hz, 1H, H-3′), 1.41 (q, J=12.6 Hz, 1H, H-2); ¹³C NMR (151 MHz, CDCl₃): δ 170.3 (C═O), 170.0 (C═O), 169.9 (C═O), 169.4 (C═O), 163.9 (C═O), 157.0 (ArC), 153.7 (ArC), 150.8 (ArC), 135.3 (ArC), 134.4 (ArC), 130.9 (ArC), 128.5 (ArC), 128.2 (ArC), 127.9 (ArC), 123.7 (ArC), 106.7 (C-1′″), 96.8 (C-1′), 95.4 (C-8′), 94.0 (C-1″), 80.4 (C-5), 79.5 (C-3′″), 79.3 (C-4), 79.1 (C-4′″), 74.8 (C-2′”), 74.3 (C-6), 70.6 (C-3″), 70.3 (C-6′), 70.0 (CH₂CH₂O), 69.9 (C-2′″), 68.9 (2*CH₂Ph), 65.6 (C-5′), 65.3 (C-4′), 62.9 (C-6″), 60.14 (C-7′), 60.11 (C-4″), 58.3 (C-3), 58.1 (C-1), 57.4 (C-2′), 50.6 (CH₂N₃), 48.2 (C-5′″), 31.3 (C-3′), 31.0 (C-2), 29.9 (NCH₃), 21.0 (COCH₃), 20.9 (COCH₃), 20.8 (COCH₃), 20.7 (COCH₃); ESI-HRMS: m/z calcd. for C₆₀H₆₆N₁₈NaO₂₆ [M+Na]⁺ 1477.4293; found, 1477.4232.

5-O-β-[5-Amino-3-O-(2-aminoethyl)-5-deoxy-D-ribofuranosyl] apramycin heptaacetate salt (DCWSU185) A stirred solution of substrate R (67 mg, 0.046 mmol) in dioxane (1.5 mL) was treated with 3 N NaOH (1.5 mL) and heated at 100° C. for 18 h. The reaction mixture was cooled to 0° C. and neutralized with glacial acetic acid before it was concentrated in vacuo. The crude mixture was passed through a silica gel column (eluent: 25% methanol/DCM). The resulting solid (20 mg, 0.023 mmol) was dissolved in a water methanol:water mixture (1:1, 0.5 mL) and treated with N-(diethylcarbamoyl)-N-methoxyformamide (30 μL, 0.17 mmol) and triethylamine (2 μL). The reaction mixture was stirred for 2 h and quenched with aqueous ammonium hydroxide (0.25 mL) and concentrated. The crude product was purified using silica gel column chromatography (eluent: 5% to 15% ammonical MeOH in DCM). A part of the solid residue (12 mg, 0.014 mmol) dissolved in dioxane (3 mL) followed by the addition of 1 N NaOH (0.5 mL) and 1 M P(CH₃)₃ in THF (0.2 mL), and stirred at 50° C. for 45 min. The reaction mixture was then concentrated to dryness and dissolved in aqueous acetic acid (pH 4, 1 mL) before it was charged to a Sephadex column (CM Sephadex C-25). The column was flushed with D.I. water (20 mL), then gradient eluted of 0.1%-1.0% NH₄OH in D.I. water. The fractions containing the products were combined, acidified with glacial acetic acid and lyophilized to afford the peracetate salt of DCWSU185 in (14.5 mg, 56%) as a white solid; [α]_(D) ²⁵=+72.53 (c 0.7, H₂O); ¹H NMR (600 MHz, D₂O): δ 5.73 (d, J=4.0 Hz, 1H, H-1′), 5.31 (d, J=3.7 Hz, 1H, H-1″), 5.26 (s, 1H, H-1′″), 5.03 (d, J=8.6, 1H, H-8′), 4.40 (s, 1H, H-6′), 4.26 (d, J=4.4 Hz, 1H, H-2′″), 4.03 (td, J=7.5, 3.8 Hz, 1H, H-4′″), 3.93-3.86 (m, 2H, H-4, H-3′″), 3.83-3.71 (m, 4H, H-5, H-4′, H-3″, H-5″), 3.69-3.57 (m, 4H, CH₂CH₂O, H-6″), 3.56-3.44 (m, 4H, H-6, H-2′, H-5′, H-2″), 3.35-3.26 (m, 1H, H-3), 3.23-3.11 (m, 3H, H-1, H-7′, H-5″), 3.11-2.99 (m, 4H, H-4″, H-5, CH₂CH₂O), 2.59 (s, 3H, NCH₃), 2.24 (dt, J=13.1, 4.4 Hz, 1H, H-2), 2.20 (dt, J=10.1, 4.7 Hz, 1H, H-3′), 1.93-1.83 (m, 1H, H-3′), 1.68-1.59 (m, 1H, H-2); ¹³C NMR (151 MHz, D₂O): 6 108.9 (C-1′“), 94.4 (C-1′), 92.7 (C-1”), 92.5 (C-8′), 83.2 (C-5), 79.2 (C-3″), 77.0 (C-4′“), 73.6 (C-4), 72.7 (C-2”), 72.0 (C-6), 70.2 (C-2″), 69.5 (C-5″, C-5′), 68.3 (C-3″), 65.9 (C-4′), 65.8 (CH₂CH₂O), 62.6 (C-6′), 60.2 (C-6″), 59.5 (C-7′), 52.0 (C-4″), 50.0 (C-1), 48.7 (C-3), 47.6 (C-2′), 42.1 (C-5′”), 39.2 (CH₂CH₂O), 30.0 (NCH₃), 28.2 (C-2), 27.0 (C-3′); ESI-HRMS: m/z calcd. for C₂₈H₅₆N₇O₁₄ [M+H]⁺ 714.3885; found, 714.3868.

5-β-[3-O-(2-Aminoethyl)-5-deoxy-5-formamido-D-ribofuranosyl] apramycin hexaacetate salt (DCWSU186). A stirred solution of substrate R (67 mg, 0.046 mmol) in dioxane (1.5 mL) was treated with 3 N NaOH (1.5 mL) and heated at 100° C. for 18 h. The reaction mixture was cooled to 0° C. and neutralized with glacial acetic acid before it was concentrated in vacuo. The crude mixture was passed through a silica gel column (eluent: 25% methanol/DCM). The resulting solid (20 mg, 0.023 mmol) was dissolved in a water methanol:water mixture (1:1, 0.5 mL) and treated with N-(diethylcarbamoyl)-N-methoxyformamide (30 μL, 0.17 mmol) and triethylamine (2 μL). The reaction mixture was stirred for 2 h and quenched with aqueous ammonium hydroxide (0.25 mL) and concentrated. The crude product was purified using silica gel column chromatography (eluent: 5% to 15% ammonical MeOH in DCM). A part of the solid residue (20 mg, 0.022 mmol) was dissolved in dioxane:water (1:1, 0.6 mL) followed by the addition 1 M P(CH₃)₃ in THF (0.3 mL), and stirred at 50° C. for 45 min. The reaction mixture was then concentrated to dryness and dissolved in aqueous acetic acid solution (pH 4, 1 mL) before it was charged to a Sephadex column (CM Sephadex C-25). The column was flushed with D.I. water (20 mL), then gradient elution of 0.1%-1.0% NH₄OH in D.I. water. The fractions containing the product were combined, acidified with acetic acid, and lyophilized to afford the peracetate salt of DCWSU186 in (13.9 mg, 57%) as a white solid; [α]_(D) ²⁵=+55.35 (c 0.2, H₂O);¹H NMR (600 MHz, D₂O): δ 7.94 (s, 1H, CHO), 5.69 (d, J=3.9 Hz, 1H, H-1′), 5.30 (d, J=4.0 Hz, 1H, H-1”), 5.15 (d, J=3.0 Hz, 1H, H-1′″), 5.03 (d, J=8.6 Hz, 1H, H-8′), 4.40 (t, J=2.7 Hz, 1H, H-6′), 4.16 (dd, J=4.9,3.0 Hz, 1H, H-2′″), 3.97 (q, J=5.6 Hz, 1H, H-4′″), 3.88 (t, J=9.6 Hz, 1H, H-4), 3.83-3.68 (m, 5H, H-5, H-4′, H-3″, H-5″, H-3′″), 3.68-3.55 (m, 4H, H-6″, CH₂CH₂O), 3.54-3.44 (m, 4H, H-6, H-2′, H-5′, H-2″), 3.40 (dd, J=14.5, 4.6 Hz, 1H, H-5′″), 3.33 (ddd, J=14.3, 10.4, 4.3 Hz, 1H, H-3), 3.29 (dd, J=14.5, 6.1 Hz, 1H, H-5′″), 3.20 (dd, J=8.6, 2.8 Hz, 1H, H-7′), 3.18-3.12 (m, 1H, H-1), 3.10 (t, J=10.3 Hz, 1H, H-4″), 3.05-2.98 (m, 2H, CH₂CH₂O), 2.59 (s, 3H, NCH₃), 2.28 (dt, J=12.6, 4.3 Hz, 1H, H-2), 2.18 (dt, J=11.2, 4.6 Hz, 1H, H-3′), 1.88 (d, J=11.8 Hz, 1H, H-3′), 1.72-1.63 (m, 1H, H-2);¹³C NMR (151 MHz, D₂O): δ 164.8 (CHO), 110.3 (C-1′″), 94.4 (C-1′), 93.6 (C-1″), 92.8 (C-8′), 84.8 (C-5), 79.3 (C-4′″), 78.8 (C-3′”), 74.8 (C-4), 73.1 (C-2′″), 72.3 (C-6), 70.2 (C-2″), 69.7 (C-5″), 69.3 (C-5′), 68.2 (C-3″), 65.9 (C-4′), 65.8 (CH₂CH₂O), 62.6 (C-6′), 60.2 (C-6″), 59.3 (C-7′), 52.0 (C-4″), 49.6 (C-1), 48.5 (C-3), 47.6 (C-2′), 40.1 (C-5′″), 39.2 (CH₂CH₂O), 30.0 (NCH₃), 27.9 (C-2), 26.7 (C-3′); ESI-HRMS: m/z calcd. for C₂₉H₅₆N₇O₁₅ [M+H]⁺ 742.3834; found, 742.3861.

Example 12 Key intermediate A

-   See the synthetic scheme of FIG. 17.

6,2″,3″,6″-Tetra-O-acetyl-1,3,2′,4″-tetraazido-6′,7′-oxazolidino-apramycin (A). A stirred solution of 1,3,2′,4″-tetraazido-6′,7′-oxazolidino-apramycin (100 mg, 0.15 mmol) in dry pyridine (0.3 mL) was cooled to 0° C. and treated with acetic anhydride (60 μL, 0.62 mmol). The reaction mixture was allowed to warm up to rt and stirred overnight. The reaction progress was monitored by TLC and additional acetic anhydride (0.5-1 equiv) was added as needed. After completion, the reaction mixture was diluted with EtOAc and the organic layer was washed with aqueous NaHCO₃ followed by brine, dried with Na₂SO₄, and concentrated. The crude product was purified via silica gel chromatography eluting with 0.6% to 0.8% methanol in DCM to give A (76 mg, 61%) as a white solid; [α]_(D) ²⁵=+101.6 (c 3.1, DCM); ¹H NMR (600 MHz, CDCl₃): δ 5.35 (t, J=9.9 Hz, 1H, H-3″), 5.30 (d, J=3.7 Hz, 1H, H-1″), 5.15 (d, J=3.5 Hz, 1H, H-1′), 4.93 (d, J=2.9 Hz, 1H, H-8′), 4.93-4.87 (m, 2H, H-6, H-2″), 4.81 (dd, J=8.6, 3.2 Hz, 1H, H-6′), 4.61 (dd, J=10.5, 3.2 Hz, 1H, H-5′), 4.31 (dd, J=12.3, 2.2 Hz, 1H, H-6″), 4.20 (dd, J=12.3, 5.1 Hz, 1H, H-6″), 3.84 (dd, J=8.7, 3.0 Hz, 1H, H-7), 3.80 (dt, J=10.9, 5.5 Hz, 1H, H-4′), 3.72 (ddd, J=10.7, 5.1, 2.3 Hz, 1H, H-5″), 3.66 (ddd, J=12.3, 9.9, 4.7 Hz, 1H, H-3), 3.62-3.53 (m, 3H, H-2′, H-4″, H-5), 3.49 (ddd, J=12.5, 10.0, 4.5 Hz, 1H, H-1), 3.45 (t, J=9.5 Hz, 1H, H-4), 2.89 (s, 3H, NCH₃), 2.41 (dt, J=13.3, 4.6 Hz, 1H, H-2), 2.29 (dt, J=10.9, 4.5 Hz, 1H, H-3), 2.13 (s, 3H, COCH₃), 2.10 (s, 3H, COCH₃), 2.10 (s, 3H, COCH₃), 2.07 (s, 3H, COCH₃), 1.89 (q, J=11.7 Hz, 1H, H-3), 1.60 (q, J=12.7 Hz, 1H, H-2); ¹³C NMR (151 MHz, CDCl₃): δ 170.37 (C═O), 170.34 (C═O), 169.91 (C═O), 169.88 (C═O), 157.0 (NC=O), 98.8 (C-1′), 94.9 (C-8), 94.5 (C-1″), 83.8 (C-4), 74.9 (C-6), 74.3 (C-5), 70.7 (C-3″), 70.1 (C-2″), 69.8 (C-6), 68.8 (C-5″), 65.5 (C-5), 65.1 (C-4), 62.8 (C-6″), 60.1 (C-2′), 59.9 (C-7′), 58.4 (C-3), 58.0 (C-1), 57.6 (C-4″), 32.0 (C-2), 30.6 (C-3), 29.8 (C-NCH₃), 20.9 (COCH₃), 20.7 (COCH₃); ESI-HRMS: m/z calcd. for C₃₀H₃₉N₁₃NaO₁₆ [M+Na]⁺ 860.2535; found, 860.2522.

TABLE 1 O5-ribosylated apramycin derivatives MIC (μg/mL) IC50 (μM) Compound 3′″ 5′″ WT AAC(3)-IV APH(3′)-I APH(3′)-II APH(3′)-III APH(3′)-VI Bac Mit Cyt apramycin — — 2-4 >128 1-2 4 1 4 0.08 68 71 DC146 OH — 8 32 4 4 1 8 0.09 215 321 DC131 OH OH 4 >32 64 8 4 4 0.11 295 319 DC177 OH Form. 8 >32 4 8 2 8 0.23 399 >500 DC201 OH NH2 8 16 2-4 4 1 4 0.12 113 81 DC214 OH N- 4 8-16 2 4 1 4 0.09 178 85 NH2- ethyl DC178 OH-ethyl OH 8 >32 >64 8 2 16 0.22 647 >500 DC124 NH2-ethyl OH 2 >32 64 2 0.5 4 0.06 57 181 DC185 NH2-ethyl NH2 1 >32 1 1 0.25 2 0.03 34 26 DC186 NH2-ethyl Form 2 >32 2 2 0.25 2 0.06 69 105 DC138 ring OH 2 >32 16 2 1-2 4 0.10 2.2 18 paromomycin ring OH 1-2 128 >128 >128 >128 >128 0.02 86 19

Legend to Tables: GEN, gentamicin; AMK, amikacin; PLZ, plazomicin; APR, apramycin; AG212, Escherichia coli ATCC25922; AG215, Klebsiella pneumonia; AG220, Pseudomonas aeruginosa ATCC27853; AG225, Acinetobacter baumannii pittii; AG290, Enterobacter cloacae; AG192, SZ380, Mycobacterium smegmatis. MICs for AG192 have been determined in the presence of 0.5 μg/mL of ampicillin in the medium to mimic the synergistic effect of aminoglycoside and β-lactam antibiotics combination therapy in the treatment of Enterococcus infections in humans.

TABLE 2 5-modified apramycin derivatives MIC (μg/mL) IC50 (μM) Compound Modification WT AAC(3)-IV apmA Bac Mit Cyt Apramycin — 2-4 >128 64 0.08 68 71 DC176 1-N-LHABA 2 4 16 0.11 166 326 DC169 5-deoxy 4 >32 16 0.06 45 42 DC161 5-epi 2 >32 2 0.05 20 17 DC191 5-epi-1-N-LHABA 2-4 4-8 8 0.20 98 87 DC170 5-deoxy-5-F 4 >32 32 0.06 62 74 DC168 5-deoxy-5-F epi 2 >32 4 0.05 30 28 DC167 6-O-(2OH-ethyl) 8 >32 >64 0.18 379 382 DC207 5-O-(3-hydroxypropyl) 8 >128 >128 0.60 >1000 >1000 DC213 5-O-(3-aminopropyl) 4 64 64-128 0.21 327 210 DC208 5-O-(2,3-dihydroxypropyl) 4-8 64 >128 0.21 434 >1000 DC209 5-O-(3-amino-2-hydroxypropyl) 2-4 8 64-128 0.04 146 105 DC212 5-O-(3-amino-2-hydroxypropyl) 4 0.10 158 112

TABLE 3 6-modified apramycin derivatives MIC (μg/mL) IC50 (μM) Compound Modification WT AAC(3)-IV apmA Bac Mit Cyt Apramycin — 2-4 >128 64 0.08 68 71 DC167 6-O-(2OH-ethyl) 8 >32 >64 0.18 379 382

TABLE 4 Antibiotic potency against bacterial reference strains MIC (μg/mL) Disk diffusion AG212 AG215 AG290 AG220 AG225 SZ380 ATCC19977 25 nmol E. coli K. pneumonia E. cloacae P. aeruginosa A. baumannii M. smegmatis M. abcessus N. gonorrhoeae GEN 0.5 0.25 0.25 0.5-1   0.5-1   2-4 AMK 2 1 1 2 2 2 PLZ 0.5-1   0.25-0.5  0.5 2-4 2 4 APR 4 2 4 4 4 2 <8 mm DC146 16 4 4 32 8 4 DC131 8 2 4 64 16 16 DC177 8 4 8 >64 16 2 16 DC201 4 2 2 4-8 4-8 0.25 1-2 DC214 2 1 1-2 8 8 0.25 2 DC178 8 4 8 >64 16 2 32 DC124 2 1-2 1-2 16-32 8 8 DC185 2 0.5-1   1 1-2 2 1 DC186 2-4 1 1-2 16-32 8 8 DC138 2 1 2 16 4 2 DC176 2-4 2 4 16 8 0.5 2 DC169 4 2 2 4 4 0.125 1 DC161 2 1 2 2 2 0.5 10 mm DC191 2 1-2 2 4 8 0.5 2 DC170 4 2 4 8 4-8 0.25 1 DC168 4 1 4 4 4 0.125 1 DC167 16 4 8 32 16 2 DC207 16 8 16 64 32 1 8 DC213 4-8 2 4-8 8 8 0.25 1 DC208 8 4 4 16-32 16 0.5 2 DC209 2-4 1 1 2-4 4 0.125 0.5-1   DC212 4 2 4 4 4

TABLE 5 Antibacterial activity against representative clinical isolates AG042 AG003 AG173 AG039 MRSA AG033 AG001 AG055 E. coli E. coli AG163 MRSA AAC(6′)-I AG031 AG032 P. aer. E. coli E. coli AAC(3)- AAC(3)- E. coli AG038 AAC(6′)-I ANT(4′)-I P. aer. P. aer. APH(3′)-II WT WT II IV APH(3′)-I MRSA ANT(4′)-I APH(2′) APH(3′)-II APH(3′)-II AAC(6′)-I GEN 1 0.5 32-64 0.25-0.5  0.25-0.5  64 0.5 0.5 16 AMK 4 2-4 16-32 4 4 64 PLZ 2-4 2-4 2-4 2-4 2-4 2 4 4 16-32 APR  8-16 8 8 ≥128 4 4-8 8 8 8-16 8 16-32 DC146 16 16 16 128 8 16-32 16-32 16 64 64  64-128 DC131 16 16-32 16 16-32 8-16 64 64 64 64-128  64-128 128 DC177 8 16 8 >64 8 32 16-32 32 >32 >32 >32 DC201 4 2-4 16 DC214 2 16 4 8-16 DC178 32 16 16 32-64 8 16-32 32 32 >32 >32 >32 DC124 8 8 4-8 4 4-8   8-16 8 8 32-64  32-64 128 DC185 2 2 1-2 4 2 1 1 1 2 2 2 DC186 2 4 2 32 2 4 4-8 4-8 16 32 64 DC138 4 8 4 1-2 8 2-4 2-4 2 32-64  64 64 DC176 4 8 4 2-4 4 4-8 4-8 8 16 32 >32 DC169 4 4 4 32 2-4 2 4 8 8 16 DC161 4 4 4-8 64 4 4 2-4 4 4 8 DC191 8 4-8 4 DC170 8 4 8 64 4-8 4-8 8 8-16 16 32 DC168 8 4 4 128 2-4 2-4 4 8-16  8-16 32 DC167 16 16 16 >128 8-16 16-32 16-32 64 32-64  32-64  64-128 DC207 16 >128 32 128 DC213 16 128 4 16-32  DC208 8 >64  8-16 32 DC209 2 32 4 1-2 4 DC212 8 4 8

TABLE 6 Activity against G1405-methylated 16S-rRNA Clinical isolates E. coli K. pneum. Enterob. Engineered E. coli AG153 AG269 AG302 A baum. E. coli E. coli E. coli E. coli E. coli E. coli AAC(3)-II AAC(3)-II AAC(3)-II AG227 pH430 AG103 pH424 pH425 pH426 pH427 APH(3′)-II AAC(6′)-I AAC(6′)-I APH(3′)-I WT armA armA rmtB rmtC rmtF rmtB rmtB rmtC armA GEN 0.25 >128 >128 >128 >128 >256 >256 >256 >256 AMK 1 >128 >128 >128 >128 >256 >256 >256 >256 PLZ 0.5 >32 APR 2-4 1-2 2-4 4 4 4 8 2 4 2 DC146 8 1 4 4 8 4 DC131 4 1 2 4 4 4 DC177 8  2-4 8 8 16 8 DC201 8 2 8 4 4  8-16 DC214 4 2 2 2 1-2 4-8 DC178 8 2 2 8 8 8 DC124 2 0.5 1 4 2 2 4 2 4 16 DC185 1 0.5-1  2 2 2 2 4 1 1 2 DC186 2 0.5-1  2 2 4 2 DC138 2 <0.125 1 1 1 1 DC176 2 0.25-0.5 2 2 4 4 4 2 2 2 DC169 4 1 2 4 4 4 DC161 2 2 2 2 2 DC191 2-4 2 4 2 2-4 4 DC170 4 2 2 4 4 4 DC168 2 1 2 2 2 2 DC167 8 4 8 16 16 16 DC207 8 4 8 8  8-16 16-32 DC213 4 4 32 4-8 4-8 4-8 DC208 4-8 2 8 4 4 8 DC209 2-4 2 2-4 1 2 2-4 

1. A compound characterized by a general formula (100)

wherein E is selected from H, CO—R^(E), CONHR^(E), CON(OH)R^(E) and unsubstituted C₁ to C₄ alkyl or amino- and/or hydroxyl-substituted C₂ to C₄ alkyl, wherein R^(E) is H or an unsubstituted or amino- and/or hydroxyl-substituted C₁ to C₆ alkyl (particularly R^(E) is H or an amino- and/or hydroxyl-substituted C₁ to C₅ alkyl), particularly wherein E is selected from H and (S)-4-amino-2-hydroxybutyryl, (S)-3-amino-2-hydroxypropionyl, —CON(OH)(CH₂)₂NH₂), (2R,3S)-2-hydroxy-4,5-diamino-pentanoyl, and (2S,3R)-2,5-dihydroxy-4-aminopentanoyl; V is selected from H and CH₂—D, wherein D is selected from OH, NH₂, NHCHO, NHR^(D) and NHCONHR^(D), wherein R^(D) is selected from H, OH, unsubstituted or amino- and/or hydroxy-substituted C₁ to C₆ alkyl, particularly wherein D is selected from OH, NHCHO and NHCONH₂; U and W are selected from the following alternatives: one of U and W is —R^(W) and the other one is selected from H, F and OH, or one of U and W is —OR^(W) and the other one is H, or one of U and W is F and the other one is H, both are H or both are F, or one of U and W is OH and the other one is H, wherein R^(W) is selected from an amino- and/or hydroxy-substituted C₁ to C6 alkyl, CH₂(CH₂)_(n)NH(CH₂)₃NH₂ and CH₂(CH₂)_(n)—R^(N), wherein n is selected from 1, 2 or 3, R^(N) is selected from NXY and a moiety characterized by formula (400)

wherein X and Y are independently selected from H, and unsubstituted or amino- and/or hydroxyl-substituted C₁ to C₃ alkyl, particularly from H and CH₃, CH₂CH₃ and CH₂CH₂OH or CH₂CH₂NH₂ and Z is selected from O, NX and CH₂, or one of U and W (particularly W) is described by a moiety characterized by formula (300), (301), (304) or (305) and the other one of U and W is H

wherein R″ is selected from H and an amino- and/or hydroxy-substituted C₁ to C₆ alkyl, particularly wherein one of U and W (particularly W) is

with the proviso that the molecule is not described by the following combination of parameters: D is OH, U is H and W is OH. Furthermore, with effect to certain countries not including Australia, Brazil, Mexico, Singapore, the USA, and Ukraine, the following compounds are disclaimed: V and U are H and W is OH, D is OH, U is H and W is O(CH₂)₂NH₂, D is OH, U is H and W is a moiety characterized by formula (302).
 2. The compound according to claim 1, wherein V is CH₂OH.
 3. The compound according to claim 1, wherein V is H.
 4. The compound according to claim 1, wherein V is selected from CH₂NHCHO and CH₂NHCONH₂.
 5. The compound according to claim 1, wherein V is CH₂NHR^(D) and R^(D) has the same meaning as indicated in claim
 1. 6. The compound according to any one of the preceding claims, wherein E is a. H or b. CO—R^(E), wherein R^(E) is an amino- and/or hydroxy-modified C₁ to C₅ alkyl.
 7. The compound according to any of the preceding claims, wherein one of U and W is —R^(W) and the other one is selected from H, F, OH, wherein R^(W) has the same meaning as indicated above.
 8. The compound according to any of the preceding claims 1 to 6, wherein one of U and W is —OR^(W) and the other one is H, wherein R^(W) has the same meaning as indicated above.
 9. The compound according to any one of the preceding claims, wherein R^(W) is selected from (CH₂)₂OH, (CH₂)₂NH₂, (CH₂)₂NMe₂, (CH₂)₂NEt₂, (CH₂)₂NHMe, (CH₂)₂NHEt, (CH₂)₃OH, (CH₂)₃NH₂, (CH₂)₃NMe₂, (CH₂)₃NEt₂, (CH₂)₃NHMe, (CH₂)₃NHEt, CH₂CHOHCH₂OH, CH₂CHOHCH₂NH₂, CH₂CHOHCH₂NMe₂, CH₂CHOHCH₂NEt₂, CH₂CHOHCH₂NHMe and CH₂CHOHCH₂NHEt.
 10. The compound according to any of the preceding claims 1 to 6, wherein one of U and W is F and the other one is H, both are H or both are F.
 11. The compound according to any of the preceding claims 1 to 6, wherein one of U and W is OH and the other one is H.
 12. The compound according to any of the preceding claims 1 to 9, wherein a. W is —R^(W) and U is selected from H, F, OH, or b. W is —OR^(W) and U is H, wherein R^(W) has the same meaning as indicated above.
 13. The compound according to claim 1, characterized by a general formula (110)

wherein R^(AP) designates a moiety described by formula (2)

E has the meaning as defined in claim 1 or 6; V is selected from H and CH₂—D, wherein D is selected from OH, NH₂, NHCHO and NHCONHR^(D), wherein R^(D) is selected from H, OH, unsubstituted or amino- and/or hydroxy-substituted C₁ to C₃ alkyl, particularly wherein D is selected from OH, NHCHO and NHCONH₂; W is F and U is selected from OH and F and

denotes the position where the apramycin backbone is attached to the compound described by general formula (110).
 14. The compound according to any one of the preceding claims 1 to 6, characterized by a general formula (112), (113) or (114)

wherein U is selected from OH and F and n, R^(AP), R″, R^(N) and V have the same meaning as indicated above.
 15. The compound according to any one of the preceding claims 1 to 6, wherein E is H, V is CH₂NHCHO, U is H and W is OH [5-O-β-(5′″-Formamido-5′″-deoxy-D-ribofuranosyl) apramycin DCWSU177].
 16. The compound according to claim 14, characterized by the general formula a. (112), E is H, R^(N) is OH, V is CH₂OH and n is 1 [5-O-β-[3′″-O-(2-hydroxyethyl)-D-ribofuranosyl] apramycin; DCWSU178]; b. (112), E is H, R^(N) is NH₂, V is CH₂NH₂ and n is 1 [5-O-β-[5-amino-3-O-(2-aminoethyl)-5-deoxy-D-ribofuranosyl] apramycin; DCWSU185]; c. (112), wherein E is H, V is CH₂NHCOH, R^(N) is NH₂ and n is 1 [5-O-β-[3-O-(2-aminoethyl)-5-deoxy-5-formamido-D-ribofuranosyl] apramycin; DCWSU186].
 17. The compound according to formula (100), wherein a. E, U and V are H and W is —OR^(W), and R^(W) is selected from (CH₂)₂OH, (CH₂)₂NH₂, (CH₂)₂NMe₂, (CH₂)₂NEt₂, (CH₂)₂NHMe, (CH₂)₂NHEt, (CH₂)₃OH, (CH₂)₃NH₂, (CH₂)₃NMe₂, (CH₂)₃NEt₂, (CH₂)₃NHMe, (CH₂)₃NHEt, CH₂CHOHCH₂OH, CH₂CHOHCH₂NH₂, CH₂CHOHCH₂NMe₂, CH₂CHOHCH₂NEt₂, CH₂CHOHCH₂NHMe and CH₂CHOHCH₂NHEt; b. E and U are H, V is CH₂OH and W is a moiety described by formula (300), with R″ selected from H, (CH₂)₂OH, (CH₂)₂NH₂, (CH₂)₂NMe₂, (CH₂)₂NEt₂, (CH₂)₂NHMe and (CH₂)₃NHEt; c. E and W are H, U is OH and V is selected from CH₂OH and CH₂NH₂; d. E is H, V is CH₂D with D being selected from OH, NH₂ and NHCHO, and one of U and W is F, and the other one of U and W is H.
 18. These compounds are claimed with effect in Australia, Brazil, Mexico, Singapore, the USA, and Ukraine: compounds according to formula (100), wherein U is H and a. V is H and W is OH, b. D is OH, U is H and W is O(CH₂)₂NH₂, c. D is OH, U is H and W is a moiety characterized by formula (302).
 19. The intermediates in a synthesis for an apramycin derivative antibacterial drug: a. 3-O-(2-azidoethyl)-5-O-benzyl-1,2-O-isopropylideneo-α-D-ribofuranose (E FIG. 1); b. 3-O-(2-azidoethyl)-5-O-benzyl-1,2-di-O-(4-nitrobenzoyl)-α-D-ribofuranose (F FIG. 1) c. 5,6,2″,3″,6″-penta-O-acetyl-1,3,2′,4″-tetraazido-5-epi-6′,7′-oxazolidino-apramycin (j; FIG. 12); d. 6,2″,3″,6″-tetra-O-acetyl-1,3,2′,4″-tetraazido-5-epi-6′,7′-oxazolidino-apramycin (k; FIG. 12) e. 5,2″,3″,6″-tetra-O-acetyl-6-O-allyl-1,3,2′,4″-tetraazido-6′,7′-oxazolidino-apramycin (AK; FIG. 16) f. 1,2,3-tri-O-acetyl-5-deoxy-5-phthalimido-α-D-ribofuranose (I; FIG. 5); g. 2,3-di-O-acetyl-5-deoxy-5-phthalimido-D-ribofuranosyl trichloroacetimidate (J; FIG. 5); h. 3-O-(2-azidoethyl)-5-di(benzyloxycarbonyl)amino-5-deoxy-1,2-O-isopropylidene-α-D-ribofuranose (P; FIG. 7) i. 3-O-(2-azidoethyl)-5-di(benzyloxycarbonyl)amino-5-deoxy-1,2-di-O-(p-nitrobenzoyl)-α/β-D-ribofuranose (Q; FIG. 7); and with effect for Australia, Brazil, Mexico, Singapore, the USA, and Ukraine: j. 6,2″,3″,6″-tetra-O-acetyl-1,3,2′,4″-tetraazido-6′,7′-oxazolidino-apramycin (A; FIG. 17)
 20. A compound characterized by a general formula (200)

wherein A or B or G is OR¹, and if one of A and B is OR¹, the other is H and G is OH, or if G is OR¹, one of A and B is OH and the other one is H, wherein R¹ is an unsubstituted C₁ to C₆ alkyl or an amino- and/or hydroxy-substituted C₂ to C₆ alkyl, particularly R¹ is an amino- and/or hydroxy-substituted or C₂ to C₆ alkyl; more particularly, R¹ is selected from (CH₂)₂OH, CH₂CH₂CH₃, (CH₂)₂NH₂, (CH₂)₂NMe₂, (CH₂)₂NEt₂, (CH₂)₂NHMe, (CH₂)₂NHEt, (CH₂)₃OH, (CH₂)₃NH₂, (CH₂)₃NMe₂, (CH₂)₃NEt₂, (CH₂)₃NHMe, (CH₂)₃NHEt, CH₂CHOHCH₂OH, CH₂CHOHCH₂NH₂, CH₂CHOHCH₂NMe₂, CH₂CHOHCH₂NEt₂, CH₂CHOHCH₂NHMe and CH₂CHOHCH₂NHEt, or or wherein one of A and B is F and the other one is H, or A and B together form a carbonyl oxygen, and G is OH; and E is selected from H, CO—R^(E), CONHR^(E), CON(OH)R^(E) and unsubstituted C₁ to C₄ alkyl or amino- and/or hydroxyl-substituted C₂ to C₄ alkyl, wherein R^(E) is H or an unsubstituted or amino- and/or hydroxyl-substituted C₁ to C₆ alkyl (particularly R^(E) is H or an amino- and/or hydroxyl-substituted C₁ to C₅ alkyl), particularly E is selected from H and (S)-4-amino-2-hydroxybutyryl, (S)-3-amino-2-hydroxypropionyl, —CON(OH)(CH₂)₂NH₂), (2R,3S)-2-hydroxy-4,5-diamino-pentanoyl, and (2S,3R)-2,5-dihydroxy-4-aminopentanoyl; with the proviso that the molecule is not described by any one of the following combination of parameters: A and G are OH and B and E are H, A and G are OH, B is H and E is unsubstituted C₁ to C₄ alkyl, or amino- and/or hydroxyl-substituted C₂ to C₄ alkyl, A and G are OH, B is H and E is COC(OH)(CH₂)₂NH₂ A, B and E are H and G is OH, A and E are H and B and G are OH A and E are H, B is F and G is OH. Furthermore, with effect to certain countries not including Australia, Brazil, Mexico, Singapore, the USA, and Ukraine, the following compounds are disclaimed: B is H, G is OH and A is selected from —OCH₂CH₂EtOH, —OCH₂CHOHCH₂OH (glyceryl), and —OEt.
 21. The compound according to claim 20, wherein one of A and B is F.
 22. The compound according to claim 20, wherein one of A and B is —OR¹, wherein R¹ has the meaning as indicated above.
 23. The compound according to claim 20, G is OR¹.
 24. The compound according to any one of claims 20 to 23, wherein E is a. H or b. CO—R^(E), wherein R^(E) is an amino- and/or hydroxy-modified C₁ to C₅ alkyl.
 25. A compound according to claim 20, wherein E is H and: a. A is F, B is H and G is OH; b. B is H, G is OH and A is —OR¹, with R¹ being selected from (CH₂)₂OH, (CH₂)₂NH₂, (CH₂)₂NMe₂, (CH₂)₂NEt₂, (CH₂)₂NHMe, (CH₂)₂NHEt, (CH₂)₃OH, (CH₂)₃NH₂, (CH₂)₃NMe₂, (CH₂)₃NEt₂, (CH₂)₃NHMe, (CH₂)₃NHEt, CH₂CHOHCH₂OH, CH₂CHOHCH₂NH₂, CH₂CHOHCH₂NMe₂, CH₂CHOHCH₂NEt₂, CH₂CHOHCH₂NHMe and CH₂CHOHCH₂NHEt;
 26. A compound according to claim 20, wherein E is -COCHOH(CH₂)₂NH₂, E is particularly (S)-2-hydroxy-4-aminobutyl, and: a. G is OH and A and B are selected from the alternatives: A is H and B is F or A is H and B is OH or A is F and B is H or A and B are both H or A and B together form a carbonyl O; b. B is H, G is OH and A is —OR¹, with R¹ being selected from (CH₂)₂OH, (CH₂)₂NH₂, (CH₂)₂NMe₂, (CH₂)₂NEt₂, (CH₂)₂NHMe, (CH₂)₂NHEt, (CH₂)₃OH, (CH₂)₃NH₂, (CH₂)₃NMe₂, (CH₂)₃NEt₂, (CH₂)₃NHMe, (CH₂)₃NHEt, CH₂CHOHCH₂OH, CH₂CHOHCH₂NH₂, CH₂CHOHCH₂NMe₂, CH₂CHOHCH₂NEt₂, CH₂CHOHCH₂NHMe and CH₂CHOHCH₂NHEt; c. A is OH, B is H, and G is —OR¹, with R¹ being selected from (CH₂)₂OH, (CH₂)₂NH₂, (CH₂)₂NMe₂, (CH₂)₂NEt₂, (CH₂)₂NHMe, (CH₂)₂NHEt, (CH₂)₃OH, (CH₂)₃NH₂, (CH₂)₃NMe₂, (CH₂)₃NEt₂, (CH₂)₃NHMe, (CH₂)₃NHEt, CH₂CHOHCH₂OH, CH₂CHOHCH₂NH₂, CH₂CHOHCH₂NMe₂, CH₂CHOHCH₂NEt₂, CH₂CHOHCH₂NHMe and CH₂CHOHCH₂NHEt.
 27. A compound characterized by a general formula (201)

wherein E is selected from CO—R^(E), CONHR^(E), CON(OH)R^(E) and unsubstituted C₁ to C₄ alkyl or amino- and/or hydroxyl-substituted C₂ to C₄ alkyl, wherein R^(E) is H or an unsubstituted or amino- and/or hydroxyl-substituted C₁ to C₆ alkyl (particularly R^(E) is H or an amino- and/or hydroxyl-substituted C₁ to C₅ alkyl), particularly E is selected from H and (S)-4-amino-2-hydroxybutyryl, (S)-3-amino-2-hydroxypropionyl, —CON(OH)(CH₂)₂NH₂), (2R,3S)-2-hydroxy-4,5-diamino-pentanoyl, and (2S,3R)-2,5-dihydroxy-4-aminopentanoyl.
 28. A compound as disclosed in any one of the previous claims for use in the therapy of bacterial infection by systemic administration, particularly wherein the infection is caused by a pathogen comprised in the family Enterobacteriaceae, particularly in the genera Enterobacter, Escherichia and Klebsiella, or selected from a genus comprised in the group of Acinetobacter, Mycobacteria, Pseudomonas and Staphylococcus.
 29. A compound as disclosed in any of claims 1 to 0, including a. a compound according to claim 1 defined by formula (100), wherein i. D is OH, U is H and W is OH ii. V and U are H and W is OH; iii. D is OH, U is H and W is O(CH₂)₂NH₂, iv. D is OH, U is H and W is a moiety characterized by formula (302) b. a compound according to claim 19 defined by formula (200), wherein i. A and G are OH, B is H and E is unsubstituted C₁ to C₄ alkyl, or amino- and/or hydroxyl-substituted C₂ to C₄ alkyl ii. A and G are OH, B is H and E is —COC(OH)(CH₂)₂NH₂ iii. A, B and E are H and G is OH, iv. A and E are H and B and G are OH v. A and E are H, B is F and G is OH. vi. B is H, G is OH and A is selected from —OCH₂CH₂EtOH, —OCH₂CHOHCH₂OH (glyceryl), and —OEt for use in the therapy of bacterial infection, wherein the infection is caused by a pathogen comprising the AAC(3)-IV resistance determinant.
 30. A compound according to any of claims 1 to 0, including a. a compound according to claim 1 defined by formula (100), wherein i. D is OH, U is H and W is OH ii. V and U are H and W is OH; iii. D is OH, U is H and W is —O(CH₂)₂NH₂, iv. D is OH, U is H and W is a moiety characterized by formula (302) b. a compound according to claim 20 defined by formula (200), wherein i. A and G are OH, B is H and E is unsubstituted C₁ to C₄ alkyl, or amino- and/or hydroxyl-substituted C₂ to C₄ alkyl ii. A and G are OH, B is H and E is COC(OH)(CH₂)₂NH₂ iii. A, B and E are H and G is OH, iv. A and E are H and B and G are OH v. A and E are H, B is F and G is OH. vi. B is H, G is OH and A is selected from —OCH₂CH₂EtOH, —OCH₂CHOHCH₂OH (glyceryl), and —OEt for use in the therapy of bacterial infection, wherein the infection is caused by a pathogen, selected from a genus comprised in the group of Enterobacter, Klebsiella, Acinetobacter, and Mycobacteria.
 31. A compound according to claim 1 defined by formula (100), wherein V is CH₂NH₂, W is —OR^(W), and R^(W) is selected from (CH₂)₂OH, (CH₂)₂NH₂, (CH₂)₂NMe₂, (CH₂)₂NEt₂, (CH₂)₂NHMe, (CH₂)₂NHEt, (CH₂)₃OH, (CH₂)₃NH₂, (CH₂)₃NMe₂, (CH₂)₃NEt₂, (CH₂)₃NHMe, (CH₂)₃NHEt, CH₂CHOHCH₂OH, CH₂CHOHCH₂NH₂, CH₂CHOHCH₂NMe₂, CH₂CHOHCH₂NEt₂, CH₂CHOHCH₂NHMe and CH₂CHOHCH₂NHEt, particularly wherein R^(W) is selected from (CH₂)₂NH₂, (CH₂)₂NMe₂, (CH₂)₂NEt₂, (CH₂)₂NHMe, (CH₂)₂NHEt, (CH₂)₃NH₂, (CH₂)₃NMe₂, (CH₂)₃NEt₂, (CH₂)₃NHMe, (CH₂)₃NHEt, CH₂CHOHCH₂NH₂, CH₂CHOHCH₂NMe₂, CH₂CHOHCH₂NEt₂, CH₂CHOHCH₂NHMe and CH₂CHOHCH₂NHEt, more particularly R^(W) is selected from (CH₂)₂NH₂ and (CH2)3NH2, and wherein U is H and E is defined as in claim 1, particularly E is selected from H and (S)-4-amino-2-hydroxybutyryl, (S)-3-amino-2-hydroxypropionyl, —CON(OH)(CH₂)₂NH₂), (2R,3S)-2-hydroxy-4,5-diamino-pentanoyl, and (2S,3R)-2,5-dihydroxy-4-aminopentanoyl, for use in the therapy of bacterial infection, wherein the infection is caused by a pathogen comprised in the family Enterobacteriaceae, particularly in the genera Enterobacter, Escherichia and Klebsiella, or selected from a genus comprised in the group of Acinetobacter, Mycobacteria, Pseudomonas and Staphylococcus. 